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STELLINGEN 
1. De covalente eiwitbinding die optreedt tijdens oxidatie van chloorbenzenen kan 
volledig verklaard worden uit de vorming van chinonen. 
Dit proefschrift. 
2. Bij de cytochroom P450 afhankelijke oxidatie van halogeenfenolen bepaalt de 
substituent op de positie para ten opzichte van de hydroxyl groep het karakter 
van het gevormde product (hydrochinon of benzochinon). 
Dit proefschrift. 
3. De vorming van tetrachloorbenzochinon uit pentachloorfenol speelt geen rol in 
de door hexachloorbenzeen geïnduceerde porfyrie. 
Dit proefschrift. 
4. De door de auteurs met enige verbazing geconstateerde bevinding dat na bloot-
stelling van ratten aan broombenzeen het belangrijkste protein-5 adduct een 
gedebromineerd adduct is, kan eenvoudig verklaard worden uit een directe oxi-
datie van p-broomfenol tot benzochinon onder afsplitsing van het bromide 
anion, gevolgd door alkylering van eiwit. 
D.E. Slaughter andR.P. Hanzlik (1991), Chem. Res. Toxicol. 4,349-359. 
Dit proefschrift. 
5. Het feit dat het broombenzeen-3,4-epoxide niet spontaan reageert met glutat-
hion roept twijfels op bij de gangbare hypothese dat het 3,4-epoxide door alky-
lering van celbestanddelen verantwoordelijk is voor de hepatotoxiciteit na 
blootstelling aan broombenzeen. 
T.J. Monks et al. (1982), Chem.-Biol. Interact. 41,203-216. 
6. Inhibitie van glutathion transferases biedt meer mogelijkheden in de therapie 
van multidrug-resistente tumoren dan inhibitie van de glutathion synthese met 
buthionine sulfoximine. 
P.J. van Bladeren andB. van Ommen (1991), Pharmacol. Ther. 51,35-46. 
K.D. Tew et al. (1988), Cancer Res. 48,3622-3625. 
7. Bij de huidige risicobenadering in het stoffenbeleid ligt het accent nog te veel 
op een stof-per-stof aanpak. In geval van stofgroepen met vergelijkbare 
effecten wordt het milieu en de gezondheid mogelijk onvoldoende beschermd 
en moet men in principe uitgaan van een gecombineerde, groepsgewijze 
benadering. 
8. De ontwikkeling van alternatieven voor dierproeven wordt vooral in de weg 
gestaan door het feit dat te veel onderzoekers die zich daarmee bezig houden te 
conservatief zijn. Zij concentreren zich op vervanging van bestaande in vivo 
methoden in plaats van te zoeken naar werkelijk alternatieve methoden voor 
extrapolatie en risicoschatting. 
GJ. Mulder, NRC1110611992. 
9. Het feit dat het rendement van de AIO-opleidingen binnen de gestelde termijn 
van vier jaar in de alfa- en gammawetenschappen beduidend lager is dan in de 
bètawetenschappen suggereert ten onrechte een kwaliteitsverschil tussen de 
desbetreffende AIO-ers en/of wetenschappen. 
Volkskrant, 08/08/1992. 
10. De beperkte mogelijkheden voor vrouwen in Nederland om de opvoeding van 
kinderen te combineren met een carrière leidt tot een voor de maatschappij 
zorgwekkende ontwikkeling, namelijk dat de voortplanting en opvoeding van 
de komende generaties met name in handen komt van laag-opgeleide vrouwen. 
L. Thooft, Opzij, Oktober 1992. 
11. Het in de marketing veel toegepaste begrip 'milieuvriendelijk produkt' bestaat 
slechts in relatieve zin; het gebruik in absolute zin is derhalve misleidend voor 
de consument. 
12. Het bestaansrecht van de moderne Olympische Spelen ligt, in tegenstelling tot 
wat velen denken, niet in de aaneenrijging van sportieve hoogtepunten, maar in 
de stelselmatige opsomming van commerciële aandachtspunten. 
Stellingen behorend bij het proefschrift: 
'The relationship between biotransformation and toxicity of halogenated benzenes: 
nature of the reactive metabolites and implications for toxicity.' 
Cathaline den Besten, Wageningen 18 december 1992. 
Voor Nico 
Voor mijn ouders 
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Chapter 1 
GENERAL INTRODUCTION 
One of the major goals in the field of toxicology is to elucidate the mechanisms by 
which xenobiotics produce detrimental biological responses in organisms. A large number 
of xenobiotics are as such biologically inert, and many of their toxicological effects are 
mediated through the formation of 'active' metabolites. However, in spite of the extensive 
research in the past decades, both the nature of the interaction between such 'active' 
metabolites (either chemically stable or chemically reactive) and the various cellular 
targets, as well as the mechanisms by which these interactions eventually lead to cell death 
are still relatively poorly understood. 
Halogenated benzenes like bromobenzene and hexachlorobenzene have served as 
model compounds in numerous studies, in an attempt to elucidate the actual mechanism(s) 
of aromatic hydrocarbon toxicity. These compounds, in itself relatively harmless because 
of their chemical stability, are bioactivated to products ultimately responsible for the 
observed toxic effects. In the present study this model approach is extended to a range of 
chlorinated benzene congeners with the ultimate aim of identifying metabolic activation 
pathways which are relevant from a toxicological point of view. Knowledge on the 
different pathways by which a chemical can be metabolised into reactive products increases 
our understanding of the relationship between the chemical structure of xenobiotics and 
their effects on living systems. Moreover, such knowledge will be helpful in identifying 
chemical groupings in a given molecule, which predispose that molecule to a sequence of 
processes which might eventually lead to toxicity. 
Biotransformation reactions 
Organisms are constantly exposed to a large number of xenobiotics (i.e., chemicals 
foreign to the body), such as drugs, pesticides, natural food constituents, food additives 
and industrial chemicals. Unlike bacteria, many of which are capable of degrading and 
utilising a broad range of chemicals as carbon and energy source (Reineke and Knackmuss, 
1984; Schraa et al., 1986), animals have evolved ways for elimination of the chemical 
rather than utilisation. Most xenobiotics are lipophilic and would remain in the body 
indefinitely were it not for metabolism resulting in more water soluble derivatives. This 
process of biotransformation is regulated by several enzyme systems (Table 1.1), which 
can be conveniently divided into two classes, referred to as Phase I and Phase II enzymes. 
Phase I enzymes catalyse so-called 'transformation' reactions, which introduce or unmask 
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a polar functional group (e.g., -OH, -NH2, -SH) in lipophilic molecules through oxidation, 
reduction or hydrolysis. These functional groups can then be used to append other small 
endogenous moieties such as glutathione, glucuronic acid or sulphate in Phase II 
metabolism ('conjugation' reactions). In this fashion, lipophilic xenobiotics can, in 
principle, be transformed into more water soluble products capable of being excreted from 
the body (Sipes and Gandolfi, 1986). 
Biotransformation of xenobiotics predominantly occurs in the liver, although in the last 
decade considerable interest has developed into extrahepatic biotransformation. The major 
tissues of extrahepatic metabolism are those involved in absorption and excretion of 
chemicals, such as lung, kidney, skin and gastrointestinal mucosa (Gram et al., 1986; Dahl 
and Hadley, 1991; Kaminski and Fasco, 1992). 
An interesting feature of biotransformation enzymes is the fact that their activities can 
be enhanced or depressed following treatment of organisms with a variety of chemicals. 
This may consequently alter the pharmacological or toxicological response, not only of the 
compound itself, but also of other chemicals and drugs. Studies on induction and inhibition 
have mostly been concerned with the cytochromes P450, and pretreatment of rodents with 
known P450 inducers (or inhibitors) is often used as a tool to unravel metabolic activation 
pathways of chemicals. However, it should be realized that many compounds which induce 
P450 enzymes also induce Phase II enzymes. For example, pretreatment of rats with 
phénobarbital (PB) or 3-methylcholanthrene (3-MC) not only increases the activity of P450 
(major isoenzymes P450IIB1 and P450IA1, respectively), but also of epoxide hydrolase 
(Oesch, 1972), UDP-glucuronyltransferase (Owens, 1977) and glutathione 5-transferase 
(Vos et al., 1988). The enzyme-inducing potential of a compound needs not necessarily to 
be classified as a toxic event, but can also be regarded as an adaptive response of the 
organism in its struggle for survival in a chemically-complex world. 
Cytochrome P450: general aspects 
The cytochrome P450 monooxygenase system plays a crucial role in the 
biotransformation of numerous substrates of both exogenous (such as drugs and pesticides) 
and endogenous origin (such as steroids and fatty acids) (Wislocki et al, 1980). Although 
classified as an oxygenase, conditions of low oxygen tension may favor cytochrome P450 
mediated reductive biotransformation of xenobiotics like haloalkanes, nitroaromatics or 
azodyes (Sipes and Gandolfi, 1986). Cytochrome P450 is incorporated in the 
endoplasmatic reticulum in combination with an electron donating system consisting of the 
haemprotein cytochrome b5, and the flavoproteins NADPH-cytochrome P450 reductase 
and cytochrome b5 reductase. The catalytic site contains a haem prosthetic group, whose 
ferrous-carbon monoxide complex exhibits an absorption maximum near 450 nm relative to 
the complex without carbon monoxide (Omura and Sato, 1964). 
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Table 1.1 Major enzymes involved in the biotransformation and bioactivation of xenobiotics. 
Enzyme 
(Action) 
Phase I 
Cytochrome P450 
aliphatic C-oxidation 
aromatic C-oxidation 
Ak>xidation 
5-oxidation 
reduction 
Flavin monooxygenase 
N-oxidation 
5-oxidation 
Substrate 
hexane 
aflatoxin B, 
acetaminophen 
parathion 
carbon tetrachloride 
halothane 
MPTP 
thioacetamide 
Reactive 
metabolite 
diketone 
8,9-oxide 
benzoquinone 
imine 
paraoxon 
radical 
radical 
MPP+ 
sulfene, sulfine 
Reference 
Couri and Milks, 
1982 
Swenson et al., 1977 
Van der Straat et al, 
1988 
Neal and Halpert, 
1982 
Micoet al., 1982 
Pohl and Gillette, 
1984 
Markey etal. , 1984 
Hanzliketal., 1980 
Phase II Conjugation with 
Epoxide hydrolase H20 
GSH Glutathione S-
transferase 
Glucuronyl-
transferase 
Sulfotransferase 
N-methyl 
transferase 
benzo[a]pyrene-
7,8-oxide 
1,2-dibromoethane 
tetrafluoroethylene 
UDPGA 2-naphtylamine 
PAPS N-hydroxy-2-acetyl 
aminofluorene 
SAM 4,4'-bipyridinium 
diolepoxides 
thiiranium ion 
fluorothiono-
acylfluoride 
hydroxylaminea 
nitrenium ion 
paraquat 
Oesch and 
Guenthner, 1983 
Van Bladeren et al, 
1980 
Commandeur et al., 
1989 
Young and Kadlubar, 
1982 
Van den Goorbergh 
etal. , 1985 
Ansher and 
Jakoby, 1990 
Abbreviations: GSH, glutathione; H20, water; MPTP, l-methyl-4-phenyltetrahydropyridine; 
MPP+, l-methyl-4-phenyl pyridinum ion; PAPS, 3'-phosphoadenosine 5'-phosphosulfate; 
SAM, S-adenosyl-L-methionine; UDPGA, uridine 5'-diphosphoglucuronic acid. " proximate 
reactive metabolite. 
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Table 1.2 Nomenclature and characteristic reactions catalysed for the major inducible forms of 
cytochrome P450. 
Inducer 
Polycyclic aromatic 
hydrocarbons 
Cytochrome P450 
Sub- Iso-
family enzyme 
IA 1 
2 
Species 
rat, human", 
rabbit, mouse 
rat, human, 
rabbit, mouse 
Characteristic reaction(s) catalysed 
7-ethoxyresorufin O-deethylase, 
benzo[a]pyrene hydroxylase 
phenacetin O-deethylase, 
caffeine 3-demethylase, 
4-aminobiphenyl iV-hydroxylase 
Phénobarbital IIB rat 
Ethanol, acetone 
Glucocorticoids, 
Macrolide antibiotics 
HE 
IIIA 
2 
4 
1 
1,2 
3,4 
5 
6 
7 
rat 
rabbit 
rat, human 
rabbit 
rat 
human 
human 
rabbit 
human 
(foetal) 
7-pentoxyresorufin O-deethylase, 
7,12-DMBA 7-methyl hydroxylase 
7,12-DMBA 12-methyl hydroxylase 
benzphetamine A'-demethylase 
aniline 4-hydroxylase 
nitrosodimethylamine 
N-demefhylatase 
testosterone 6ß-hydroxylase 
cyclosporin A'-demethylase, 
nifedipine dehydrogenase, 
testosteron 6ß-hydroxylase 
testosteron 6ß-hydroxylase 
erythromycin A'-demethylase 
dehydroepiandrosterone 
3-sulphate 16<x-hydroxylase 
Peroxisome 
proliferators 
IVA rat lauric acid w-hydroxylase 
References: George and Farrell, 1991; Murray and Reidy, 1990; Gonzalez, 1989; Wrighton et 
ai, 1985; Guengerich and Shimada, 1991; Okey, 1990. a mainly extrahepatic. 
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Multiplicity of cytochrome P450 
While mammalian cytochrome P450 was originally believed to exhibit a remarkable 
lack of substrate specificity, it is now apparent that the diversity of oxidative reactions 
towards both endogenous and foreign compounds lies in the multiplicity of the P450 
proteins (Table 1.2). With the purification, isolation, and characterization of multiple 
forms of cytochrome P450 in the last decades (Ryan and Levin, 1990; and references cited 
therein), the need for a unified classification became apparent. In 1987, Nebert and co-
authors introduced a systematic nomenclature in which individual P450 proteins are 
assigned into families or subfamilies based on the extent of structural homology (i.e., 
amino acid sequences)1. This rationale has since then been widely accepted and updates of 
this classification have already been published (Nebert et al., 1989; 1991). The major 
advantage of this unified nomenclature is that structurally similar P450's are easily 
recognized, regardless of the species, the inducer or the catalytic activity examined. 
Regulation of the cytochrome P450 isoenzymes after exposure to chemical agents is 
primarily the consequence of changes in the levels of P450 apoprotein. Elevation of P450 
protein levels generally involves increased transcription of the P450 gene, resulting in 
elevated levels of specific mRNAs as in the case of induction of P450IA1 by 2,3,7,8-
tetrachlorodibenzodioxin or 3-methylcholanthrene (Poland et al, 1987), P450IIB1/IIB2 by 
phénobarbital (Atchison and Adesnik, 1983), P450IIIA1 by dexamethasone (Simmons et 
al, 1987), and P450IVA by Clofibrate (Hardwick et al, 1987). In addition, regulation of 
some P450s occurs by a post-transcriptional mechanism, resulting in elevated mRNA levels 
without increased transcription as described for P450IA2 (Pasco et al, 1988). Post-
transcriptional regulation at the protein level (through stabilization of the protein against 
degradation) is observed with the ethanol/acetone inducible P450IIE1 (Song et al, 1989) 
and the glucocorticoid-responsive P450IIIA1/2 (Watkins et al, 1986). 
General features of catalysis 
The catalytic mechanism of cytochrome P450 mediated oxidation is depicted in Figure 
1.1. Extensive reviews have been published concerning the most recent insights into 
reductive activation of molecular oxygen and incorporation of the reactive oxygen species 
into the substrate (Mansuy et al, 1989; White, 1991; Guengerich and MacDonald, 1984; 
1990). Binding of the substrate to the oxidized form of P450 (step 1) facilitates the uptake 
of the first electron donated by the flavoprotein NADPH cytochrome P450 reductase (step 
1
 Those P450 proteins derived from genes with > 40 % sequence identity are included in 
the same family (indicated by a Roman numeral); those from genes with >55 % sequential 
homology are included in the same subfamily (indicated by a capital letter). The individual 
gene products are indicated by an Arabic numeral (Nebert et al, 1987). 
13 
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2) (Backes and Eyer, 1989). The substrate-cytochrome P450 complex combines with 
molecular oxygen (step 3), followed by the uptake of a second electron, preferentially via 
NADPH cytochrome P450 reductase, but in some instances also via cytochrome b5 (step 
4). However, before introduction of the second electron, decomposition of the oxycomplex 
may occur, resulting in the formation of superoxide anion ("oxidase" activity of 
cytochrome P450; step 8) (Kuthan and Ullrich, 1982). Details regarding the next step are 
still not precisely understood, but involve cleavage of the O-O bond, reduction of one 
oxygen atom to a water molecule, and the generation of an activated iron-oxene 
intermediate (step 5). Finally, oxygen insertion into the substrate (step 6) is believed to 
result from two sequential one-electron transfers (Guengerich and MacDonald, 1984; 
1990). Depending on its structure, the substrate is activated via hydrogen abstraction, 
electron removal from a heteroatom or radical addion of the iron-oxene species to a double 
bond. The oxidation process is then completed by radical recombination reactions. The 
NADPH e 
cytochrome P450 - « — NADPH 
reductase 
\ cytochrome b5 
NADH 
cytochrome b5 
reductase 
NADH 
Figure 1.1 Catalytic cycle of substrate oxidation by cytochrome P450. [Fe] represents the 
haem group in the active site involved in the reductive activation of molecular oxygen. [S] 
denotes the substrate to be oxidized, [SO] represents the oxidized substrate. For further 
explanation, see text. 
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oxidized substrate diffuses out of the enzyme {step 7) and a new catalytic cycle can be 
repeated with fresh substrate. Alternatively, peroxycompounds like alky Hydroperoxides 
(Nordblom et al., 1976), sodium periodate and -chlorite (Hrycay et al., 1976), and 
iodosylbenzene derivatives (Gustafsson et al., 1979) may serve as both oxygen and 
electron donor {step 9), and thus substitute molecular oxygen and NADPH in the 
cytochrome P450 mediated oxidation. 
Conjugation enzymes: general aspects 
Phase I biotransformation reactions are usually followed by phase II reactions to ensure 
rapid elimination from the organism. Conjugation enzymes attach a strongly polar group to 
a substrate with a suitable functional group (either a product of Phase I biotransformation, 
a xenobiotic which already possesses such a moiety, or an endogenous compound such as 
steroid hormones and bile acids). Like Phase I enzymes, Phase II enzymes are widely 
distributed among organisms, and can be found in many tissues including the liver, kidney, 
lung and intestinal mucosa. Pronounced species differences in conjugation reactions exist, 
which appear to be associated with evolutionary development. For example, the cat has a 
defective glucuronidation pathway, whereas the dog lacks the enzyme arylamine //-acetyl 
transferase and the pig is deficient in sulfation (Sipes and Gandolfi, 1986; Williams, 1975). 
Conjugation of nucleophilic substrates 
The most common reaction of nucleophilic substrates is the conjugation with uridine 5'-
diphosphoglucuronic acid (UDPGA), catalysed by UDP-glucuronosyltransferase (GT). 
Numerous endogenous and exogenous compounds may serve as substrates, provided they 
have sufficient lipophilic character and possess functional group(s) of a nucleophilic nature 
such as alcohols, carboxylic acids, primary and secundary amines, and free sulhydryl 
groups. The resulting products are O-, N- or 5-glucuronides. In addition, certain 
nucleophilic carbon atoms have been shown to form C-glucuronides, such as carbon atoms 
with 2 neighbouring carbonyl groups, or ethynilic carbons (Abolin et al, 1980). An 
interesting aspect is the ability of man and monkey but not rodents to glucuronidate tertiary 
amine drugs to form quaternary ammonium glucuronides (Mulder et al., 1990). Depending 
on the size of the substrate, glucuronides are excreted into bile (MW > 350 Da) or urine 
(MW <250 Da) (Sipes and Gandolfi, 1986). In man, urinary excretion seems to be 
favored over biliary excretion (Klaassen and Watkins, 1984). 
GT's are localized in the endoplasmatic reticulum. Multiple forms have been observed 
in most species, with overlapping substrate selectivity. Many GT's catalyse the conjugation 
of more than one xenobiotic, and vice versa, many xenobiotics are substrates for more 
15 
General introduction 
than one isoenzyme of GT. To date, 11 rat liver isoenzymes have been identified, of which 
some show activity exclusively towards endogenous substrates (3a-hydroxy steroid GT, 
bilirubin GT), or exclusively towards exogenous substrates (4-nitrophenol GT) and others 
towards both endo- and exogenous substrates (17ß-hydroxysteroid GT) (Mulder et al., 
1990). 
A similarly important conjugation reaction for nucleophilic groups is the conjugation 
with inorganic sulfate (3'-phosphoadenosine 5'phosphosulfate, PAPS), catalysed by the 
cytosolic sulfotransferases (ST). Classification of ST's is based on the nature of the 
substrate and its functional moiety: alcohol sulfotransferases (aliphatic primary and 
secundary alcohols), phenol sulfotransferases (phenolic substrates) and amine N-
sulfotransferase (aliphatic and aromatic amines). However, it should be realized that the 
various isoenzymes display a broad substrate selectivity, i.e., hydroxylamines may serve as 
substrates of phenol ST, and phenols and hydroxysteroids may act as substrates of amine 
ST (Mulder and Jakoby, 1990). Sulfate conjugates are mainly excreted in urine (Mulder et 
al., 1985). After biliary excretion, both glucuronide and sulphate conjugates may be 
hydrolyzed by ß-glucuronidase and arylsulphatase in the gut, and the aglycone may be 
taken up again (enterohepatic circulation). 
Since many substrates of sulfation can also be glucuronidated, there is competition 
between these two pathways. In addition, O-methylation of certain substrates such as 
catechols (catalysed by catechol O-methyl transferase ) may also compete (Thakker and 
Creveling, 1990). In general, the sulfation pathway has a higher affinity (lower Km) for 
the same substrate than the glucuronidation pathway. In contrast, glucuronidation has a 
higher capacity. Thus, in general, at low substrate concentration sulfation is the 
predominant route, whereas at high substrate concentration glucuronidation is (Mulder and 
Jakoby, 1990). 
Conjugation of electrophilic substrates 
Electrophilic centres in a xenobiotic, e.g., alkylating anticancer drugs, or its metabolite, 
e.g., arene oxides, may be conjugated with glutathione (7-glutamyl cysteinyl glycine, 
GSH). Although these reactions have spontaneous rates which vary considerably depending 
on the reactivity of the electrophile, conjugation with GSH is usually catalysed by the GSH 
S-transferases (GST). The glutathione conjugates are then transported to the kidney and 
converted into the corresponding mercapturic acids by a series of enzymatic processes: 
removal of the 7-glutamic acid and of glycine by 7-glutamyl transpeptidase and cysteinyl-
glycine dipeptidase, respectively, followed by acetylation of the residual cysteine moiety by 
iV-acetyltransferase (Sipes and Gandolfi, 1986). 
The GST's are a family of isoenzymes with broad and overlapping substrate selectivity. 
Although membrane-bound forms of GST have been detected (Morgenstern et al., 1988), 
16 
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GST activity is mainly located in the cytosol. GST's are dimers of subunits and within a 
dimer, each subunit functions independently of the other (Mannervik and Jensson, 1982). 
The GST's are now known to be a multi-gene family of isoenzymes, which can be divided 
into three classes (alpha, mu and pi), based on similarity in structural, physical and 
catalytic properties of their subunits (Ketterer and Mulder, 1990; Vos and Van Bladeren, 
1990). 
In addition to their crucial role in catalyzing glutathione conjugation, GST's may also 
be important in intracellular binding and/or transport of endogenous and xenobiotic non-
substrate ligands (Listowsky et al, 1988). 
Metabolites which contain a (usually) highly reactive, electrophilic epoxide moiety may 
undergo hydrolytic cleavage to less reactive vicinal dihydrodiols. This reaction is catalysed 
by the enzyme epoxide hydrolase (EH), which was first thought to be exclusively located 
in the endoplasmatic reticulum (microsomal epoxide hydrolase, mEH; Oesch, 1972). In 
later studies on the mammalian metabolism of certain alkyl epoxides, the existence of a 
cytosolic EH (cEH) was demonstrated (Gill et al, 191 A). The two forms of EH have 
complementary substrate specificity to some extent, in that many epoxides, e.g., arene 
oxides, which are good substrates for mEH are poor substrates for cEH, and vice versa, 
e.g., rrans-disubstituted oxiranes are good substrates for cEH but not for mEH (Hammock 
and Hasagawa, 1983). More recent studies have pointed to the fact that the common 
nomenclature of 'microsomal' and 'cytosolic' epoxide hydrolase is not semantically 
precise: metabolic and immunochemical studies demonstrated the existence of membrane-
bound forms of cEH (Guenthner and Oesch, 1983), whereas mEH-like activity was 
detected in cytosolic fractions of human tissue (Schladt et al, 1988). Therefore, a revision 
of the nomenclature for EH is desirable, e.g., based on a system of unique identifiers for 
each isoenzyme such as the currently accepted P450 nomenclature. 
Bioactivation 
Although most xenobiotics are converted in the body to metabolites that are less toxic 
than the parent compound ('detoxication'), it has become increasingly clear that many 
toxicological effects of xenobiotics are mediated through the formation of reactive 
metabolites ('toxication', 'metabolic activation' or 'bioactivation'). Bioactivation of 
chemicals is now known to be catalysed by almost all of the enzymes involved in the 
process of biotransformation (cf. Table 1.1). For example, the conjugation of 
dibromoethane with glutathione catalysed by GSH S-transferase results in the formation of 
a reactive thiiraniium ion (Van Bladeren et al, 1980), responsible for the carcinogenicity 
of the parent compound in rats and mice. Glucuronidation of certain N-hydroxy arylamines 
generates proximate carcinogens and provides a means of transportation to the bladder, 
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where they are converted to the ultimate carcinogenic species (Kadlubar et al., 1977). The 
sulfate conjugate of iV-hydroxy-2-acetylaminofluorene is converted to a reactive nitrenium 
ion, which binds to cellular macromolecules and induces hepatocarcinogenicity (Mulder 
and Jakoby, 1990). However, the majority of bioactivation reactions involve oxidation, 
which largely can be attributed to the action of cytochrome P450. Oxidation of 
(halogenated) hydrocarbons to reactive carbonyl compounds, epoxidation of polycyclic 
aromatic hydrocarbons to (diol-) epoxides, and N-oxidation of aromatic amines to 
hydroxylamines (and -esters) are just several model reactions of the many mechanisms of 
bioactivation known to date. These reactions have been reviewed in more detail elsewhere 
(Guengerich and Liebler, 1985; Guengerich and Shimada, 1991; Van Bladeren, 1988). 
A number of key steps can be distinguished in the general mechanism responsible for 
the effect caused by a given compound in a given cell. Most molecules offer several 
primary regions of attack to biotransformation enzymes. Depending on the concentration of 
the various enzymes in a particular cell, the extent of formation of the reactive 
intermediate may be influenced, and thus also the extent of the toxic effect. A reactive 
intermediate usually has electrophilic properties and will react with nucleophilic sites in 
cellular macromolecules. Membranes, nucleic acids and proteins are obvious targets. 
Depending on the properties of the electrophiles, certain sites will be favored. One of the 
most successful theories in this respect is the theory of 'Hard and Soft Acids and Bases' 
(Pearson and Songstad, 1967). This theory predicts that hard electrophiles (low 
polarizibility and small atomic radii) will preferentially react with hard nucleophiles, while 
the soft species (high polarizibility and relatively greater atomic radii) will also react best 
with each other. 
However, detoxication reactions will compete with the reaction of the reactive 
intermediate with tissue macromolecules, and convert them to harmless metabolites that are 
eliminated from the body. For epoxides, for instance, epoxide hydrolase as well as the 
GSH S-transferases are of major importance in their detoxication. For other electrophiles, 
in addition to the GSH 5-transferases, glutathione itself and sometimes amino acids such as 
methionine constitute a first line of defence. Again, depending on both exogenous, e.g., 
nutritional, as well as endogenous factors, e.g., differentiation status, organ, genetic 
deficiencies, the relative concentration of activating and detoxifying enzyme systems may 
vary, with a concomitant variation in the extent of toxicity. Ultimately, the balance 
between formation and detoxication of the reactive intermediate will determine whether it 
can elicit its toxic effect. 
18 
Chapter 1 
Halogenated benzenes: occurrence in the environment 
Halogenated benzenes have long been of concern regarding the possible toxic 
consequences of human exposure, due to their ubiquitous environmental distribution and 
their tendency for bioaccumulation in animal and human tissue. Virtually all chlorinated 
benzenes have been found in the various waterbodies (Oliver and Nicol, 1982), and reports 
on the presence of residues in human fat and milk have indeed been published (Mes et al., 
1986; Wagner et al, 1991). 
Chlorine-substituted benzenes represent by far the most important group, with 
widespread economical use as chemical intermediates in industry, and among others, as 
solvents, dye carriers, space deodorants and moth repellents. Input into the ecosystem 
results primarily from industrial and municipal waste water and agricultural runoff, with 
additional input of chlorinated phenols and benzenes by chlorination treatment processes 
(Deichmann, 1982). Natural sources of chlorinated benzenes in the environment have not 
been identified. A considerable body of data is nowadays available on their consequences 
of (sub-)chronic exposure or on reproductive and teratologic effects in laboratory animals, 
although for several isomers there are still large data gaps to fill before accurate risk 
estimates can be made. 
Metabolism of chlorinated benzenes 
Table 1.3 gives a summary of the main studies on the biotransformation of chlorinated 
benzenes. For a more extensive overview, the reader is referred to documents drawn up by 
the United States Environmental Protection Agency (US EPA, 1985) or the World Health 
Organization (WHO, 1987). Some general remarks can be made. Biotransformation of the 
higher substituted congeners (tetra-, penta-, hexa-) is slower and a greater proportion of 
the compound is excreted unchanged in the faeces or expired air compared to the mono-
and di-substituted congeners, although variation in kinetic behaviour is observed for the 
different isomers of the same congener (cf. metabolism of tetrachlorobenzene isomers; Chu 
et al., 1984b). Considerable species variation exists both in qualitative and quantitative 
sense (cf. metabolism of 1,2,4-trichlorobenzene in the rat and monkey; Lingg et al., 
1982). This interspecies variation in metabolism could very well reflect differences in the 
relative concentration of the various (iso-)enzymes involved. However, with the exception 
of bromobenzene and hexachlorobenzene, there is a huge lack of detailed in vitro 
metabolism studies of halogenated benzenes, which would help assess the relative 
contribution of the various (iso-)enzymes to the overall metabolism. Ultimately, 
interspecies variation in metabolism could have toxicological implications. For example, 
extensive studies on the microsomal metabolism of bromobenzene revealed the existence of 
a toxic route to /j-bromophenol (catalysed by P450IIB1) and a non-toxic route to o-
bromophenol (catalysed by P450IA1) (Lau et al, 1980). 
19 
General introduction 
Table 1.3 Main results of studies on distribution and metabolism of chlorinated benzenes. 
Compound 
(Reference) 
Species; 
Study Protocol 
Results 
MCB 
(Lindsay Smith 
etal., 1972) 
Dutch rabbit (9); 
oral gavage of 0.5 g 
[14C]MCB twice daily for 
4 consecutive days. 
Collection of excreta for 
7 days 
After 7 days, 19.6% of the total dose was 
excreted into urine, 1.5% into faeces and 
< 1% was found in tissues. Urinary 
metabolites were glucuronides (33.6%), 
sulphates (33.9%), mercapturic acids 
(23.8%), MCP (2.8%, p > m > o ) , 
diphenols (4.2%), 3,4-dihydro-3,4-
dihydroxychlorobenzene (0.6%). 
MCB 
(Sullivan 
etal., 1983) 
Sprague-Dawley rat (d); 
inhalation of 100, 400 or 
700 ppm for 1 or 5 days 
All tissues contained radioactivity 
immediately following single exposure 
and at 48 hr post-exposure with highest 
levels in fat. Disproportionate increase in 
respiratory elimination of parent 
compound and dose-dependent decrease in 
mercapturic acid percentage of urinary 
metabolites from 68% at 100 ppm to 51% 
at 700 ppm. 
1,3-DCB 
(Parke & 
Williams, 1955) 
Chinchilla rabbits; 
oral gavage of 0.5 g/kg 
in olive oil 
Elimination of 1,3-DCB was virtually 
complete in 5 days. Metabolites consisted 
of 2,4-DCp-mercapturic acid (minor), and 
sulphate and glucuronide conjugates of 
2,4-DCP (major), 3,5-DCP and 3,5-
DCC. 
1,4-DCB 
(Kimura 
etal, 1979) 
Wistar rat (<?); 
oral gavage of 200 or 
800 mg/kg in corn oil 
At 1 hr post-dosing, levels in fat were 
lOx blood levels. Levels in fat, kidney, 
liver and lung peaked between 6-12 hr 
and were below detection limit at 48 hr in 
all tissues except fat (still detectable at 
120 hr). Major metabolite was 2,5-DCP 
(conjugated), whereas trace amounts of 
methyl sulfoxide and methyl sulphone 
metabolites were identified. 
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Compound 
(Reference) 
Species; 
Study Protocol 
Results 
1,3-DCB 
(Kimura 
etal., 1984) 
Wistar rat (d); 
oral gavage of 200 mg/kg 
in corn oil 
Absorption and elimination rates of 1,3-
DCB were greater than of 1,4-DCB and 
concentration in fat was lower. Sulfur 
containing metabolites were detected in 
blood and excreta: 2,4-/ 3,5- DCp-
methylsulfoxides/ -sulphones; 2,4- and 
3,5-DCp-mercapturic acids were excreted 
into urine to a considerable extent. 
1,4-DCB, 
1,2-DCB 
(Azouz 
etal., 1955) 
Chinchilla rabbits; 
oral gavage of 0.5 g/kg 
in olive oil (1,4-DCB) or 
in water (1,2-DCB) 
Elimination of 1,2-DCB was complete in 
5-6 days post-dosing, whereas excretion 
of metabolites of 1,4-DCB was still 
appreciable after 6 days. Major 
metabolites of 1,2-DCB were sulphate and 
glucuronide conjugates of 3,4-DCP; 
minor metabolites of 1,2-DCB: conjugates 
of 2,3-DCP, 3,4-DCC and 4,5-DCC, and 
3,4-DCp-mercapturic acid. Metabolites of 
1,4-DCB were 2,5-DCP (major) and 
DCHQ (minor). 
1,4-DCB 
(Hawkins 
etal., 1980) 
CFY rat (5); 
inhalation of 1000 ppm 
[14C] 1,4-DCB, 3 hr/day 
for 10 days. P.O. and s.c. 
administration of 250 
mg/kg for up to 10 days. 
Single exposure (1000 
ppm inn., 250 mg/kg 
p.o. or s.c.) to bile-duct-
cannulated rats 
Tissue concentrations at 24 hr were 
similar for all routes of exposure with 
highest levels in fat, and to a lesser extent 
in kidney, liver and lung. Excretion of 
1,4-DCB was primarily into urine (91-
97%), and was complete in 5 days. Bile 
contained 46-63 % of excreted compound 
at 24 hr. Major metabolites were 2,5-
DCPsulphate (46-54%) and -glucuronide 
(31-34%). Minor metabolites were DCHQ 
and a mercapturic acid. 
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Compound 
(Reference) 
Species; 
Study Protocol 
Results 
1,2,3-TRICB 
1,2,4-TRICB 
1,3,5-TRICB 
(Jondorf 
et al, 1955) 
Chinchilla rabbit; 
oral gavage of 0.5 g/kg 
in arachis oil 
Rate of metabolism: 1,2,3- > 1,2,4- > 
1,3,5-TRICB (at 5 days post-dosing, 
62%, 38%, 23% excreted as phenolic 
conjugates, respectively). 
Major metabolite of 1,2,3-TRICB was 
2,3,4-TRICP with small amounts of 
3,4,5-TRICP, 3,4,5-TRICC, 2,3,4-
TRICp-mercapturic acid. 
Major metabolites of 1,2,4-TRICB were 
2,4,5- and 2,3,5-TRICP with minor 
amounts of 3,4,6-TRICC, and 2,3,5-
/2,4,5-TRICp-mercapturic acid. 
2,4,6-TRICP was the only phenol 
detected in urine of 1,3,5-TRICB-treated 
animals, and unchanged compound was 
found in faeces. 
1,2,3-TRICB 
1,2,4-TRICB 
1,3,5-TRICB 
(Chu et al., 
1987) 
Sprague-Dawley rat (d); 
oral gavage of 10 mg/kg 
of each [14C]-labelled 
isomer in corn oil. 
Serial sacrifices at 
0.5, 1 and 24 hr, and 
after 2, 7, 14, 28 and 
56 days 
For all isomers, blood levels peaked 
between 2-4 hr post-dosing. Fat, skin and 
liver had high concentrations of parent 
compound, whereas kidney and muscle 
had high levels of metabolites. 95% and 
88% of the dose of 1,2,3- respectively 
1,3,5-TRICB was excreted after 48 hr. 
Faecal excretion amounted to more than 
1/3 of total excretion. 
1,2,4-TRICB 
(Lingg 
etal., 1982) 
Charles River albino 
rat (<J), 
Rhesus monkey (9); 
oral (p.o.) or 
intravenous (i.v.) 
administration of 10 
mg/kg [14C]-1,2,4-TRICB 
Excretion into urine and faeces at 24 hr 
post-dosing in rats amounted to 84% and 
11% (p.o.), and 78% and 7% (i.v.), 
respectively. Urinary metabolites were 
2,3,5-/2,4,5-TRICp-mercapturic acid 
(60%), 2,3,5-/2,4,5-TRICthiophenol 
(33%) and 2,3,5-/ 2,4,5-TRICP (1-10%). 
- continued -
22 
Chapter 1 
Compound 
(Reference) 
Species; 
Study Protocol 
Results 
1,2,4-TRICB 
continued 
Excretion into urine at 24 hr postdosing 
in monkeys was 40% (p.o.) and 22% 
(i.V.), with < 1% in faeces for both 
routes. Urinary metabolites consisted of 
glucuronides of 3,4,6-TRIC-3,5-cyclo-
hexadiene-l,2-diol (both isomers, 48-
61%) and of 2,3,5-/2,4,5-TRICP (14-
37%), and free TRICP (1-37%). 
1,2,4-TRICB 
(Tanaka 
etal., 1986) 
Wistar rat (c?); 
oral gavage of 50 mg/kg 
[14C]-1,2,4-TRICB 
66% and 17% were excreted into urine 
and faeces, respectively, in 7 days; 2,1% 
was exhaled as DCB and unchanged 
compound. Tissue residues were evenly 
distributed with the exception of higher 
concentrations in fat. Major metabolites in 
urine were free 2,4,5- and 2,3,5-TRICP 
and their conjugates. Minor metabolites 
were 5- or 6-sulhydryl-, methylthio-, 
methylsulfoxide and methylsulphone 
products. 
1,2,3,4-TCB 
Sprague-Dawley rat (d); 
oral gavage of 10 mg/kg 
of the [14C]-labelled 
isomers in corn oil 
1,2,3,5-TCB 
XX 
1,2,4,5-TCB 
(Chu et al., 
1984b) 
For 1,2,3,4- and 1,2,3,5-TCB, 46-51% of 
the doses was excreted into urine and 
faeces within 48 hr, which increased 
slightly to 51-55% of the dose within 7 
days. Only 8% of the dose of 1,2,4,5-
TCB was excreted, increasing to 21% in 
7 days. 1,2,3,4-TCB yielded 2,3,4,5- and 
2,3,4,6-TCP, and traces of TCthiophenol 
and 2,3,4-TRICP. 
1,2,3,5-TCB yielded 2,3,4,6-TCP, iso-
meric hydroxy-TRICthiophenols, and a 
TRICP. 
1,2,4,5-TCB yielded 2,3,5,6-TCP, TCHQ 
and a TRICP. 
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Compound 
(Reference) 
Species; 
Study Protocol 
Results 
1,2,3,4-TCB 
1,2,3,5-TCB 
1,2,4,5-TCB 
(Kohli et al., 
1976) 
rabbit (d); 
i.p. injection of 300 mg 
in vegetable oil. 
Collection of excreta 
for 10 days 
1,2,3,4-TCB was the most extensively 
metabolised isomer, yielding 2,3,4,5-TCP 
(major) and 2,3,4,6-TCP (minor). 
1,2,3,5-TCB was metabolised to 2,3,4,5-, 
2,3,5,6- and 2,3,4,6-TCP. 1,2,4,5-TCB 
yielded only 2,3,5,6-TCP. 
1,2,3,4-TCB 
1,2,3,5-TCB 
1,2,4,5-TCB 
XX 
(Schwartz et al., 
1987) 
Squirrel monkey (a); 
oral gavage of 50 mg/kg 
or 100 mg/kg of the 
[14C]-labelled isomers in 
corn oil, twice per week 
over 3 wk 
1,2,3,4-TCB was eliminated mainly, and 
1,2,3,5- and 1,2,4,5-TCB exclusively, in 
the faeces. Parent compound accounted 
for 50% (1,2,3,4- and 1,2,3,5-TCB) and 
> 99% (1,2,4,5-TCB) of total faecal 
radioactivity. Major faecal metabolites of 
1,2,3,4-TCB were 2,3,4,5-TCP (22%) 
and 2,3,4,5-TCp-mercapturic acid (18%). 
Major faecal metabolites of 1,2,3,5-TCB 
were TCP isomers (14%, 9% and 2% for 
2,3,4,6-, 2,3,5,6-, 2,3,4,5-TCP) and 
2,3,4,6-TCp-sulfinic acid (15%). 
Urinary metabolites of 1,2,3,4-TCB were 
2,3,4,5-TCP (15%) and 2,3,4,5-TCp-
mercapturic acid. 
PCB 
(Kohli etal., 1976) 
rabbit (â); 
i.p. injection of 300 mg 
in vegetable oil. 
Collection of excreta over 
10 days 
Urinary metabolites were 2,3,4,5-TCP 
and PCP, both detected at 1 % of 
administered dose after 10 days post-
dosing. 
PCB 
(Koss& 
Koranski, 1977) 
rat (2); 
i.p. injection of 403 
jimol/kg in olive oil. 
Collection of excreta for 
4 days 
Only 3% of dose was eliminated in 
unchanged form in faeces. Metabolites 
excreted both in urine and faeces included 
PCP (9%), 2,3,4,5-TCP, hydroxy-
2,3,4,5-TCthiophenol, and traces of 
another isomer of TCP. TCHQ was only 
detected in urine. 
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Compound 
(Reference) 
Species; 
Study Protocol 
Results 
PCB 
(Rozman 
etal, 1979) 
Rhesus monkey (â, 9); 
oral gavage of 0.5 mg/kg 
Absorption was at least 95%. Faecal 
excretion (99% parent compound) was 
about twice the amount of the urinary 
excretion. After 40 days following a 
single dose, total excretion amounted to 
40.2% and 33.2% for d and 9 monkeys, 
respectively. Highest residual 
concentration in fat and bone marrow, 
followed by lymph nodes, thymus, 
adrenal cortex and large intestine. Urinary 
metabolites were PCP > 2,3,4,5-TCP > 
2,3,5,6-TCP. No sex related differences 
in metabolism. 
HCB 
(Koss 
etal., 1976) 
Wistar rat (2); 
i.p. injection of of 
repeated single dosis of 
130 mg/kg in olive oil 
(total dose 390 mg/kg) 
After 28 days, 7% and 27% of total dose 
was excreted in urine and faeces, 
respectively. 70% and <10% of total 
faecal and urinary radioactivity was 
excreted as parent compound. Major 
metabolites in urine were PCP, TCHQ, 
PCthiophenol, and minor metabolite was 
TCthiophenol. PCP and PCthiophenol 
were the only 2 faecal metabolites. 
HCB 
(Koss 
etal, 1978) 
Wistar rat (9); 
oral gavage of 50 mg/kg 
(i.e. 178 /imol/kg) in 
olive oil every other day 
for 15 weeks. Serial 
sacrifices every 3 wks 
An equilibrium between intake and 
elimination was reached after 9 weeks, 
with 1 g of liver containing 1 /xmol HCB, 
50 nmol PCP, 5 nmol TCHQ and 0.1 
nmol PCthiophenol. Concentration in fat 
was about 30-60 times higher. After 
cessation of administration, the rate of 
elimination of HCB decreased. 
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Compound 
(Reference) 
Species; 
Study Protocol 
Results 
HCB 
(Jansson & 
Bergman, 1978) 
Wistar rat (eî); 
two i.p. injections of 25 
mg/kg in peanut oil. 
Collection of excreta over 
12 days. 
The following sulfur metabolites of HCB 
were detected in excreta after methylation 
of the extracts: HCB > PCanisole > 
l,4-bis-(methylthio)-TCB > 
PCthioanisole. 
Abbreviations: see list of abbreviations; DC, dichloro-; PC, pentachloro-; TC, tetrachloro-; 
TRIC, trichloro-; capital "P" as in DICP denotes 'phenol', whereas lowcast "p" as in DICp-
mercapturic acid denotes 'phenyl' residu. 
Toxicity of chlorinated benzenes 
Table 1.4 presents an overview of the main studies on the toxicity of chlorinated 
benzenes. For an elaborate review of the toxicity of chlorinated benzenes, the reader is 
again referred to documents drawn up by foreign bodies (US EPA, 1985; WHO, 1987). 
Effects in rat are mainly confined to the liver, kidney, thyroid and lung. In mice, bone 
marrow also seems to be affected. Based on the sparse relevant data available it appears 
that, with the exception of hexachlorobenzene and 1,4-dichlorobenzene, there is little 
potential for progressive toxicity with chronic administration beyond that observed in the 
subchronic studies. The hepatocarcinogenic potential of hexachlorobenzene has been 
clearly demonstrated in rats, mice and hamster (Smith et al, 1985; Cabrai et al., 1977). 
Interestingly, tumours occurred predominantly in females. This coincides with the greater 
susceptibility of this sex to the induction of porphyria by hexachlorobenzene (see below), 
suggesting a link between these two manifestations of toxicity (Smith et al, 1985). The 
increased incidence of renal tumours in male rats but not in female rats after long-term 
oral administration of 1,4-dichlorobenzene (NTP, 1987) may very well be related to the 
induction of Protein Droplet Nephropathy and the resulting enhanced cell replication 
(Goldsworthy et al, 1988). 
Hexachlorobenzene is known for its strong porphyrinogenic action. However, in spite of 
all the efforts over the past decades, the mechanism of hexachlorobenzene-induced hepatic 
porphyria, which becomes manifest through the accumulation and excretion of porphyrins 
as a result of a disturbance of the haem synthesis by irreversible inhibition of the key 
enzyme uroporphyrinogen decarboxylase (UROG-D), has only been partially resolved (Van 
Ommen and Van Bladeren, 1989). Several lower chlorinated benzenes (1,4-
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dichlorobenzene, 1,2,4-trichlorobenzene, 1,2,3,4-tetrachlorobenzene) have also been 
reported to produce some increase in urinary porphyrin excretion (Rimington and Ziegler, 
1963), although an extremely high dose regimen was used and doubts were raised about 
the purity of the compound. Chronic feeding studies with lower doses failed to show the 
porphyrinogenic action of lower chlorinated benzenes (Carlson, 1977). 
Table 1.4 Main results of studies on the subchronic toxicity of chlorinated benzenes. 
Compound 
(Reference) 
Species; 
Study Protocol 
Effects 
MCB 
(Irish, 1963) 
Rat, rabbit, 
guinea pig; 
inhalation of 0 - 200 -
475 -1000 ppm, 7 h/d, 5 
d/wk, 32 exposures over 
44 days 
No effect at 200 ppm; slight increase in 
Li wt and slight LI histopathological 
changes at 475 ppm; at 1000 ppm, 
histopathological changes in LU, LI and 
KI. Growth depression and increase in 
mortality (guinea pig). 
MCB 
(Kluwe et al. 
1985) 
Fischer-344 rat (â,9) 
B6C3F, mouse (â,2); 
oral gavage in corn oil of 
0-60 - 125 - 250 - 500 -
750 mg/kg/d, 5 d/wk, 
13 wk 
Reduced survival and reduction in BW 
gain at >250 mg/kg. Dose-dependent 
increase in LI wt, centrilobular 
degeneration and necrosis; slight increase 
in KI wt, degeneration of proximal renal 
tubuli; slight decrease in SP wt, with 
lymphoid or myeloid depletion of TH, SP 
and BM at >250 mg/kg. At 500 mg/kg, 
increase in serum AP, 7-GT and liver 
porphyrin (rat), and polyuria and 
porphyrinuria (rat & mouse). 
1,2-DCB 
(Hollingsworth 
etal., 1958) 
rat, guinea pig (c?,2); 
inhalation of 0 -49 -93 
ppm, 5 h/d, 5 d/wk for 
6-7 months 
rat (2); oral gavage in 
olive oil of 0-18.8-188-
376 mg/kg/d, 5 d/wk, 
138 x in 192 days 
At 93 ppm, a significant decrease in BW 
(â rat), and decrease in SP wt (â guinea 
pig) was observed. No effect at 49 ppm. 
No effect observed on BW gain. 
Significant increase in LI and KI wt (at 
> 188 mg/kg) and decrease in SP wt (376 
mg/kg). No effects at 18.8 mg/kg. 
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Compound 
(Reference) 
Species; 
Study Protocol 
Effects 
1,2-DCB 
(Robinson 
etal, 1991) 
Sprague Dawley rat 
oral gavage in corn oil of 
0 - 37.5 - 75 - 150 - 300 
mg/kg/d (10 days); 
0 - 2 5 - 1 0 0 - 4 0 0 
mg/kg/d (90 days) 
300 mg/kg/d, (cf): decrease in final BW 
and organ weights (HE, KI, SP, TE, 
TH), and rel. organ weight (SP, TH). 
Increase in abs. and rel. LI weight; 
300 mg/kg/d, (9): decrease in abs. and 
rel. SP weight, and increase in abs.and 
rel. LI weight. Both sexes showed 
increase in water consumption, ALT, 
leukocyt count (c? only) and in incidence 
of LI necrosis (â only). In 90 d study, 
effects in the 400 mg/kg/d group were 
similar as those described above. In 
addition, 9 rat showed increase in abs. 
and rel. KI wt. LI damage was observed 
in both sexes. 
1,4-DCB 
(Hollingsworth 
etat., 1956) 
rat, guinea pig; 
inhalation of 0 - 96 - 158 
ppm, 7 h/day, 5 d/wk for 
157-199 days 
rat (9); 
oral gavage in olive oil of 
0 - 18.8- 188-376 
mg/kg/d, 5 d/wk, 138x 
in 192 days 
rabbit; 
oral gavage in olive oil of 
0 - 500 mg/kg/d, 5 d/wk, 
in 376 days; 1000 mg/kg, 
5 d/wk in 219 days 
Growth depression in guinea pig. Increase 
in LI wt (guinea pig, rat) and KI wt (rat). 
Cloudy swelling or granular degeneration 
in LI (rat, 158 ppm). No histopathological 
changes observed at 96 ppm. 
At 188 and 376 mg/kg, there was an 
increase in LI wt, KI wt, and a decrease 
in SP wt (376 mg/kg only). Slight 
cirrhosis and focal necrosis in LI at 
highest dose. 
Increase in mortality at 1000 mg/kg. BW 
loss, tremor and slight changes in liver 
(cloudy swelling, focal necrosis) were 
observed at both doses. 
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(Reference) 
Species; 
Study Protocol 
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1,4-DCB 
(Loeser and 
Litchfield, 1983) 
rat(<?,9); 
inhalation of 0 - 75 - 500 
ppm, 5 h/d, 5 d/wk for 
76 wk followed by 36 wk 
unexposed 
No increase in mortality. Increase 
observed in LI wt and KI wt at 500 ppm. 
Slight elevation of urinary protein and 
coproporphyrin output in 500 ppm group. 
No effects observed at 75 ppm. 
1,2,3-TRICB 
1,2,4-TRICB 
1,3,5-TRICB 
(Côte et al., 1988) 
Sprague Dawley rat 
oral in diet for 90 days, 
0 - 1 - 10 - 100 - 1000 
ppm 
1,2,3-TRICB: Growth suppression at 10 
or 1000 ppm; mild to moderate 
morphological changes in LI and THYR 
at 1000 ppm. 
1,2,4-TRICB: Increase in rel. LI and KI 
wt, and in microsomal enzyme activities 
at 1000 ppm; mild to moderate 
histological changes in LI and THYR at 
1000 ppm. 
1,3,5-TRICB: Moderate histological 
changes in KI, LI and THYR at 1000 
ppm; increase both in abs. and rel. LI and 
KI wt at 1000 ppm. No haematological 
changes. Male rat is more sensitive than 
female. Dose-dependent accumulation 
observed in LI and fat: 1,3,5- > 1,2,4-
> 1,2,3-TRICB. 
1,2,4-TRICB 
(Coate et al., 
1977) 
Sprague Dawley rat (d), 
New Zealand White 
rabbit (â), 
cynomolgus monkey (6); 
inhalation of 0 - 25 - 50 -
100 ppm, 7 h/d, 5 d/wk 
for 26 wk 
No effect on BW gain. No haematological 
or serum biochemical changes. In rat, 
mild hepatocytomegaly and non-dose 
dependent hepatocyte vacuolization was 
observed in addition to liver granulance, 
biliary hyperplasia, and hyaline 
degeneration in KI after 4 and 13 wk of 
exposure. No effects were observed after 
26 wk. No effects in rabbit or monkey 
after 26 wk. 
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Compound 
(Reference) 
Species; 
Study Protocol 
Effects 
1,2,4-TRICB 
(Kociba et al., 
1981) 
Sprague Dawley rat, 
New Zealand white rabbit 
Beagle dog (all d); 
inhalation of 0 - 30 - 100 
ppm, 7 hr/d, 5 d/wk, 
30 exposures in 44 days 
No effect on BW gain, hematologic and 
serum biochemical parameters. No 
histopathologic changes in tissues 
examined. Increased urinary excretion of 
porphyrins in rats (30 - 100 ppm). 
Increase in abs. LI wt (rat, 100 ppm), rel. 
LI wt (rat, dog, 100 ppm; rabbit, 30 -
100 ppm), rel. KI wt (rat, 100 ppm), and 
abs. and rel. TE wt (rabbit 100 ppm). 
1,2,4,5-TCB 
(Braun et al., 
1978) 
XX 
Beagle dog (2d, 29); 
oral in diet for 2 years at 
5 mg/kg/d, followed by a 
recovery period of 20 
months 
After 18 mo of exposure, all clinical 
parameters were normal. After 24 mo, 
serum alkaline phophatase activity and 
bilirubin levels were slighly elevated, 
which returned to normal within 3-mo of 
recovery. No morphological changes in 
tissues were observed after a 20-mo 
recovery period. 
1,2,3,4-TCB 
1,2,3,5-TCB 
1,2,4,5-TCB 
XX 
(Chu et al, 1984a) 
Sprague Dawley rat 
oral in diet for 90 days, 
0 - 0 . 5 - 5 - 5 0 -500 ppm 
1,2,4,5-TCB: Increased LI and KI wt 
(<?,$, 500 ppm). Increased serum choles-
terol (â, 5, 500 ppm) and hepatic micro-
somal enzyme activities (AH, APDM; 50 
ppm(cî), 500 ppm (o\ ?)). 
Slight decrease in hemoglobin and 
hematocrit. Dose-dependent changes in 
severity and prevalence of renal lesions 
(extensive epithelial necrosis with 
intratubular casts) and of hepatic lesions 
(hepatocytomegaly), with male rat being 
more sensitive than female rat. 
Less severe changes observed with other 
two isomers. Dose-dependent 
accumulation in LI and fat: 
1,2,4,5- > > 1,2,3,5- > 1,2,3,4-TCB. 
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Compound 
(Reference) 
Species; 
Study Protocol 
Effects 
PCB 
(Linder et al., 
1980) 
TY y ^ \ 
Sherman rat (c?,9); 
oral in diet, 
9: 0 - 125-250-500 
1000 ppm for 280 
days 
<5:0- 125- 1000 ppm 
for 100 days 
No effect observed on BW gain. Dose-
dependent accumulation in fat. No 
evidence of porphyria (2). Increased 
WBC at 1000 ppm. Decrease in HB, RBC 
and HC (<?) at 1000 ppm. Increase in 
ADR wt and KI wt (d, 1000 ppm). 
Increase in relative LI wt (^250 ppm). 
Hepatocellular enlargement (500, 1000 
ppm). Dose-related increase in hyaline 
droplet formation (6) in KI; at 1000 ppm, 
focal renal tubular atrophy and interstitial 
lymphatic infiltration. 
HCB 
(Vos et al., 
1971) 
Japanese quail (â,9); 
oral in diet for 90 days, 
0 - 1 - 5 - 2 0 - 8 0 ppm 
Tremor and mortality occurred in birds 
fed 80 ppm. Li damage (hepatocellular 
enlargement, bile duct proliferation, 
necrosis), SP erytrophagocytosis, 
pigments in KI tubules, reduced 
reproduction were noticed in 80 ppm 
group. No effect on shell-thickness index. 
Increased LI wt, slight LI damage and 
increased faecal porphyrin level in 5 ppm 
group. NOEL, 1 ppm. 
HCB 
(Kuiper-Goodman 
etal., 1977) 
Charles River rat (d,9); 
oral in diet for 
3, 6, 9, 12 and 15 wk; 
0 - 0 . 5 - 2 - 8 - 3 2 
mg/kg/d. 
Surviving rats fed HCB-
free diet for 1 wk up to 
33 wk 
Hepatocytomegaly was observed at 2 
mg/kg/d. Increased porphyrin levels were 
noticed in LI, KI, SP (2, >8 mg/kg/d), 
increased LI wt (>8 mg/kg/d), KI wt, SP 
wt (32 mg/kg/d). Centrilobular LI lesions 
( ^  8 mg/kg/d) and splenomegaly (32 
mg/kg/d). At 32 mg/kg/d, increased 
mortality and ataxia (9) and intension of 
tremors (d,9). After termination of 
exposure, there was an increase in LI 
porphyrin levels (9, 0.5 mg/kg/d 
(transient), 2 mg/kg/d). 
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Compound 
(Reference) 
Species; 
Study Protocol 
Effects 
HCB 
(Van Ommen 
et ai, 1989) 
Wistar rat (2); 
oral in diet for 10 wk; 
0.03 % HCB with or 
without co-administration 
ofTAO(0.3 %). 
Increase in LI porphyrin levels (600-fold 
over control) and increase in urinary 
porphyrin levels after 3 weeks. Co-
treatment of rats with HCB and TAO 
resulted in an near-absence of porphyria. 
Abbreviations: see list of abbreviations; abs., absolute; ADR, adrenal; AH, arylhydrocarbon 
hydroxylase; ALT, alanine aminotransaminase; AP, alkaline phosphatase; APDM, 
aminopyrine demethylase; BM, bone marrow; BW, body weight; HC, hematocrit; HE, heart; 
HB, haemoglobin; KI, kidney; LI, liver; LU, lung; NOEL, no effect level; RBC, red blood 
cel; rel., relative; SP, spleen; TE, testis; TH, thymus; THYR, thyroid; WBC, white blood 
eel; wt, weight. 
Multiple reactive metabolites of halogenated benzenes 
As with many other lipophilic compounds, the toxicity observed after exposure to 
halogenated benzenes is believed to be due to metabolites rather than to the parent 
compound. Studies attempting to explain the mechanism of toxicity of (halogenated) 
aromatic hydrocarbons have mainly focussed on the model compounds bromobenzene and 
hexachlorobenzene. In recent years, the routes for metabolic activation of these compounds 
have been found to be more complicated than was previously assumed. 
The various pathways for the metabolic activation of halogenobenzenes are summarized 
in Figure 1.2. Oxidative attack by cytochrome P450 results in the formation of an 
intermediate, most commonly depicted as an epoxide, an electrophilic intermediate which 
may covalently interact with tissue macromolecules. The spontaneous isomerization to 
phenols, the conversion of epoxides to dihydrodiols as catalysed by epoxide hydrolase, and 
the conjugation of epoxides with glutathione, either spontaneously or enzymatically by 
GSH S-transferases, are alternative pathways that compete with the reaction of epoxides 
with tissue macromolecules. For fully halogenated benzenes, an alternative mechanism of 
oxidation has recently been proposed, which proceeds without the obligatory formation of 
epoxides as intermediates in the oxidative dehalogenation to pentahalogenated phenols 
(Rietjens and Vervoort, 1992). This mechanism includes direct formation of a 
benzohaloquinone cation with a positive charge on a halogen substituent para with respect 
to the position of oxidative attack, and subsequent elimination of the halogen from the 
molecule as a halogen anion. 
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Figure 1.2 Different routes for metabolic activation of halogenated benzenes. 
Secondary metabolism of phenols to hydroquinones and benzoquinones may pose 
additional stress to a cell in the form of sulfhydryl alkylation and/or oxidation, or in the 
form of oxidative stress due to redox cycling. Enzyme mediated conjugation of phenols 
and hydroquinones with glucuronic acid or sulphate may prevent the formation of reactive 
benzoquinones, whereas, once formed, benzoquinones may be quickly reduced to their 
corresponding hydroquinones, e.g., by the action of DT-diaphorase. Finally, conjugation 
of quinones with glutathione can lead to the formation of products which leave the liver 
and are targetted to the kidney, where they may elicit a toxic response through a 
mechanism that is still unknown (Monks and Lau, 1990). 
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Thus, multiple pathways are involved in the generation of (proximate) toxic metabolites 
of halogenobenzenes: epoxides as primary metabolites, benzoquinones as secondary 
metabolites, and benzoquinone-derived glutathione conjugates. In the next section, the role 
of these different reactive metabolites in the toxicity of halogenobenzenes is briefly 
discussed. 
Epoxides and their role in hepatotoxicity 
The primary target of toxicity for halogenated benzenes is the liver parenchymal cell. 
Although different degrees of hepatotoxic effects have been described for a broad range of 
halogenated benzenes, mechanistic investigations have virtually only been applied to the 
case of bromobenzene. 
Early studies by Brodie et al, (1971) and Reid and Krishna (1973) demonstrated that 
the development of centrilobular liver necrosis in rats treated with bromobenzene and other 
halogenated benzenes was associated with the covalent binding of reactive material to 
cellular macromolecules in the necrotic zone. Pretreatment of rats with phénobarbital 
potentiated both covalent binding and liver necrosis, while inhibition of oxidative 
metabolism by SKF-525 had the opposite effect, indicating an important role for the P450 
monooxygenase system in the metabolic activation of these compounds. 
The protective effect of glutathione, and hence the electrophilic nature of the reactive 
metabolite involved, was demonstrated by increased liver necrosis in bromobenzene-treated 
rats, which were pretreated with diethylmaleate, a compound known to drastically reduce 
glutathione levels in the liver (Reid and Krishna, 1973). This was confirmed in in vitro 
studies, which demonstrated that the toxicity of bromobenzene was much more pronounced 
in hepatocytes isolated from rats pretreated with phénobarbital and diethylmaleate than in 
those isolated from rats which were only pretreated with phénobarbital. Inclusion of 
precursors of glutathione in the incubation medium, i.e., cysteine or methionine, protected 
against bromobenzene-induced cytotoxicity, while inhibition of glutathione synthesis by 
methionine sulfoximine abolished this protective effect of glutathione precursors (Thor and 
Orrenius, 1980). 
On the basis of identification of the major urinary metabolites and the correlation of 
hepatotoxicity with changes in their ratio, hepatotoxicity was ascribed to bromobenzene-
3,4-epoxide. The increased susceptibility of PB-pretreated rats to bromobenzene-induced 
hepatotoxicity was associated with an increased urinary excretion of p-bromophenol, which 
is formed via the 3,4-epoxide. In contrast, 3-MC-pretreated rats showed a diminished 
hepatotoxicity after administration of bromobenzene, while they selectively excreted o-
bromophenol, which is formed via the 2,3-epoxide (Lau and Zannoni, 1979). These 
metabolic routes were confirmed in vitro with liver microsomes from Pb and 3-MC treated 
rats (Lau and Zannoni, 1979; Monks et ai, 1984b). Additional evidence for the role of 
bromobenzene-3,4-epoxide as the hepatotoxic metabolite of bromobenzene emerged from 
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studies using two different strains of mice (Lau et al, 1980). It was found that Balb/cJ 
mice possessed a significantly higher activity of the toxic 3,4-epoxide pathway than 
C57BL/J mice, whereas the activity of the non-toxic 2,3 epoxide pathway was similar in 
either strain. The higher ratio of /j-bromophenol versus o-bromophenol excreted by Balb/cJ 
mice was associated with extensive hepatic necrosis, in contrast to the minimal pathological 
changes in the livers of C57BL/J mice. These studies on the metabolism of bromobenzene 
have generated an interesting example of the differential role of different P450 isoenzymes 
in the metabolism and toxicity of a xenobiotic. However, the (bio)chemical basis of this 
difference in the toxicity of two potentially reactive epoxides remains to be elucidated. 
In a recent study, the metabolism of chlorobenzene to o- and p-chlorophenol in human 
and mouse microsomes paralleled the metabolism of bromobenzene, yielding kinetic 
parameters similar to those measured for bromobenzene (Kerger et al, 1988). Apparently, 
chlorobenzene is metabolised by the same P450 isoenzymes as bromobenzene, and the type 
of halogen substitution has little effect on enzyme affinity. In this context, it is interesting 
to note that the ratio of p- to o-halophenol production in human microsomes amounted to 
4.8 for both halogenobenzenes, compared to 1.3 and 1.4 in mouse microsomes for 
bromobenzene and chlorobenzene, respectively. This suggests that human microsomes 
preferentially metabolise halogenobenzenes through the hepatoxic 3,4-epoxide pathway, 
implying that humans may be rather susceptible to the hepatotoxic effects generated by 
halogenobenzenes. 
Quinones as mediators of toxic effects 
Although the role of bromobenzene-3,4-epoxide in the hepatotoxicity of the parent 
compound, bromobenzene, seems to be firmly established, more recent developments have 
stressed the importance of secondary metabolites in the toxicity and/or carcinogenicity of a 
variety of aromatic hydrocarbons. Secondary metabolites have been found to interact more 
readily with cellular macromolecules than the primary epoxides. For example, the bulk 
amount of covalent binding observed in microsomal incubations with benzene appeared to 
arise from further oxidation of initially formed phenol (Tunek et al., 1980; Smart and 
Zannoni, 1985). Furthermore, the majority of reactive metabolites of 2,2'-dichlorobiphenyl 
formed by rat liver microsomes arose from secondary metabolism of phenolic metabolites, 
whereas arene oxides, the primary products, only played a minor role in protein binding of 
dichlorobiphenyl (Hesse et al., 1978). 
A major fraction of the covalent binding of bromobenzene to microsomal protein could 
be ascribed to secondary metabolites, presumably benzoquinones, of o- and /7-bromophenol 
(Buben et al., 1988). Additional support for the importance of benzoquinone metabolites in 
the covalent binding of bromobenzene both in vitro and in vivo comes from studies with 
3H/14C labelled bromobenzene (Narasimhan et al., 1988). A major decrease was observed 
in the 3H/14C-ratio in covalently bound material compared to the substrate and soluble 
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metabolites formed, indicating that benzoquinones (which have a higher oxidation state, 
and thus a lower 3H/14C-ratio) contribute to a large extent to the covalent binding. In this 
respect, it is interesting to note that the 3H/14C-ratios for tissue adducts in lung and kidney 
were considerably higher suggesting a differential role for the various reactive 
intermediates in different organs. The exact role of these chemically reactive quinones in 
the hepatotoxicity of bromobenzene is still unclear, because conditions which increased the 
covalent binding of p-bromophenol in vitro (phénobarbital pretreatment and glutathione 
depletion) did not cause hepatotoxicity in vivo (Monks et al, 1984a). 
Covalent binding observed upon microsomal metabolism of the fully substituted 
benzene, i.e., hexachlorobenzene, was completely inhibited in the presence of the reducing 
agent ascorbic acid (Van Ommen et al., 1986). A concomitant increase in the formation of 
the secondary metabolite tetrachlorohydroquinone was detected, strongly indicating 
tetrachlorobenzoquinone as the ultimate binding species involved. 
By virtue of their electrophilic nature, quinones may spontaneously react with 
nucleophilic centers in the cell, and thus covalently bind to cellular protein and DNA. 
Quinones derived from hexachlorobenzene are unique in their reactivity toward 
nucleophiles. Unlike other benzoquinones, which form stable hydroquinone adducts upon 
reaction with sulfhydryl groups and which have to be reoxidized before being able to react 
again, tetrachlorobenzoquinone remains in its oxidized state and, consequently, the 
conjugates formed are still reactive towards nucleophiles. This is illustrated by the fact that 
the reaction of tetrachlorobenzoquinone with glutathione does not only result in the 
formation of mono-substituted glutathionyl conjugates, but also of di-, tri-, and possibly 
fully substituted glutathionyl conjugates (Van Ommen et al, 1986). The unique reactivity 
of tetrachlorobenzoquinone even after conjugation with glutathione, is demonstrated by the 
interaction of this conjugate with GSH 5-transferase. This enzyme was inhibited in an 
irreversible way at almost equimolar ratios by this compound, and evidence was presented 
for the fact that the glutathione-moiety of the conjugate targets the molecule to the active 
site, while the quinone structure reacts with an essential sulfhydryl group in or near the 
active site, resulting in loss of enzymatic activity (Van Ommen et al, 1988). 
In addition to alkylating properties, quinones also possess the capacity for redox 
cycling, thereby generating reactive oxygen species (Kappus, 1986). This may impose a 
condition of oxidative stress on cells, which may ultimately lead to cell damage. 
Tetrachlorobenzoquinone has been shown not to initiate redox cycling in vitro (Van 
Ommen et al., 1988), but the potency for redox cycling in vivo may differ from the in 
vitro situation, e.g., due to differences in oxygen pressure and redox state of the cells. 
The question whether tetrachlorobenzoquinone is responsible for the porphyrinogenic 
action of hexachlorobenzene in vivo still remains a matter of debate and future research. 
Several metabolites of hexachlorobenzene have been tested in vivo for their ability to 
induce porphyria or to inhibit uroporphyrinogen D-carboxylase, a key enzyme in the 
haemsynthesis (Goerz et al., 1978; Wainstock de Calmanovici and San Martin de Viale, 
1980). None of the metabolites tested had a direct porphyrinogenic effect, although 
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pentachlorophenol and tetrachlorohydroquinone were capable of increasing the 
porphyrinogenic action of hexachlorobenzene (Debets et al., 1980). The fact that the 
primary metabolite pentachlorophenol is not porphyrinogenic when administered to rats 
would argue against a possible relationship of the secondary metabolite tetrachloro-
benzoquinone with porphyria. However, the distribution, biotransformation and excretion 
of an orally delivered compound, and hence its toxic effects, might differ from the 
situation in which the compound is metabolically formed. For example, induction of P450 
enzymes by hexachlorobenzene may be a prerequisite for the possible toxic action of HCB 
through its metabolite, by changing the relative contribution of conjugation and oxidative 
reactions in favor of the latter. In addition, it is conceivable that pentachlorophenol formed 
upon oxidation of hexachlorobenzene by cytochrome P450 does not leave the active site, 
but instead is oxidised by the same P450 molecule to its (hydro-)quinone derivatives. In 
this respect, it is interesting to note that in a recent study selective inhibition of a specific 
isoenzyme, cytochrome P450-p (P450IIIA1) inhibited oxidation of hexachlorobenzene in 
vivo and resulted in a decrease of the urinary excretion of porphyrins (Van Ommen et al., 
1989). 
Glutathione conjugates as proximate toxicants in nephrotoxicity 
Exposure to halogenobenzenes has not only been described to cause hepatotoxicity, but 
also lead to the development of renal necrosis. A single dose of bromobenzene or 
chlorobenzene to mice caused extensive necrosis of the proximal convoluted tubules within 
24-48 hours (Reid, 1973). The development of necrosis was associated with covalent 
binding of radioactive material at the site of necrosis. As with hepatotoxicity, the 
biotransformation of the parent compound is a prerequisite for the development of 
nephrotoxicity, since prior inhibition of metabolism blocked both renal toxicity and 
covalent binding to kidney proteins. In addition, pretreatment of mice with phénobarbital, 
which induces hepatic but not renal xenobiotic metabolism, resulted in a significantly 
higher binding of bromobenzene metabolites to kidney protein. 
The conclusion of Reid (1973) that a hepatic metabolite of bromobenzene was 
responsible for the covalent binding and, presumably, the nephrotoxicity led to 
investigations into the nephrotoxic potency of several hepatic metabolites of bromobenzene. 
In mice, all three bromophenol isomers and 4-bromocatechol were found to be nephrotoxic 
when injected intravenously at only 10% of a nephrotoxic dose of bromobenzene (Rush et 
al., 1984). In contrast, /^-bromophenol and 4-bromocatechol were not nephrotoxic in rats 
after intraperitoneal administration (Monks et al., 1984a). Apparently, species differences 
in biotransformation and/or susceptibility to bromobenzene-induced toxicity exist. In 
addition, differences in routes of administration may influence the fate of the chemical 
administered and, hence, its effect. 
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It was subsequently shown that o-bromophenol, a major metabolite of bromobenzene, 
caused severe renal damage in non-induced rats at only 1/5 of the dose required by 
bromobenzene to produce similar necrosis in phenobarbital-induced rats (Lau et al., 
1984b). When [14C]-o-bromophenol was administered to rats, the amount of covalently 
bound radioactive material to kidney proteins was four times greater than to liver proteins. 
Interestingly, liver microsomes converted o-bromophenol to covalently bound material and 
2-bromohydroquinone, whereas kidney microsomes did not (Lau et al., 1984a,b). These 
observations were consistent with the view that a hepatic metabolite of bromobenzene (and 
of o-bromophenol) was transported to the kidney, where it elicited toxicity. 
Further studies revealed the formation of several isomeric mono- and disubstituted 
glutathione conjugates of 2-bromohydroquinone. Conjugation of potentially toxic 
electrophiles (like benzoquinones) with glutathione is usually associated with detoxication 
and excretion into urine as their corresponding mercapturic acids. However, glutathione 
conjugates of 2-bromohydroquinone were shown to be potent and selective nephrotoxicants 
(10-50 /tmol/kg, i.V.; Monks et al, 1985). Perhaps suprisingly, mono-glutathione 
conjugates exhibited less toxicity than the di-substituted conjugates. 
Metabolism of the conjugate to reactive thiols by the renal tubular cells (through the ß-
lyase pathway) might be the mechanism of activation. However, structure-activity studies 
with bromo-2,5-dihydroxy-thiophenol and isomeric bromothiophenols indicated that the 
quinone function of this compound is a more important determinant of toxicity than the 
thiol group (Monks et al., 1988). 
The role of 7-glutamyl transpeptidase (7-GT), a key enzyme in the transport of 
glutathione conjugates into renal tubular cells, is ambiguous. Firstly, 7-GT activity may be 
required for transport of the hydroquinone glutathione conjugates into renal proximal 
tubular cells. In fact, inhibition of 7-GT by AT-125 decreased the accumulation of 2-
bromohydroquinone glutathione conjugates into kidney slices (Lau et al., 1988). Secondly, 
7-GT-mediated formation of a relatively labile hydroquinone-cysteine conjugate may 
facilitate oxidation to the reactive benzoquinone form and may thus be involved in the 
generation of the ultimate toxic metabolite. Indeed, the oxidation potential is decreased in 
the following order (and thus the ease to oxidise is increased): 2-bromohydroquinone > 2-
bromohydroquinone glutathion-5-yl conjugate > 2-bromohydroquinone cystein-5-yl 
conjugate (Monks and Lau, 1990b). 
Thirdly, 7-GT mediated hydrolysis of the bromohydroquinone glutathion-5-yl conjugate 
to its cystein-S-ylglycine derivative may also be regarded as a detoxication route of 
hydroquinone glutathione conjugates by means of oxidative cyclization resulting in the 
formation of a 1,4-benzothiazine, which is subsequently excreted into urine (Monks et al., 
1990). The striking difference between the glutathione conjugate of menadione, which was 
not nephrotoxic, and its N-acetylcysteine derivative, which was nephrotoxic, may be 
related to their relative sensitivity towards cyclization, since cyclization is hindered in the 
mercapturic acid (Lau et al., 1990). 
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In contrast to the bioactivating role of 7-GT in the nephrotoxicity of bromohydroquinone 
glutathione conjugates, the nephrotoxic action of the structurally related glutathione 
conjugates of 2,5-dichlorohydroquinone and 2,3,5-trichlorohydroquinone was actually 
decreased by 7-GT activity (Mertens et al, 1991). Thus, multiple renal transport 
mechanisms may be involved in the accumulation of glutathione-conjugated hydroquinones, 
and/or differences may exist in the relative rate for the pathways leading to toxicity or 
detoxication (oxidative cyclization, N-acetylation vs -deacetylation, protein arylation) for 
different halogenated benzoquinones. 
INVESTIGATIONS INTO THE ROLE OF BIOTRANSFORMATION IN THE 
TOXICITY OF HALOGENATED BENZENES 
IN VIVO IN VITRO 
Identification of metabolite 
profiles in plasma, urine, 
faeces, bile (cf. table 1.3) 
Assessment of tissue 
depletion of GS H; 
increased enzyme activity 
in body liquids; disturbed 
hormone levels, (cf. table 1.4) 
METABOLISM 
TOXICITY 
Identification of metabolites ir 
incubations with microsomes, 
hepatocytes 
Detection of (covalently) 
bound metabolites to 
macromolecules; assessment of 
disturbed cellular levels of 
GSH, NAD(P)H, ATP 
Figure 1.3 Multi-pathway approach to the study of the role of biotransformation 
in the toxicity of halogenated benzenes. 
Scope of the present investigation 
The main objective of the present investigation is to compare a range of structurally 
related chemicals with respect to their pathways of metabolic activation. With reference to 
Figure 1.2 and page 32-39, different reactive products may be formed upon (oxidative) 
biotransformation of halogenated benzenes: epoxides as chemical intermediates in the 
primary oxidative event, and benzoquinone metabolites as secondary products. Target sites 
of either class of metabolites in relation to toxicity still remain to be identified. 
In an attempt to characterise and evaluate the contribution of the different routes to 
bioactivation, the whole series of halogenated benzenes should be taken into account. The 
ultimate aim of the present thesis includes the development of a set of general rules 
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concerning the role of metabolism in the toxic effects generated by these chemicals. As 
schematically presented in Figure 1.3, this question can be addressed in a number of ways. 
In order to define a meaningful correlation between the observed toxic effects and the 
various reactive intermediates involved in their metabolism, detailed in vitro studies on the 
microsomal oxidation of different congeners of chlorinated benzenes are described in Part 
I (chapter 2, 3, and 4). As a quantification of metabolic activation, covalent binding of 
radiolabeled compound to microsomal protein and DNA is detected. In addition, the 
differential role of cytochrome P450 isoenzymes in the oxidation of chlorinated benzenes is 
assessed. In chapter 5, a mechanism is proposed for the formation of the reactive 
benzoquinone metabolites. 
Part II describes the toxicity and fate of chlorinated benzenes in vivo. In order to 
extrapolate data on microsomal metabolic activation of chlorinated benzenes, studies 
focussing on target-organ toxicity of a range of chlorinated benzenes after a single 
exposure have been performed (chapter 7) to determine the role of chemically reactive and/ 
or biologically active (chemically stable) metabolites in the various toxic symptoms. 
Finally, a detailed semi-chronic study is performed comparing the toxicologic profile and 
the metabolic profile of 2 congeners, hexachlorobenzene and pentachlorobenzene, which 
have been shown to produce qualitatively similar products in vitro (chapter 8 and 9). 
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Chapter 2 
THE METABOLISM OF PENTACHLOROBENZENE 
BY RAT LIVER MICROSOMES: 
The nature of the reactive intermediates formed 
Abstract 
Metabolism of [14C]-pentachlorobenzene by liver microsomes from dexamethasone 
induced rats resulted in the formation of pentachlorophenol and 2,3,4,6-tetrachlorophenol 
as major primary metabolites in a ratio of 4:1, with 2,3,4,5- and 2,3,5,6-tetrachloro-
phenols as minor primary metabolites. Thus, the unsubstituted carbon atom was the 
favourite site of oxidative attack, but the chlorine-substituted positions also played a 
sizable role. As secondary metabolites both para- and orf/jo-tetrachlorohydroquinone are 
formed (1.4 and 0.9 % of total metabolites, respectively). During the cytochrome P450-
dependent conversion of pentachlorobenzene, 5 - 15 % of the total amount of metabolites 
became covalently bound to microsomal protein. Ascorbic acid inhibited this binding to a 
considerable extent, indicating that benzoquinone metabolites play an important role in 
the binding. However, complete inhibition was never reached by ascorbic acid, nor by 
glutathione, suggesting that other reactive intermediates, presumably epoxides, are also 
involved in covalent binding. 
C. den Besten, M.M.CG. Peters, P.J. van Bladeren, Biochem. Biophys. Res. Commun. 163 
(1989) 1275-1281. 
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Introduction 
Chlorinated benzenes are widely used as chemical intermediates in the synthesis of 
organic compounds, and as solvents, pesticides, space deodorants and other industrial 
products (US EPA, 1985). Because of their lipophilic character and their relative 
resistance to chemical and biological degradation, they tend to accumulate in animal and 
human tissue (Veith et al, 1979; Jan, 1983). Hence, there is concern over the 
consequences to human health of chronic exposure to these agents. Toxic symptoms after 
exposure to chlorinated benzenes range from adverse effects on the nervous system to 
liver and kidney damage, sometimes accompanied by severe porphyria (Brown et al, 
1969; Reid, 1973; Rimington and Ziegler, 1963). 
Investigations into the metabolism of halogenated aromatics have shown that epoxide 
formation is involved in their hydroxylation by the cytochrome P450 containing mono-
oxygenases (Jondorf et al, 1958, Daly et al, 1972, Kohli et al, 1976). These reactive, 
electrophilic intermediates have been implicated in the toxicity associated with these 
compounds. For example, the hepatotoxic effects after bromobenzene or chlorobenzene 
administration to rats is thought to be mediated by their 3,4-epoxide intermediate (Lau 
and Zannoni, 1979). 
However, in recent years a considerable role in the metabolic activation of aromatics 
has been ascribed to secondary metabolism, resulting in the formation of electrophilic 
quinones. For example, studies on the microsomal metabolism of benzene have shown 
that quinone metabolites (and perhaps the semiquinone intermediates) are the ultimate 
covalently binding species to microsomal protein (Tunek et al, 1980). Furthermore, it 
has been demonstrated in our laboratory that hexachlorobenzene (HCB) is hydroxylated 
by rat liver microsomes to pentachlorophenol (PCP), which is further metabolised to 
tetrachlorohydroquinone (TCHQ) (Van Ommen et al, 1985). Covalent binding to 
microsomal protein as a result of the oxidative biotransformation of hexachlorobenzene 
appears to be completely mediated by tetrachlorobenzoquinone (TCBQ), which is formed 
upon oxidation of TCHQ (Van Ommen et al, 1986). 
Although a number of investigations describe the urinary and faecal products of the 
various chlorinated benzenes in different species (Kohli et al, 1976, Rozman et al, 
1979), there is a lack of detailed studies on the relationship between formation of 
reactive metabolites and the toxicity caused by these compounds. As a first step, the 
study presented here describes the in vitro metabolism of pentachlorobenzene by rat liver 
microsomes, with special emphasis on the formation of reactive metabolites. 
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Materials and Methods 
Chemicals 
[14C]-Pentachlorobenzene (PCB, s.a. 19.2 mCi/mmole) was purchased from Sigma 
Chemical Co., St. Louis, USA, with a radiochemical purity of 99.0 %. Impurities 
consisted of 0.4 % tetrachlorobenzene and 0.5 % hexachlorobenzene that were present in 
identical amounts both before and after metabolism of PCB, 0.02 % 2,3,4,6-
tetrachlorophenol (TCP) and 0.04 % 2,3,4,5-TCP. NADPH was from Boehringer 
Mannheim, Germany. PCB was from Merck, Schuchardt, Germany (> 98 %). All other 
chemicals have been described elsewhere (Van Ommen et al, 1985). 
Preparation of microsomes 
Male Wistar rats (300 g) were pretreated with dexamethasone (4 daily administrations 
by oral gavage of 300 mg/kg body weight dissolved in 2 % Tween 80). Control rats 
were untreated. Microsomes were prepared as described previously (Van Ommen et al, 
1985) and stored at -80 °C until used. Cytochrome P-450 was determined according to 
Omura and Sato (1964). Protein concentrations were determined by the method of Lowry 
(1951). 
Microsomal incubations 
Unless otherwise stated, incubations were carried out with dexamethasone (DEX)-
induced microsomes. A standard incubation mixture was used, containing 1 raM 
NADPH, 3 mM MgCl2, 0.1 M potassium phosphate buffer pH 7.4, 0.25-1.0 mg 
microsomal protein and 50 pM PCB. PCB and NADPH were present at saturating 
amounts. [14C]-PCB was diluted to a specific activity of 5 mCi/mmole. After a 2 min 
preincubation in a shaking waterbath at 37 °C of all components except NADPH, the 
substrate was added in 50 jitl of acetone. The reaction was started by adding NADPH 
(final volume 2.0 ml) and, unless otherwise stated, terminated after 10 minutes by the 
addition of HCl (final concentration 0.6 N). Control incubations were without NADPH. 
Extraction of f'4C]-PCB and metabolites 
Extraction of the incubation mixture with 2x2 ml of diethyl ether removed > 99 % 
of the radioactivity from the aqueous phase. After overnight drying of the extracts on 
Na2S04, the organic solvent was removed under a stream of nitrogen gas and the residues 
were dissolved in 75 /d of methanol. 
H PLC analysis 
Reversed phase chromatography was performed using a Perkin-Elmer Series 4 
HPLC, fitted with a 150 x 4.6 mm ID Lichrosorb 5RP18 column and a Co:Pell ODS 
precolumn. The eluent was monitored at 254 nm. After injection of 30 /*1 sample 
together with 3 ^1 of a solution containing the marker metabolites (see legend to Figure 
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2.1), all radioactivity was eluted isocratically with 60 % methanol/ 40 % Tris-phosphate 
buffer (50 mM, pH 2.5 or pH 8.0, see legend to Figure 2.1) for 2 minutes, followed by 
a linear gradient to 100 % methanol in 10 minutes, and a stationary phase at 100 % 
methanol for 10 min. For determination of radioactivity in the eluent, 0.5 ml fractions 
were collected followed by scintillation counting (5 ml Atomlight, Du Pont) in a Tri-
Carb liquid scintillation counter (Packard, Brussels, Belgium). In the assay described 
above, the 2,3,4,6- and the 2,3,5,6-TCP isomers co-eluted in one peak (cf. Figure 2.1). 
In order to distinguish between all 3 isomers of TCP, samples were also eluted on a 
Nucleosil 5RP18 column (150 x 4.6 mm) with a linear gradient from 50% methanol/ 50 
% potassium dihydrogen phosphate (20 mM, pH 4.5) to 85 % methanol/ 15 % potassium 
dihydrogen phosphate in 30 minutes, followed by 20 minutes at 85 % methanol (k' 
2,3,5,6-TCP, 12.6; k' 2,3,4,6-TCP, 13.0; k' PCP, 13.8; k' 2,3,4,5-TCP, 14.4). It 
became evident that 2,3,4,6-TCP was the major TCP isomer formed (ratio 2,3,5,6- : 
2,3,4,6-: 2,3,4,5-TCP = 1 : 11.6 : 1.9). 
Covalent binding to protein 
Covalently bound material was measured after extensive washing of the protein pellet 
with organic solvents: 3x5 ml of methanol, 3x5 ml of ethanol, 2x5 ml of ethyl acetate, 
2x5 ml of diethyl ether. No radioactivity was detected in the final ether-wash. The final 
pellet was solubilized in 1 M NaOH overnight at 40 °C and diluted with 1 volume of 
distilled water. An aliquot was taken for determination of the radioactive content. Protein 
content of the digests was determined according to Lowry (1951). 
Results 
Figure 2.1 A shows the separation of PCB and 8 possible metabolites by a reversed-
phase HPLC system using a Tris-phosphate buffer of pH 2.5 as the aqueous phase. 
Analysis of the ether extracts of microsomal incubations of [14C]-PCB revealed 2 major 
radioactivity peaks, eluting before the substrate, which were identified as PCP and 
2,3,4,6-TCP. Minor peaks of radioactivity were identified as 2,3,4,5-TCP, 2,3,5,6-TCP, 
/»-TCHQ and o-TCHQ, respectively. The identity of the fractions was confirmed by 
conducting a base run, in which the acid Tris-phosphate buffer was replaced by a Tris-
phosphate buffer of pH 8.0. Due to this increase in pH, the retention times of phenols 
and hydroquinones change, depending on their pKa value (Figure 2. IB). A small amount 
of radioactivity (0-2.5 % of the radioactivity present), characterized by a relatively high 
polarity, remained unidentified. 
Oxidation of PCB by liver microsomes from DEX-treated rats was measured as a 
function of varying microsomal protein concentration and varying incubation times 
(Table 2.1). It is shown that under these circumstances, oxidation of PCB was linear up 
to 0.25 mg microsomal protein/ml, while the maximum conversion rate was already 
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Figure 2.1 HPLC-analysis of metabolites of pentachlorobenzene converted by 
dexamethasone-induced rat liver microsomes. A, acid run (50 mM Tris-phosphate pH 2.5 
as the aqueous component); B, base run (50 mM Tris-phosphate pH 8.0 as the aqueous 
component). Marker metabolites: 1, p-tetrachlorohydroquinone (p-TCHQ); 2, o-TCHQ; 3, 
2,3,4,6-tetrachlorophenol (TCP), 2,3,5,6-TCP; 4, 2,3,4,5-TCP; 5, pentachlorophenol 
(PCP); 6, 1,2,3,4-tetrachlorobenzene (TCB); 7, 1,2,3,5-TCB; 8, pentachlorobenzene 
(PCB). 
reached within 5 min. 
Conversion of PCB was dependent on enzymatic activity (cf. no conversion with 
boiled microsomes) and appeared to be cytochrome P450 mediated: in incubations 
without NADPH, no metabolites were detected, and the use of the classical inhibitor of 
cytochrome P450 activity, metyrapone, decreased metabolism of PCB by 83 % (Table 
2.2). 
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Table 2.1 Metabolism of [14C]-pentachlorobenzene by liver microsomes from 
dexamethasone-induced rats. 
Incubation 
Conversion 
(%) 
protein (mg/ml) 
0.125 
0.25 
0.5 
time (min) 
5 
10 
20 
9.9 
16.0 
15.9 
6.6 
8.6 
11.9 
PCP 
62.2 
51.4 
54.9 
68.0 
63.5 
60.3 
Individual metabolites 
TCP 
(2,3,4,6+ 
2,3,5,6)a 
15.9 
15.7 
16.3 
22.9 
18.4 
19.1 
2,3,4,5-
TCP 
3.2 
2.8 
2.8 
3.3 
3.3 
2.8 
as percentage of total metabolites 
1,4-
TCHQ 
1.4 
3.3 
1.3 
1.7 
1.5 
1.3 
1,2-
TCHQ 
0.9 
0.9 
0.7 
0.3 
0.6 
0.8 
not 
iden-
tified 
8.5 
15.7 
9.8 
0 
5.1 
7.0 
CVB 
7.9 
10.2 
14.2 
3.8 
7.6 
8.7 
Note. Incubations were performed at 37 °C with a standard incubation mixture containing 
3 mM MgClj, 0.1 M potassium phosphate buffer pH 7.4, 1 mM NADPH and 50 nM PCB 
with 0.25 mg microsomal protein (final volume 2.0 ml) for 10 minutes, unless stated 
otherwise. Conversion is expressed as the sum of the percentage of extracted metabolites and 
the percentage of radioactivity covalently bound to protein. Both the conversion, determined 
by HPLC analysis and the covalent binding were corrected for blank values, obtained from 
incubations without NADPH. Data are means of at least duplicate observations, and the 
standard deviation was generally less than 10%. * 2,3,4,6-TCP and 2,3,5,6-TCP were 
formed in a ratio of 12:1 (see under Materials and Methods). CVB, covalent binding. 
Metabolism-dependent covalent binding of [14C]-PCB to microsomal protein was 
detected after extensive organic extraction. In incubations with boiled microsomes or in 
the absence of NADPH, the protein fraction contained a very small amount of 
radioactivity, which was independent of incubation time or amount of protein present. 
Furthermore, covalent binding was dependent on the activity of the cytochrome P450 
complex, since both carbon monooxide and metyrapone blocked binding to a great extent 
(Table 2.2). 
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Table 2.2 Microsomal metabolism and covalent binding of [14C]-pentachlorobenzene by liver 
microsomes from dexamethasone-treated rats. 
Incubation 
Complete mixture (DEX) 
minus NADPH 
Boiled microsomes 
Control microsomes 
Complete mixture (DEX) 
+ CO 
+ metyrapone (0.5 raM) 
+ ascorbic acid 
1.0 mM 
10.0 mM 
+ glutathione (1.0 mM) 
+ TCPO(l.OmM) 
Conversion 
20 
12 
17 
89 
85 
115 
76 
(%) 
100 
nil 
nil 
± 2 
± o 
± 4 
± 12 
± 3 
± 7 
+ 8 
Covalent 
(%) 
100 
3 + 
4 ± 
4 ± 
5 ± 
4 ± 
34 ± 
23 ± 
22 ± 
81 ± 
binding 
1 
0 
0 
1 
1 
1 
1 
2 
4 
Note. A complete incubation mixture (control) contained 0.25 mg DEX-induced 
microsomes, 3 mM MgCl2, 0.1 M potassium phosphate buffer pH 7.4, 1 mM NADPH and 
50 /tM PCB (final volume 2.0 ml). Incubations were performed at 37°C for 10 minutes. 
Data are based on 2-6 observations and are expressed as a percentage of the conversion and 
covalent binding of control incubations (conversion 9.6 ± 1.3 nmoles/10 min/0.25 mg, 
covalent binding 0.74 ± 0.1 nmoles/10 min/0.25 mg, mean ± S.D., n = 6). TCPO, 1,1,1-
trichloropropene oxide. 
Ascorbic acid, a strong reducing agent, inhibited the covalent binding of reactive 
PCB metabolites by 60 - 70 %. A concomitant increase in the formation of TCHQ was 
detected, which was comparable to the decrease in covalent binding (data not shown). 
The presence of 1 mM of glutathione (GSH), a nucleophilic sulfhydryl compound, 
resulted in a strong decrease in the amount of protein bound metabolites, while 36 % of 
the total amount of metabolites formed remained in the aqueous phase after organic 
extraction. However, considerable binding was still observed. 
In an attempt to study the involvement of epoxide intermediates in the protein binding 
of PCB, 1,1,1-trichloropropene oxide (TCPO), an inhibitor of epoxide hydrolase, was 
added to a standard incubation mixture. If epoxide metabolites were to be the ultimate 
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binding species, an increase in covalent binding in the presence of TCPO would be 
expected, due to a prolonged lifetime of the reactive epoxide metabolites. However, a 
slight decrease both in protein binding and metabolism was observed. 
Discussion 
Dexamethasone, a compound known to increase isoenzyme P450IIIA1 in rat liver 
(Wrighton et ah, 1985), is a powerful inducer of metabolism of chlorinated benzenes: 
previous studies in our laboratory demonstrated that conversion of HCB was by far 
highest in DEX-induced microsomes compared to microsomes from rats pretreated with 
phénobarbital, 3-methylcholanthrene, isosafrole and HCB (Van Ommen, 1987). In the 
present study, metabolism of PCB in DEX-induced microsomes was 5 times higher than 
in control microsomes. 
Based on the results presented in this study, a route for microsomal metabolism of 
PCB is proposed (Figure 2.2). It is demonstrated that PCB can be metabolised at 
different positions at the aromatic ring. The primary oxidative attack is not limited to the 
unsubstituted carbon atom, resulting in the formation of PCP, but can also take place at 
the more sterically hindered chlorine-substituted position, as is demonstrated by the 
formation of the different TCP-isomers. Apparently, rearrangement to 2,3,4,6-TCP is the 
most favourable situation, since this isomer predominated over the other two isomers. 
However, it should be noted that secondary oxidations to hydroquinones might influence 
the ratio of the different primary metabolites. The formation of various TCP-isomers 
from PCB in different species has been described in previous studies (Kohli et al, 1976, 
Rozman et al, 1979, Engst et al., 1976). 
In addition to the formation of ether-soluble products, PCB is substantially 
metabolised to reactive metabolites that covalently bind to microsomal protein. The fact 
that, with increasing incubation times and increasing amounts of protein, the protein 
binding increases at the cost of primary metabolites, seems to support a role for 
secondary metabolism, i.e., benzoquinone formation, in the covalent binding of PCB. 
The protective action of both glutathione and ascorbic acid on the protein binding of 
reactive metabolites has been described in previous reports for hexachlorobenzene (Van 
Ommen et al, 1986) and bromobenzene (Buben et al., 1988). Selective inhibition of 
protein binding by glutathione emphasizes the electrophilic nature of the reactive 
metabolite(s). The detection of radioactivity (36 % of total metabolites formed) in the 
aqueous phase after addition of glutathione agrees with the findings of Van Ommen et 
al, (1986) that glutathione readily forms water-soluble adducts with TCBQ. However, 
both arene oxides and quinones are electrophilic species, and thus capable of reacting 
with sulfhydryl compounds. The finding that ascorbic acid caused a loss of protein 
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binding together with a comparable increase in the formation of TCHQ, seems to 
indicate TCBQ (and perhaps the semiquinone radical) as the most important binding 
species. 
As expected, these data are in agreement with studies on the microsomal metabolism 
of HCB, in which TCBQ was suggested as the only binding species involved, since both 
HCB and PCB produce PCP as their primary metabolite. However, in contrast to protein 
binding resulting from HCB metabolism, binding by PCB metabolites could not 
completely be inhibited by ascorbic acid. Increasing the ascorbic acid concentration to 10 
mM decreased the covalent binding only slightly more (Table 2.2), suggesting that, 
although to a lesser extent than TCBQ, other reactive species are involved in the protein 
binding of PCB. The question whether epoxides are responsible for this remaining 
protein binding, and whether binding selectivity is different for the different reactive 
species, warrants further investigations. 
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Figure 2.2 Proposed metabolic route for pentachlorobenzene in rat liver microsomes. 
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METABOLIC ACTIVATION OF 
1,2,4-TRICHLOROBENZENE AND PENTACHLOROBENZENE 
BY RAT LIVER MICROSOMES: 
a major role for quinone metabolites 
Abstract 
Microsomal metabolism of [14C]-l,2,4-trichlorobenzene (1,2,4-TRICB) and [14C]-
pentachlorobenzene (PCB) was studied with special emphasis on the conversion 
dependent covalent binding to protein and DNA. 1,2,4-TRICB was metabolised by 
microsomes from dexamethasone-pretreated rats to 2,3,6- and 2,4,5-trichlorophenol, and 
to a lesser extent to 2,4,6- and 2,3,5-trichlorophenol, and trichlorohydroquinone. About 
10 % of all metabolites became covalently bound to protein in a rather nonselective way. 
Both for 1,2,4-TRICB and PCB, a strong correlation between secondary metabolism to 
hydroquinones and covalent binding was established. Protein binding of 1,2,4-TRICB 
was completely inhibited by the addition of ascorbic acid, indicating quinone metabolites 
as the sole reactive species formed. Both 1,2,4-TRICB and PCB alkylated DNA, 
although to a much lesser extent than protein (0.5 % and 0.3 % of all metabolites, 
respectively). Nonquinone intermediates, presumably epoxides, were responsible for a 
minor portion of the observed DNA binding, since complete inhibition by ascorbic acid 
was not reached. The differential role of cytochrome P450 both in primary and 
secondary metabolism was demonstrated by the use of microsomes from rats pretreated 
with different inducers. Dexamethasone (DEX) microsomes (cytochrome P450IIIA1) 
showed the highest activity towards these chlorinated benzenes (14 nmol/mg/5 min for 
1,2,4-TRICB and 36 nmol/mg/10 min for PCB), both with regard to the formation of 
phenols and to the formation of protein-bound metabolites. In addition, DEX microsomes 
preferentially formed 2,3,5-trichlorophenol, whereas other microsomal suspensions 
formed 2,4,5-trichlorophenol as the major isomer. The present study cleary demonstrates 
the high alkylating potency of secondary quinone metabolites derived from chlorinated 
benzenes, and poses a need for réévaluation of the role of epoxides in the observed 
toxicity of these compounds. 
C. den Besten, M.C.C. Smink, E.J. de Vries, P.J. van Bladeren, Toxicol. Appl. Pharmacol. 108 
(1991) 223-233. 
Microsomal activation of chlorobenzenes 
Introduction 
Halogenated benzenes are produced in large quantities for use as solvents and in the 
synthesis of many organic compounds. As a consequence of their intense industrial use, 
they have become ubiquitous environmental pollutants and have been identified by the US 
Environmental Protection Agency as priority pollutants for hazard evaluation. Many 
investigations concerning their distribution in the environment (Oliver et al, 1982), their 
bioaccumulation in animal and human tissue (Jan and Malnersic, 1980; Mes et al, 
1986), and their microbial (De Bont et al, 1986) and mammalian degradation (Jondorf et 
al., 1958) have been described. In addition, a substantial number of studies describes the 
adverse effects of halogenobenzenes, ranging from neurological disorders to effects on 
liver, kidneys and lungs, sometimes accompanied by porphyria (Brodie et al, 1971; 
Rimington and Ziegler, 1963). It is generally accepted that halogenated benzenes, like 
many other xenobiotics, require metabolic activation before they exert their toxic effects. 
For example, the toxicity of bromobenzene and hexachlorobenzene, two halogenated 
benzenes which have been the subject of many investigations, is decreased by inhibition 
of mono-oxygenase activity and is increased by selective induction of specific isoenzymes 
of cytochrome P450 (Brodie et al, 1971; Van Ommen et al, 1989). 
Previous studies on the metabolism of bromo- and chlorobenzene have demonstrated 
the involvement of arene oxides in the hydroxylation of the aromatic ring (Jerina and 
Daly, 1974). These electrophilic intermediates are thought to be the ultimate reactive 
species involved in the toxicity of many aromatics. In fact, the hepatotoxic effects of 
bromo- and chlorobenzene in rodents are thought to be mediated by the 3,4-epoxide 
derivatives (Lau et al, 1980). 
However, more recent developments have indicated the importance of secondary 
metabolites in the toxicity and/or carcinogenicity of a variety of aromatic compounds. In 
vitro studies have clearly demonstrated that some secondary aromatic metabolites like 
quinones or their semiquinone-anions may react more readily with cellular 
macromolecules than the primary arene oxides. For example, the major amount of 
covalent binding observed in microsomal incubations with benzene (Tunek et al, 1980) 
or 2,2'-dichlorobiphenyl (Hesse et al, 1978) appears to arise from further oxidation of 
initially formed phenol metabolites. In our laboratory, covalent binding to microsomal 
protein as a result of the oxidative biotransformation of hexachlorobenzene (Van Ommen 
et al, 1986) was found to be mediated by tetrachlorobenzoquinone (or -semiquinone), 
which is formed via oxidation of the intermediate metabolite pentachlorophenol. 
The lack of detailed investigations into the metabolic activation of halogenated 
benzenes other than the monosubstituted compounds has prompted us to investigate the in 
vitro metabolism of a range of chlorinated benzenes. In a recent study, the microsomal 
metabolism of pentachlorobenzene was described (Den Besten et al, 1989). The present 
investigation describes the microsomal conversion of 1,2,4-trichlorobenzene. Special 
64 
Chapter 3 
emphasis is put on the nature of the reactive metabolites derived from 1,2,4-
trichlorobenzene and pentachlorobenzene. Furthermore, the differential role of 
cytochrome P450 isoenzymes in the metabolism of these compounds is demonstrated. 
Materials and Methods 
Chemicals 
[I4C]-Pentachlorobenzene (PCB) and l,2,4-[14C]-trichlorobenzene (1,2,4-TRICB) were 
purchased from Sigma Chemical Co., St. Louis, MO, USA. Radiochemical impurities in 
PCB consisted of 0.4 % tetrachlorobenzene and 0.5 % hexachlorobenzene that were 
present in identical amounts both before and after metabolism of PCB, and 0.02 % 
2,3,4,6-tetrachlorophenol and 0.04 % 2,3,4,5-tetrachlorophenol. Radiochemical 
impurities of 1,2,4-TRICB consisted of 0.24 % 1,2-dichlorobenzene that was present in 
identical amounts both before and after metabolism, 0.05 % 2,3,6-trichlorophenol, 0.05 
% 2,3,5-trichlorophenol and 0.5 % polar metabolites which were not further identified. 
Reagent grade chemicals (Merck, Darmstadt, BRD) were used to adjust the specific 
activity of PCB and 1,2,4-TRICB to 10 and 5 mCi/mmole, respectively unless stated 
otherwise. NADPH was from Boehringer Mannheim GmbH, BRD. All other chemicals 
were at least of reagent grade. 
Preparation of microsomes 
Microsomes were isolated from male Wistar rats (300 g) which were pretreated with 
phénobarbital (PB, 0.1 % in drinking water for 7 days), 3-methylcholanthrene (3-MC, 3 
daily i.p. administrations of 30 mg/kg), isosafrole (ISF, 4 daily i.p. administrations of 
150 mg/kg) or with dexamethasone (DEX) as previously described (Den Besten et al, 
1989). Control rats were untreated. The livers were perfused with ice cold 0.9 % NaCl 
and homogenized in 20 mM Tris-HCl buffer (pH 7.4) containing 250 mM sucrose using 
a teflon pestel. The 11,000 g supernatant was centrifuged at 105,000 g for 95 min, after 
which the pellet was washed. Pellets were finally resuspended in 0.1 M potassium 
phosphate buffer pH 7.4 + 20 % glycerol. Microsomes were stored at -80°C until use. 
Cytochrome P450 was determined according to Omura and Sato (1964) and the protein 
concentration was determined by the Lowry assay (Lowry et al., 1951). 
Microsomal incubations 
Incubations were performed using glass tubes with a teflon-lined screw top in a 
shaking waterbath at 37°C as previously described (Den Besten et al, 1989). 
Radiolabeled substrates (50 /xM PCB or 100 /xM 1,2,4-TRICB) in acetone (2.5 % final 
concentration) were added to the incubations containing 0.1 M potassium phosphate 
buffer pH 7.4, 3 mM MgCl2, and microsomal protein (0.25 to 2 mg DEX microsomes) 
after 2 minutes of preincubation. The reaction was started by the addition of 1 mM 
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NADPH (final volume of 2.0 ml) and stopped by the addition of HCl (final concentration 
of 0.6 N) after 10 or 5 min in the case of PCB or 1,2,4-TRICB, respectively, unless 
otherwise stated. 
Extraction of metabolites 
PCB and its metabolites were extracted and prepared for HPLC analysis as previously 
described (Den Besten et al, 1989). Due to the volatile character of 1,2,4-TRICB, 
diethylether extracts of incubations with this compound were not dried under nitrogen, 
but extraction was performed with small volumes (0.5 ml) of ethyl acetate, which were 
collected separately. Four separate extractions resulted in the removal of > 99.5 % of 
the radioactivity from the aqueous phase. Direct HPLC analysis of the two first 
ethylacetate extracts (> 90 % of all radioactivity) revealed no significant differences in 
the relative composition of metabolites and substrate. Therefore, routine HPLC analysis 
was only performed on 25 p\ of the first collected ethylacetate phase. 
HPLC analysis 
Reversed-phase High Performance Liquid Chromatography was performed using a 
Perkin-Elmer Series 4 HPLC, equipped with a 250 x 4.6 mm I.D. Nucleosil 5C18 
column fitted with a Co:Pell ODS precolumn, and a gradient elution using a mobile 
phase containing methanol and 20 mM KH2P04 (see legend to Figure 3.1). The flow rate 
was 1 ml/min and the eluent was monitored at 254 nm. The following k' values were 
obtained: 2,5-dichlorohydroquinone (DCHQ), 2.7; trichlorohydroquinone (TRICHQ), 
4.1; 2,3-dichlorophenol (DCP), 6.5; 2,5-DCP, 6.9; 2,4-DCP, 7.3; 2,3,6-trichlorophenol 
(TRICP), 8.6; 2,3,4-TRICP, 9.5; 2,4,6-TRICP, 9.8; 2,4,5-TRICP, 10.2; 2,3,5-TRICP 
= 1,2-dichlorobenzene (DCB), 10.5; 1,4-DCB, 11.4; 1,3-DCB, 11.8; 1,2,4-TRICB, 
12.8. For determination of radioactivity in the eluent, fractions of 0.5 ml (or 0.2 ml in 
the area where the trichlorophenol isomers eluted) were collected followed by 
scintillation counting (5 ml of Ultima Gold, Packard) in a Tri-Carb liquid scintillation 
counter (Packard). When routine HPLC analysis was performed to determine total 
conversion rather than exact quantification of individual trichlorophenol isomers, a 
simplified assay was used employing a 150 x 4.6 mm I.D. Lichrosorb 5RP18 column 
and a mobile phase consisting of acetonitrile, methanol and water, all phases containing 
0.5 % acetic acid. The concentration of methanol in the mobile phase was kept at 30 % 
throughout the assay. All radioactivity was eluted isocratically for 2 minutes with 10 % 
acetonitrile and 60 % water, followed by a linear increase to 50 % acetonitril (2 % per 
minute for 10 minutes, followed by 4 % per minute for 10 minutes) and concluded 
isocratically with 70 % acetonitrile for 10 minutes. The k' values were: 2,5-DCHQ, 2.6; 
TRICHQ, 4.7; 2,3-DCP, 7.8; 2,4-DCP, 8.8; 2,3,6-TRICP, 10.0; 2,3,4-TRICP, 2,4,6-
TRICP, 10.7; 2,4,5-TRICP=2,3,5-TRICP, 11.1; 1,2-DCB = 1,4-DCB, 11.8; 1,3-DCB, 
12.2; 1,2,4-TRICB, 13.3. Microsomal metabolites were identified by coelution with 
marker metabolites which were injected together with the sample. The identification of 
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metabolites was confirmed by conducting a alkaline run with a mobile phase consisting of 
methanol and 20 mM Tris-phosphate buffer (pH 8.0) using a 250x4.6 I.D. Nucleosil 
5C18 column. All radioactivity was eluted by a linear gradient from 50 % methanol to 
85 % methanol in 30 minutes, and followed by 10 minutes of isocratic elution with 85 % 
methanol. Phenols and hydroquinones, which are sensitive to changes in pH, will move 
to the more polar region of the eluent, depending on their pKa value. The k' values 
were: TRICHQ, 1.3; 2,3,6-TRICP=2,4,6-TRICP, 1.9; 2,3,5-TRICP, 3.3; 2,4,5-TRICP, 
3.9; 2,3,4-TRICP, 4.2; 1,2-DCB = 1,4-DCB, 9.2; 1,3-DCB, 9.7; 1,2,4-TRICB, 10.9. 
Covalent binding to protein 
Covalently bound material to microsomal protein was measured after extensive 
washing of the protein pellet with organic solvents as previously described (Den Besten 
et al, 1989). No radioactivity was detected in the final ether-wash. The final pellet was 
digested in 1 M NaOH overnight at 40°C and diluted with 1 volume of distilled water. 
An aliquot was taken for determination of the radioactive content. Protein content of the 
digests was determined according to Lowry (1951). 
Covalent binding to DNA 
Calf thymus DNA (1 mg) was added to a standard microsomal incubation mixture (2 
ml) containing 1 mg of microsomal protein and 50 /*M PCB and 100 /JM 1,2,4-TRICB. 
After 10 minutes, the reaction was stopped by the addition of 5 ml of water-saturated 
phenol and the water phase was extracted with equal volumes of phenol, phenol: 
chloroform :isoamylalcohol (25:24:1), chloroform:isoamylalcohol (24:1) and water-
saturated diethylether. After complete removal of the diethylether under nitrogen, the 
aqueous phase was incubated with Proteinase K (0.25 mg) for 15 hours at 37°C followed 
by the extraction procedure as described above, to remove residual protein and amino 
acids. The DNA was precipitated overnight by the addition of sodium chloride to the 
water phase (final concentration 0.3 M) and 2 volumes of ice-cold ethanol. After 
centrifugation the DNA was resuspended in 1 ml of 20 mM Tris-acetate pH 7.4. The 
purity of the DNA recovered was determined by measuring the ratio of the absorbance at 
260 nm and at 280 nm (Markov and Ivanov,1974), and was in all experiments similar to 
that of pure DNA (1.92+0.05). The recovery was determined by measuring the 
absorbance at 260 nm and varied from 30% to 51%. Aliquots (0.2 ml) were taken for 
determination of radioactivity. 
Determination of lipid peroxidation 
Peroxidation of microsomal lipids, due to possible redox cycling of quinones formed 
during the metabolism of chlorinated benzenes, was determined by the measurement of 
thiobarbituric acid reactive substances (TBRS). For these determinations, incubations 
were carried out with an NADPH generating system (8 mM glucose 6-phosphate, 0.1 
unit/ml glucose 6-phosphate dehydrogenase, 0.3 mM NADP) for 30 minutes in the 
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presence of 50 jtM PCB or 100 /xM 1,2,4-TRICB. Control incubations lacked substrates. 
The formation of TBRS was measured spectrophotometrically at 532 nm as previously 
described (Buege and Aust, 1978). 
Results 
Figure 3.1 shows a typical HPLC reversed phase elution profile of the ethylacetate 
extracts of microsomal incubations with 1,2,4-TRICB. Two major peaks eluted before 
the substrate, which were identified as 2,3,6-TRICP (peak 6) and 2,4,5-TRICP (peak 9), 
respectively, as well as minor peaks that were identified as TRICHQ (peak 2), 2,4,6-
TRICP (peak 8) and 2,3,5-TRICP (peak 10). Dichlorophenols or -benzenes were not 
detected. About 9 % of the radioactivity that eluted in the first 10 ml as a rather broad 
peak was not further identified. 
In addition to extractable metabolites, products were formed that covalently interacted 
with microsomal protein. Table 3.1 shows that, with increasing protein concentration, the 
relative role of secondary metabolism, i.e., formation of hydroquinones, increased at the 
cost of primary metabolism, i.e., formation of phenols. Covalent binding to protein also 
showed an increase when the protein concentration was increased, indicating the 
involvement of secondary metabolism in the formation of reactive metabolites. 
Both conversion and covalent binding of 1,2,4-TRICB were mediated by cytochrome 
P450, as is shown by the dependence on the addition of NADPH and by the inhibitory 
action of metyrapone (Table 3.2). The covalent binding observed in incubations without 
NADPH amounted to 9 % of the total binding and was independent of either amount of 
protein present or incubation time. Glutathione reduced the covalent binding almost 
completely through the formation of water soluble conjugates, as 35 % of all metabolites 
remained in the aqueous phase (data not shown). 1,1,1-Trichloropropene oxide (TCPO), 
an inhibitor of microsomal epoxide hydrolase (Oesch et al., 1971), had no effect on the 
covalent binding to protein. Addition of 1 mM ascorbic acid, a reducing agent, resulted 
in a considerable reduction of the covalently bound protein metabolites with a 
concomitant increase in hydroquinone formation (8 % of the total conversion). When 10 
mM ascorbic acid was included in the microsomal incubation of 1,2,4-TRICB, covalent 
binding was at the level of the minus NADPH-control. However, considerable inhibition 
of total conversion, i.e., the sum of ethylacetate soluble metabolites and covalently bound 
radioactivity, was observed with increased concentrations of ascorbic acid. This could be 
a result of feedback inhibition due to the accumulation of hydroquinones and/or phenol 
metabolites. 
When the conversion of 1,2,4-TRICB was monitored with time, it was observed that 
the net rate of phenol production was highest in the first 30 seconds (6.7 nmol/mg/min) 
and gradually decreased thereafter (2.8 nmol/mg/min at 5 minutes, Figure 3.2A). In 
contrast, the formation of both hydroquinones and covalently bound metabolites increased 
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Figure 3.1 HPLC analysis of ethylacetate extracts from incubations performed with 
1,2,4-TRICB and DEX-induced microsomes. Analysis was performed using a 
Nucleosil 5C18 (250 x 4.6 mm I.D.) column. All radioactivity was eluted employing 
a mobile phase containing 50% methanol and 50% KH2P04 (20 mM in water) for 2 
minutes, followed by a linear increase to 85 % methanol in 30 minutes, and isocratic 
elution at 85 % methanol for 10 minutes. (A) UV absorption spectrum (254 nm) of 
the marker metabolites coinjected with the sample. (B) Amount of radioactivity eluted 
from the column, expressed as % of total radioactivity eluted from the column. 
Marker metabolites: 1, DCHQ; 2, TRICHQ; 3, 2,3-DCP; 4, 2,5-DCP; 5, 2,4-DCP; 
6, 2,3,6-TRICP; 7, 2,3,4-TRICP; 8, 2,4,6-TRICP; 9, 2,4,5-TRICP; 10, 2,3,5-
TRICP, 1,2-DCB; 11, 1,4-DCB; 12, 1,3-DCB; 13, 1,2,4-TRICB. 
sharply after a lagphase of 30 seconds (insert C), again demonstrating a correlation 
between secondary metabolism and covalent binding. 
A similar curve of product formation was observed when PCB was used as a 
substrate. PCB was metabolised to pentachlorophenol (PCP), tetrachlorophenols (TCP) 
and tetrachlorohydroquinone (TCHQ) as previously reported (Den Besten et al., 1989). 
Figure 3.2B demonstrates that the net formation of pentachlorophenol and 
tetrachlorophenols gradually decreased with time (6.3 nmol/mg/min at 30 seconds to 3.0 
nmol/mg/min at 10 minutes), whereas both the formation of TCHQ and covalent binding 
increased with time after an initial lagphase of 1.5 min (insert D). 
Quinones might be subjected to redox cycling with the concomitant generation of 
reactive oxygen species. Because reactive oxygen species might induce peroxidative 
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Table 3.1 Metabolism of l,2,4-[14C]-trichlorobenzene by liver microsomes from rats pre-
treated with dexamethasone. 
Incubation 
protein 
(mg/ml) 
0.5 
1.0 
Conversion3 
(nmol/5min) 
15.0 
23.0 
TRICP" 
77.1 
62.8 
TRICHQ 
4.5 
10.0 
percentage of total 
Covalently bound 
metabolites 
9.4 
17.0 
conversion 
not 
identified 
9.0 
10.2 
Note. Incubations were performed with 100 /iM 1,2,4-TRICB for 5 minutes at 37°C in the 
presence of 0.1 M potassium phosphate buffer pH 7.4, 3 mM MgCl2, 1 mM NADPH and 
microsomes from DEX-treated rats (final volume of 2 ml). Data are corrected for control 
incubations without NADPH. Variation was less than 10%. * Conversion is calculated as the sum 
of the formation of extractable metabolites, as analysed by HPLC, and the covalent binding to 
protein. b 'TRICP' denotes sum of all trichlorophenol isomers. 
Table 3.2 Microsomal conversion and covalent binding of 1,2,4-trichlorobenzene by liver 
microsomes from dexamethasone-treated rats 
Incubation 
Complete mixture 
- NAPDH 
+ metyrapone (0.5 mM) 
+ TCPO (0.5 mM) 
+ glutathione (1.0 mM) 
+ ascorbic acid 
1 mM 
5 mM 
10 mM 
Conversion 
(%) 
100a 
nil 
19 + 4 
90 ± 1 
130 ± 7 
90 + 5 
74 + 1 
65 + 5 
Covalent binding 
(%) 
100b 
9 + 3 
15 + 6 
100 ± 7 
17 + 1 
26 + 4 
19 + 1 
10 + 1 
Note. A control incubation contained 100 /iM 1,2,4-TRICB, 1 mM NADPH, 0.1M potassium 
phosphate buffer pH 7.4, 3 mM MgCl2, and 1 mg microsomal protein (final volume of 2 ml). 
Incubations were performed at 37°C for 5 min. Data are based on 2-6 observations and are 
expressed as a percentage of the conversion and covalent binding of control incubations, in which 
the following rates were observed (mean+S.D., n=10): a 14.7 + 1.4 nmol/mg/5 min, b 1.77 + 
0.20 nmol/mg/5 min. TCPO, 1,1,1-trichloropropene oxide 
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Figure 3.2 Conversion of 1,2,4-
trichlorobenzene (A) and penta-
chlorobenzene (B) by rat liver 
microsomes. Standard incubations 
were performed with 100 /tM 
1,2,4-TRICB and 1 mg micro-
somal protein, or 50 /*M PCB and 
0.25 mg microsomal protein, in a 
final volume of 2 ml, as described 
under Materials and Methods. All 
data are corrected for the binding 
in the absence of NADPH. (O) 
Total conversion; (A) phenols; 
(D) hydroquinones; ( • ) covalent 
binding. Lines without a symbol in 
inserts C and D represent the 
formation of phenols. 
10 
fime(min) 
damage to microsomal lipids, the extent of lipid peroxidation in microsomal incubations 
was determined. It was observed that the formation of TBRS was not stimulated in 
microsomal incubations containing 1,2,4-TRICB or PCB (89% and 87% of values in 
control incubations, respectively; data not shown). The results suggest that the 
hydroquinones and benzoquinones formed during the metabolism of chlorinated benzenes 
do not undergo extensive redox cycling. In a previous study, tetrachlorobenzoquinone 
was shown not to undergo redox cycling when added exogenously to a microsomal 
suspension (Van Ommen et al., 1988). 
The role of different isoenzymes of cytochrome P450 was investigated by performing 
incubations with microsomes isolated from male control rats and rats which were 
pretreated with inducers of the cytochrome P450 mono-oxygenases other than 
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Figure 3.3 Conversion to extractable metabolites ( D ) and protein bound metabolites (ES ) 
of pentachlorobenzene (A) and 1,2,4-trichlorobenzene (B) by rat liver microsomes from 
control rats and rats treated with different inducers of the cytochrome P450 
monooxygenases. Conversion is expressed as percentage increase over the values observed 
with control microsomes, which amounted to 1.98 nmol of extractable metabolites/ nmol 
P450/ 10 min, and 40 pmol of protein bound metabolites/ nmol P450/ 10 min for PCB, 
and to 2.26 nmol of extractable metabolites/ nmol P450/ 5 min and 120 pmol of protein 
bound metabolites/ nmol P450/ 5 min, for 1,2,4-TRICB, respectively. Standard incubations 
were performed with 0.5 jtM cytochrome P450, and 50 /tM PCB or 100 pM 1,2,4-TRICB 
in a final volume of 2 ml, as described under Materials and Methods. 
dexamethasone. Figures 3.3A and B clearly demonstrate that dexamethasone is the most 
powerful inducer of the microsomal metabolism of chlorinated benzenes (680% and 
570% of the activity in control microsomes for PCB and 1,2,4-TRICB, respectively). In 
addition, the amount of covalent binding expressed as percentage of total metabolism was 
significantly higher in DEX microsomes compared to control microsomes or microsomes 
from rats treated with other inducers of cytochrome P450. Figure 3.3 also indicates that 
different microsomal suspensions varied considerably in their affinity and/or catalytic 
activity towards the two chlorinated benzenes tested. 
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2,3,6 2,3,4- 2,4,6- 2,4,5- 2,3,5-
isomers of trichlorophenol 
Figure 3.4 Formation of isomers of trichlorophenol in the metabolism of 1,2,4-
trichlorobenzene by microsomes from control rats and rats pretreated with various inducers 
of the cytochrome P450 monooxygenases. ( D ) Control; ( m ) 3-MC; ( II ) ISF; ( • ) 
PB; ( m ) DEX. 
Microsomes from 3-methylcholanthrene-induced rats showed little activity towards 
PCB (53% of the activity in control microsomes), whereas they showed considerable 
activity towards 1,2,4-TRICB (240% of the activity in control microsomes). 
Figure 3.4 displays the metabolic profile of 1,2,4-TRICB by microsomes from rats 
treated with different inducers. It is noteworthy that DEX-microsomes demonstrated a 
preference for oxidative attack at the more crowded 2,3-position, resulting in the 
formation of 2,3,6-TRICP as the major isomer, whereas other microsomes oxidized the 
substrate preferentially at the unsubstituted side of the ring, resulting in 2,4,5-TRICP as 
the major trichlorophenol formed. 2,4,6-TRICP was a minor metabolite in all 
microsomal suspensions, and 2,3,4-TRICP and 2,3,5-TRICP were only formed in trace 
amounts. 
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As shown in Table 3.3, chlorinated benzenes have the potency to covalently interact in 
vitro with exogenously added DNA, although to a much lesser extent than the interaction 
with proteins (2-5% of protein binding). This DNA-binding was dependent on the 
metabolism of the chlorinated benzenes, since binding in the absence of NADPH was 
negligible. The involvement of quinones in the DNA-binding is illustrated by the 
reduction in binding in the presence of 10 mM ascorbic acid. The addition of DNA to 
the incubation mixture had no effect on the formation of soluble metabolites. 
Table 3.3 Covalent binding of chlorinated benzenes to DNA in vitro. 
Substrate 
Incubation 1,2,4-TRICB" PCBb 
(pmol bound/ mg DNA/ 10 min) 
- NADH 3 ± 2C 4 ± 0 
+ NADPH (1 mM) 131 ± 2 6 50+ 14 
+ NADPH (1 mM) 
+ ascorbic acid (10 mM) 2 3 + 5 6 ± 1 
Note. Incubations were performed for 10 min in a shaking water bath at 37°C, with 1 mg 
of microsomal protein, 3 mM MgCl2, 0.1 M potassium phosphate buffer pH 7.4, 1 mg calf 
thymus DNA, and 50 /*M PCB or 100 /*M 1,2,4-TRICB, in a final volume of 2 ml. a Total 
conversion of 1,2,4-TrCB amounted to 28.1 nmol/mg protein/10 min. b Total conversion of 
PCB amounted to 16 nmol/mg protein/10 min. c mean + SD of 2-4 observations. 
Discussion 
Liver necrosis observed after exposure to bromobenzene is believed to be due to the 
formation of its 3,4-epoxide derivative which covalently interacts with cellular 
macromolecules and causes cell death (Lau et al., 1980). However, the exact nature of 
the binding species to liver proteins has not yet been identified. In more recent studies 
the importance of secondary metabolites in the toxicity of xenobiotics has been 
recognized. Covalent binding of benzoquinones to proteins was observed during the 
microsomal conversion of phenol metabolites of bromobenzene (Lau et al., 1984a,b). In 
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fact, during metabolism of bromobenzene, a major part of the observed covalent binding 
could be ascribed to these quinone metabolites (Buben et al., 1988). Furthermore, during 
the metabolism of the fully substituted hexachlorobenzene, tetrachlorobenzoquinone 
(TCBQ) is the sole reactive metabolite formed that covalently interacts with protein and 
DNA (Van Ommen et al., 1986). A recent study into the microsomal conversion of PCB 
also indicated an important role of TCBQ in the metabolic activation of this compound 
(Den Besten et al., 1989). 
Similarly, the present study demonstrates that in the metabolism of a lower chlorinated 
benzene, 1,2,4-TRICB, quinone metabolites are also the major reactive species formed. 
The involvement of secondary metabolism in the metabolic activation is demonstrated by 
(i) the correlation in the rate of secondary metabolism, i.e., formation of hydroquinones, 
and the rate of covalent binding, both demonstrating an initial lagphase in contrast to the 
initial burst of primary oxidation, and (ii) by the complete inhibition of the covalent 
interaction with protein in the presence of the reducing agent ascorbic acid. In contrast, 
the formation of reactive metabolites from PCB could never completely be inhibited (Den 
Besten et al., 1989), which may indicate that to a small extent, reactive nonquinone 
species, presumably epoxides, interact with protein. However, the lack of increase in 
covalent binding in the presence of TCPO (Den Besten et al., 1989), an inhibitor of 
epoxide hydrolase, and the near absence of covalent binding in the first minute of 
metabolism when primary metabolism is high (Figure 3.2B), are contradictory to the 
involvement of epoxides in the covalent binding to protein. Since the ratio of covalent 
binding, i.e., formation of quinones, to TCHQ is high (> 4 after 10 minutes), it might 
be possible that the addition of 10 mM ascorbic acid is insufficient to completely prevent 
the reaction of TCBQ with microsomal protein. 
Binding of quinone metabolites to microsomal protein was of a rather non-selective 
nature and was not limited to the microsomal membrane, since soluble proteins were also 
arylated (data not shown). 
The mutagenicity and carcinogenicity of chlorinated benzenes other than 
hexachlorobenzene is still a matter of debate. The present study demonstrates the low 
DNA alkylating properties of the quinone metabolites of both PCB and 1,2,4-TRICB, 
and, hence, the low genotoxic potential of these compounds. Under conditions when 
protein binding of 1,2,4-TRICB was completely absent, and thus the formation of 
quinones completely inhibited, still about 17 % of the DNA binding was observed, which 
illustrates the relatively high affinity of epoxide metabolites to alkylate DNA. 
Cytochrome P450IIIA1, which is induced by dexamethasone over 100-fold (Wrighton 
et al., 1985), shows a unique high affinity and/or catalytic activity towards chlorinated 
benzenes. This has also been demonstrated for the fully substituted hexachlorobenzene, 
the metabolism of which was induced more than 100 times in DEX-microsomes as 
compared to control microsomes (Van Ommen et al., 1989). However, this substrate 
specificity appears to become less unique with decreasing degree of chlorination, since 
microsomes from ISF- and 3-MC treated rats converted 1,2,4-TRICB but not PCB, or 
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HCB (Van Ommen et al., 1989) to a considerable extent. The ratio of the conversion of 
PCB and 1,2,4-TRICB by DEX-microsomes to the conversion by PB-microsomes was 
remarkably constant (3.8 and 3.9, respectively). This might indicate that isoenzyme 
P450IIIA1, which is increased 20-fold in PB-microsomes (Wrighton et al., 1985), is 
responsible for the catalytic activity towards chlorinated benzenes observed in PB-
microsomes. Future experiments with purified isoenzymes of cytochrome P450 are 
needed to establish the contribution of the different isoenzymes in the metabolism of a 
range of chlorinated benzenes. 
The present study demonstrates the variation in the metabolic profile of 1,2,4-TRICB 
when different isoenzymes of cytochrome P450 are induced. This is illustrated by the 
observed variation in trichlorophenol isomers, e.g., the preferential formation of 2,3,6-
TRICP by DEX-microsomes, but not by 3-MC microsomes, whereas 2,3,4-TRICP was 
only detected in incubations with 3-MC microsomes. In addition, secondary metabolism 
to quinones, measured as covalent binding to protein, also varied depending on the 
microsomal source used: in DEX-microsomes 8.2% of all metabolites covalently 
interacted with microsomal protein, whereas in 3-MC microsomes and PB-microsomes 
the percentage of covalently bound metabolites (2.9% and 3.9%, respectively) was lower 
than in control microsomes (4.9%). A similar selective stimulation of covalent binding of 
quinone metabolites from PCB was observed. 
In the primary oxidative step of 1,2,4-TRICB the formation of 2,4,6-TRICP and 
2,3,4-TRICP can be explained via a NIH-like chlorine shift of the 2,3,5-trichloro-l,2-
benzene oxide and the l,2,4-trichloro-3,4-benzene oxide, respectively. Arene oxides have 
been shown to be intermediates in the cytochrome P450 mediated oxidation of many 
aromatic compounds, but the mechanism of their formation remains controversial. 
OH 
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Figure 3.5 Possible pathways in the formation of tetrachlorobenzoquinone (TCBQ) 
via pentachlorophenol epoxide. TCBQ may be formed by (formal) loss of a positively 
charged chlorine and subsequent oxidation of the resulting hydroquinone (route a), or 
directly via loss of a negatively charged chlorine and a proton (route b). 
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In fact, evidence is accumulating that the cytochrome P450-mediated oxidation of 
unsaturated compounds does not proceed via a direct epoxidation of the aromatic ring 
(Burka et al, 1983). A recent study on the mechanism of oxidation of aromatics using 
isotopically labeled (mono-) chlorobenzenes as probes suggested the formation of a 
tetrahedral intermediate that can rearrange to the phenol directly, or via epoxide or 
ketone intermediates (Korzekwa et al., 1989). 
The mechanism of formation of the quinones is also a matter of debate (Van Ommen 
and Van Bladeren, 1989). They might be formed by subsequent oxidation of 
hydroquinones, which would be formed via epoxidation of the primary phenol 
metabolites and subsequent (formal) loss of a positively charged chlorine (Figure 3.5, 
route a). However, electrophilic chlorine could not be trapped with 2,4- or 2,6-
dimethylphenol during microsomal oxidation of pentachlorophenol or hexachlorobenzene, 
(Van Ommen, unpublished results), although this method has been successfully applied in 
studies on the dechlorination of carbon tetrachloride (Mico and Pohl, 1982). Van Ommen 
and co-workers demonstrated that TCHQ was oxidized to TCBQ via a cytochrome P450-
dependent mechanism, most likely via the generation of reactive oxygen species (Van 
Ommen et al., 1988). However, quinones might also be formed directly upon oxidation 
of the primary phenol metabolites, via loss of a negatively charged chlorine-atom and a 
proton from the phenol-epoxide intermediate (route b). This latter pathway does not 
necessarily need an epoxide as a distinct intermediate (Guengerich and MacDonald, 
1990). Oxidation of the primary phenol metabolites via an initial hydrogen abstraction 
would yield a phenoxy radical, which could rearrange to the radical intermediates. This 
mechanism, which has been proposed for the oxidation of paracetamol (Koymans et al., 
1989), will result in the direct formation of quinones. The observation that covalent 
protein binding is detected in a fourfold excess compared to hydroquinone formation is 
supportive for such a direct formation of quinone metabolites. Additional studies need to 
be conducted in order to gain insight into the pathway that leads to the formation of these 
secondary quinone metabolites. 
In summary, the present investigation demonstrates that intermediates (presumably 
epoxides) generated during primary metabolism of 1,2,4-TRICB do not possess the 
capacity to alkylate proteins in vitro. Instead, as previously demonstrated with higher 
substituted chlorinated benzenes, quinone metabolites are the species responsible for 
covalent binding to protein. However, the extent of quinone formation in vivo might 
differ from the one obtained under the present in vitro conditions. First, the relative 
contribution of primary and secondary metabolism to the overall disposition of these 
compounds will depend on the concentration of the parent compound. For example, the 
cytochrome P450-mediated secondary oxidation of phenol metabolites could be 
diminished due to (competitive) inhibition at higher concentration of the parent 
compound. Second, the presence of conjugative (glucuronidation and sulfation) and 
reductive pathways in vivo makes predictions difficult about the relative importance of 
these two potentially reactive metabolites in the toxicity of polyhalogenated benzenes. 
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Therefore, additional studies are necessary to assess the toxic potential and the metabolic 
profile of these compounds. However, in view of the considerably higher alkylating 
potency of quinone metabolites, the importance of arene oxides in the toxicity of 
halogenated aromatics might have been overestimated so far. 
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THE INVOLVEMENT OF PRIMARY AND SECONDARY 
METABOLISM IN THE COVALENT BINDING OF 
1,2- AND 1,4-DICHLOROBENZENES 
Abstract 
The microsomal oxidation of 1,2-[14C]- and l,4-[14C]-dichlorobenzene (DCB) was 
investigated with special attention for possible differences in biotransformation that might 
contribute to the isomer-specific hepatotoxicity. Major metabolites of both isomers were 
dichlorophenols (2,5-DCP for 1,4-DCB, and 2,3- and 3,4-DCP for 1,2-DCB, 
respectively), and dichlorohydroquinones. The formation of polar dihydrodiols appeared 
to be a major route for 1,2-DCB but not for 1,4-DCB. Both the hepatotoxic 1,2-DCB 
and the non-hepatotoxic 1,4-DCB were oxidized to metabolites that covalently interacted 
with protein, and only to a small extent with DNA. Protein binding could be inhibited by 
the addition of the reducing agent ascorbic acid with a concomitant increase in the 
formation of hydroquinones and catechols, indicating the involvement of reactive 
benzoquinone metabolites in protein binding. However, in the presence of ascorbic acid, 
a substantial amount of protein-bound metabolites of 1,2-DCB was still observed, in 
contrast to 1,4-DCB where binding was nearly completely inhibited. 
This latter effect was ascribed to the direct formation of reactive benzoquinone 
metabolites in a single P450-mediated oxidation of /wra-substituted dichlorophenols (such 
as 3,4-DCP) in the case of 1,2-DCB. In contrast, the major phenol isomer derived from 
1,4-DCB, i.e., 2,5-DCP, is oxidized to its hydroquinone derivative, which needs prior 
oxidation in order to generate the reactive benzoquinone species. Residual protein 
binding in the presence of ascorbic acid could also indicate the involvement of reactive 
arene oxides in the protein binding of 1,2-DCB, but not of 1,4-DCB. However, MO 
computer calculations did not provide indications for differences in chemical reactivity 
and/or stability of the various arene oxide/oxepin tautomers that can be formed from 
either 1,2-DCB or 1,4-DCB. In conclusion, reactive intermediates in the secondary 
metabolism of 1,2-DCB lead to more covalent binding than those derived from 1,4-DCB, 
which correlates very well with their reported hepatotoxic potency. 
C. den Besten, M. Ellenbroek, M.A.E. van der Ree, I.M.CM. Rietjens, P.J. van Bladeren, 
Chem.-Biol. Interact., in press. 
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Introduction 
The hepatotoxicity of halogenated benzenes is thought to be mediated by the 
generation of (a) reactive metabolite(s) as a result of their oxidation by cytochrome P450. 
Depletion of glutathione and the covalent binding of reactive metabolites to hepatic 
proteins are common features of halogenobenzene toxicity (Brodie et al., 1971; Reid and 
Krishna, 1973). To derive a general mechanism of action for the bioactivation of these 
aromatics, bromobenzene has frequently served as a model compound (Lau and Monks, 
1988). Based on the profile of urinary metabolites of bromobenzene and on the 
correlation between changes in this pattern and in bromobenzene hepatotoxicity effected 
by pretreatment with inducing agents, toxicity and covalent binding to cellular 
macromolecules was ascribed mainly to its 3,4-oxide metabolite (Jollow et al., 1974). 
However, more recent studies stress the importance of secondary quinone metabolites in 
the covalent binding to cellular protein, both in vitro (Hesse et al., 1980; Buben et al., 
1988) and in vivo (Narasimhan et al, 1988; Slaughter and Hanzlik, 1991). 
Few studies have been conducted on halobenzenes other than bromobenzene. The type 
of halogen substituent appeared to influence the extent of hepatotoxicity observed. For 
example, fluorobenzene was much less toxic than either chloro- or bromobenzene (Brodie 
et ah, 1971). In the same study, the isomer-specific differential effect on the acute 
hepatotoxicity of dichlorobenzenes is reported: 1,2-dichlorobenzene appeared to be highly 
hepatotoxic after a single dose of 1.45 mmol/kg, whereas 1,4-dichlorobenzene produced 
little or no effect at a dose as high as 3.8 mmol/kg. This striking difference in 
hepatotoxicity between the two isomers has recently been confirmed (Den Besten et al., 
1991b; Stine et al., 1991). Furthermore, toxicity of 1,2-DCB was correlated with a 
higher rate of conversion and a higher extent of covalent binding to cellular protein 
compared to observations after exposure to 1,4-DCB (Reid and Krishna, 1973). 
The metabolic profile of dichlorobenzenes in the rabbit was reported by Williams and 
coworkers (Azouz et al., 1955), as part of an extensive series of biotransformation 
studies on halogenobenzenes. Both 1,2- and 1,4-DCB were excreted mainly as conjugated 
dichlorophenols (DCP). Minor metabolites were 3,4- and 4,5-dichlorocatechol (DCC) in 
the case of 1,2-DCB, and dichlorohydroquinone (DCHQ) in the case of 1,4-DCB. 
Formation of a mercapturic acid metabolite was reported for 1,2-DCB only. It was 
suggested that both the lack of hepatotoxic potency and the absence of mercapturic acid 
derivatives originated from the fact that /»-disubstituted benzenes cannot form sufficiently 
stable epoxides. However, in later studies a dichlorophenyl mercapturic acid was 
identified as a minor urinary metabolite in the urine of rats treated with 1,4-DCB 
(Hawkins et al, 1980). Furthermore, trace amounts of methyl thiolated metabolites of 
1,4-DCB, very probably derived from the corresponding mercapturic acids, were 
identified in blood, urine and faeces (Kimura et al, 1979). 
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Thus, the above data point at pronounced differences in, and a possible relationship 
between, both toxicity and biotransformation pathways of the two isomeric DCB's. In 
theory, differences in their biotransformation, and perhaps toxicity, may be related to 
differences in (i) the type of intermediate arene oxide formed upon the primary oxidation 
step by cytochrome P450; (ii) the reactivity and fate of these intermediates; and/or (iii) 
the formation of secondary quinone metabolites. 
The objective of the present study was to investigate these characteristics of 1,2-DCB 
and 1,4-DCB metabolism in more detail. This was done by in vitro studies on the 
microsomal metabolism of both isomers, and by AMI semi-empirical computer 
calculations on their primary (reactive) monooxygenated intermediates. Results obtained 
provided a new hypothesis for differences observed in metabolic profiles of 1,2- and 1,4-
DCB. 
Materials and Methods 
Chemicals 
l,4-[14C]-Dichlorobenzene (1,4-DCB, radiochemical purity 98.8 %) and 1,2-[14C]-
dichlorobenzene (1,2-DCB, radiochemical purity 98.8 %) were purchased from Sigma 
Chemical Co., St. Louis, MO, USA. Impurities of 1,2-DCB coeluted with 2,6-DCP and 
2,3-DCP (0.01 % each), and 3,4-DCP (0.04 %). Impurities of 1,4-DCB coeluted with 
DCHQ (0.02 %), 4-chlorophenol (0.04 %), and 2,5-DCP (0.02 %). Both substrates 
contained radioactivity that coeluted with monochlorobenzene (0.14 % and 0.16 % for 
1,2- and 1,4-DCB, respectively). For 1,2-DCB and 1,4-DCB, respectively, 1.04 % and 
1.0 % eluted as an apolar fraction (i.e., after the parent peak on reversed phase HPLC). 
Thus, with both substrates, the major portion of the impurity was present in regions that 
did not coincide with metabolite formation. Chemicals used as marker metabolites were 
obtained from commercially available sources. NADPH was from Boehringer Mannheim 
GmbH, Germany. Calf thymus DNA was from Sigma Chemical Co. All other chemicals 
were of reagent grade. 
Preparation of microsomes 
Microsomes were prepared using standard procedures as previously described (Den 
Besten et al., 1991a). For preparation of microsomes, livers were obtained from male 
Wistar rats (300 g), which were untreated (control, CON) or pretreated with 
phénobarbital (PB), 3-methylcholanthrene (3-MC), isosafrole (ISF) or dexamethasone 
(DEX) according to regimens as previously described (Den Besten et al., 1991a). 
Microsomes were stored at -80°C until use. Cytochrome P450 was determined according 
to Omura and Sato (1964) and the protein concentration was determined by the Lowry 
assay (Lowry et al., 1951). 
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Microsomal incubations 
Incubations containing 0.1 M potassium phosphate buffer pH 7.4, 3 raM MgCl2, and 1 
mg microsomal protein from DEX-pretreated rats (unless stated otherwise) in a final 
volume of 2.0 ml were performed using glass tubes with a teflon lined screw top in a 
shaking waterbath at 37°C as previously described (Den Besten et al., 1991a). In short, 
after 2 minutes of preincubation of buffer, cofactor and protein, radiolabeled substrates 
(1.2 /iCi) in acetone (2.5 % final concentration) were added at their maximal soluble 
concentration (0.8 mM). The reaction was started by the addition of NADPH (1 raM 
final concentration) and stopped by the addition of HCl (0.6 N final concentration). 
Incubation time was kept short in first instance (2.5 min), because of the high volatility 
of the chemicals. After 2.5 min at 37°C, 90 % of the added radioactivity was still 
present in the microsomal mixture, whereas the amount of radioactivity in the aqueous 
phase decreased to approximately 50 % after 15 min of incubation. However, incubations 
were also performed for 15 min to obtain higher conversions. In order to nearly 
completely recover all radioactivity added to the incubation (recovery >90 %), the 
reaction mixtures were frozen in liquid nitrogen before opening the tubes to perform the 
acid precipitation of the protein. The tubes were kept cool (4°C) thereafter. Incubations 
were also performed in the presence of ascorbic acid (for concentrations, see Table 4.2). 
Extraction of metabolites 
Extraction was performed with small volumes (0.5 ml) of ethyl acetate, which were 
collected separately. Four consecutive extractions resulted in the removal of 85 to 95 % 
of the total amount of radioactivity added to the incubation, whereas the sum of the 
radioactivity present in the aqueous phase and bound to protein amounted to less than 
1%. Thus, due to the volatility of the substrate, recovery was less than 100 %. Direct 
HPLC analysis was performed on 50 /xl of the first ethyl acetate extract, which contained 
about 87 % of all radioactivity extracted. 
HPLC analysis 
Reversed Phase High Performance Liquid Chromatography was performed using a 
Perking-Elmer Series 4 Chromatograph, equipped with a 150x4.6 mm i.d. Nucleosil 
5C18 column and a Co:Pell ODS precolumn with a flow rate of 1 ml/min and a mobile 
phase consisting of methanol (kept at 30 % throughout the assay), acetonitrile and water, 
using percentages as defined below. All phases contained 0.5 % acetic acid. 
Radioactivity was eluted using a gradient program, which started isocratically for 5 min 
with 10 % acetonitrile and 60 % water followed by a linear increase of 1.67 % 
acetonitrile per min for 12 min, followed by an increase of 4 % acetonitrile per min for 
10 min, and concluded by 5 min at 70 % acetonitrile. Microsomal metabolites were 
identified by co-elution with marker metabolites, which were injected together with the 
sample. Fractions of 0.5 ml were collected followed by scintillation counting (5 ml of 
Ultima Gold, Packard, Brussels, Belgium) in a Tri-Carb liquid scintillation counter 
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(Packard). Using the above described HPLC analysis, 2,5-DCP and 2,4-DCP, potential 
metabolites of 1,4-DCB, were not sufficiently separated to identify them as separate 
metabolites. Similarly, complete separation of 4,5-DCC and 2,6-DCP, potential 
metabolites of 1,2-DCB, was not reached by the above described method. Therefore, 
alkaline runs were conducted using a 250x4.6 mm i.d. Nucleosil 5C18 column, a mobile 
phase consisting of 20 raM Tris-phosphate buffer (pH 8.0) and a gradient as described 
previously (Den Besten et al., 1991a). The k' values observed in alkaline runs were as 
follows: 2,5-DCP, 9.3; 2,4-DCP, 11.5; 4,5-DCC, 5.8; 2,6-DCP, 4.7. Alkaline runs 
performed on extracts from incubations with 1,2-DCB failed to detect the formation of 
2,6-DCP. When alkaline runs were performed on ethyl acetate extracts of 1,4-DCB 
incubations, the radioactivity that coeluted with the DCP markers in the routine HPLC 
analysis, was now split in 3 fractions: one small fraction with k' 11.5 (= k' 2,4-DCP), 
and 2 larger fractions of about equal amounts of radioactivity, with k' 9.3 (= k' 2,5-
DCP) and k' 12.6, which could not be ascribed to any of the potential metabolites. In 
fact, since none of the chlorinated phenols, -catechols or -benzenes showed k' in the base 
and acid HPLC analysis comparable to the unknown fraction, this fraction (which 
amounted to 50 % of the radioactivity detected as DCP and which did not change in the 
presence of ascorbic acid) was not further identified. All data on formation of DCP (and 
total conversion) presented in this paper are corrected for this fraction. 
Covalent binding to protein and DNA 
Covalent binding to microsomal protein was measured after extensive washing of the 
protein pellet with 5 ml of the following organic solvents in series: 3x methanol, 3x 
ethanol, 2x ethyl acetate, 2x diethyl ether. Back ground radioactivity was detected in 
aliquots of the final ether wash. Data are corrected for binding observed in incubations 
without NADPH, which amounted to 1.3 nmol and 1.8 nmol for 1,2-DCB and 1,4-DCB 
respectively. This amount was independent of the amount of protein present, and slightly 
increased with longer incubation times. Covalent binding to exogenously-added calf 
thymus DNA ( 1 mg/ 2 ml of incubation) was measured in incubations using standard 
conditions as described above and extra added DNA. Incubation time was 15 min. DNA 
was purified as previously described (Den Besten et al., 1991a). Corrections were made 
for binding observed in incubations without NADPH, which amounted to 0.1 nmol/mg 
DNA/ 15 min for both 1,2-DCB and 1,4-DCB. 
Molecular orbital computer calculations 
Computer calculations were carried out on a Silicon graphics Iris 4D/85 using 
Quanta/Charmm (Polygen Inc., UK). The semi-empirical molecular orbital method was 
used, applying the AMI Hamiltonian from the AMP AC program (Quantum Chemistry 
Program Exchange No. 506; Indiana University, USA). All calculations were carried out 
with PRECISE criteria. For all calculations the self consistent field was achieved. 
Geometries were optimized for all bond lenghts, bond angles and torsion angles using the 
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Fletcher-Powell criteria. Frontier electron densities were calculated from HOMO and 
HOMO-1 characteristics or LUMO and LUMO+1 characteristics as described (Fukui et 
al., 1954). Results from these computer calculations represent data from compounds in 
vacuo, a situation different from the one in which the compounds are present in 
microsomal incubations, or bound to the active site of an enzyme. Solvation and a 
different dielectric constant might influence parameters calculated for the compounds in 
the in vacuo situation. However, in the present study, related compounds are compared 
and it can be assumed that deviations from the in vacuo situation due to solvation or 
binding to the active site of a protein will be similar for all compounds studied, and thus 
will not influence relative differences between these compounds. Results from computer 
calculations for molecules in vacuo can thus be used as an approach to study relative 
differences between related compounds also when dissolved in buffer or when bound to 
the active site of an enzyme. 
CON 3 - M C ISF PB DEX 
Inducing agent 
CON 3 -MC ISF PB DEX 
Inducing agent 
Figure 4.1 Microsomal oxidation of 1,2-DCB (A) and 1,4-DCB (B) to ethyl acetate extractable 
metabolites ( 0 ) and protein-bound species ( S ). Liver microsomes were isolated from 
control rats or rats pretreated with 3-methylcholanthrene (3-MC), isosafrole (ISF), 
phénobarbital (PB) or dexamethasone (DEX). Incubations were performed with 1.25 nmol 
P450 for 15 min (final volume 2 ml) as described under Materials and Methods. Conversion is 
expressed as nmol/ 15 min/ 1.25 nmol P450 and is corrected for values observed in 
incubations without NADPH. Variation in conversion and covalent binding was less than 10%. 
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Results 
Microsomal oxidation of 1,2-DCB and 1,4-DCB 
Using a battery of microsomes prepared from rats pretreated with selective inducers 
of the cytochrome P450 enzymes, the contribution of the various P450 isoenzymes to the 
oxidation of 1,2- and 1,4-DCB was investigated (Figure 4.1A, B). From the results 
obtained it follows that conversion of both dichlorobenzenes was significantly increased 
when using microsomes from rats pretreated with DEX. However, inducers of other 
P450 isoenzymes also enhanced oxidation of the dichlorobenzenes to a considerable 
extent. 
Figure 4.2 shows the HPLC separation profiles of 1,2-DCB (A) and 1,4-DCB (B) 
and their potential metabolites, using the gradient elution profile as described under 
Materials and Methods. The metabolic profiles of the two isomers of DCB in microsomal 
Figure 4.2 Separation of 1,2-DCB (A) and 
1,4-DCB (B) and their potential metabolites 
by HPLC (detected at UV 254 nm), carried 
out as described in the Method Section. 
Aliquots (50 1^) of ethyl acetate extracts of 
microsomal incubations with the respective 
DCB (final concentration 0.8 mM) were co-
injected with marker metabolites. Marker 
chemicals for 1,2-DCB (A) were: (1) 2,3-
DCHQ; (2) 3,4-DCC; (3) 4,5-DCC; (4) 2,6-
DCP; (5) 2,3-DCP; (6) 3,4-DCP; (7) 1,2-
DCB. Marker chemicals for 1,4-DCB (B) 
were: (1) 2,5-DCHQ; (2) 3,6-DCC; (3) 3,5-
DCC; (4) 2,5-DCP; (5) 2,4-DCP; (6) 1,4-
DCB. 
10 20 30 
time (min) 
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Table 4.1 Metabolism of 1,2- and 1,4-DCB by rat liver microsomes. 
Substrate 
Protein 
(mg) 
1,2-DCB 
1.2 
2.5 
5.0 
1,4-DCB 
1.1 
2.3 
4.5 
Conversion 
(nmol)a 
16 
24 
28 
7.3 
12.8 
21.0 
Polar" 
19.8 
20.8 
25.0 
Polar 
4.6 
4.5 
4.4 
Percentage of Total Metabolites 
DCHQ 
2,3-
11.6 
16.9 
27.0 
DCHQ 
2,5-
24.0 
23.8 
26.0 
DCC 
3,4- 4,5-
8.1 4.7 
10.0 2.5 
2.0 1.4 
DCC 
3,5-
4.4 
1.3 
2.2 
DCP 
2,3- 3,4-
19.0 9.3 
26.9 6.2 
16.9 4.1 
DCP 
2,4- / 2,5d 
38.3 
26.6 
18.0 
CVBC 
9.3 
16.2 
23.6 
CVB 
28.6 
43.9 
49.6 
Note. Incubations were performed with DEX-microsomes for 2.5 min as described under 
Materials and Methods. Data are corrected for blank incubations without NADPH. Data are 
based on 2-4 incubations. Variation was generally less than 10%, but never more than 20%. 
a
 Conversion is calculated as the sum of the formation of extractable metabolites as analysed by 
HPLC, and the amount of covalent binding to protein. b Polar metabolites denotes all 
radioactivity that eluted in the first 8 ml. ° CVB, covalent binding to protein. d Amount of 2,4-
DCP amounted to approximately 5-10 % of total DCPs, as determined in later experiments by 
performing alkaline runs (see under Materials and Methods). 
incubations are presented in Table 4.1. Both isomers are oxidized to dichlorophenols and 
dichlorohydroquinones as major metabolites. 3,4- and 4,5-DCC were detected as minor 
metabolites of 1,2-DCB. 3,5-DCC was detected in minute amounts as metabolite of 1,4-
DCB, and may be formed upon secondary oxidation of the 'shifted' 2,4-DCP, which is 
actually detected in small amounts. In addition to ethyl acetate extractable metabolites, 
radioactivity remained associated with microsomal protein even after extensive washings 
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1.2-DICB 1,4-DICB 
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80 -
60 -
40 
20 
•mm 
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B888881 D i c e 
^ DICHQ 
1 0 0 
- 80 
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40 
20 
2.5 min 15 min 
incubation time 
2.5 min 15 min 
incubation time 
o 
Figure 4.3 Time-dependent change in metabolic profile of 1,2-DCB (A) and 1,4-DCB (B) 
in microsomal incubations. Incubations were performed as described in the Method 
Section. Total conversion, which is calculated as the sum of ethyl acetate extractable 
metabolites as determined by HPLC, and radioactivity bound to protein, amounted to 12.0 
nmol/ mg/ 2.5 min and 25.6 nmol/ mg/ 15 min for 1,2-DCB, respectively; total 
conversion amounted to 10.4 nmol/ mg/ 2.5 min and 16 nmol/ mg/ 15 min for 1,4-DCB, 
respectively. 
with a range of solvents, indicating that both 1,2- and 1,4-DCB are metabolized to 
reactive species that covalently interact with protein. With increasing protein 
concentration the contribution of covalent binding and of DCHQ to total metabolism 
strongly increased, while the relative contribution of primary phenol metabolites 
decreased (Table 4.1). 
Interestingly, in incubations with 1,2-DCB a relatively high amount of polar 
metabolites (presumably dihydrodiols) is detected, whereas only trace amounts of polar 
metabolites were formed upon microsomal metabolism of 1,4-DCB. The difference in the 
amount of polar metabolites derived from 1,2- and 1,4-DCB is even more noticeable 
when the incubation time is increased from 2.5 min to 15 min (Figure 4.3). The 
contribution of polar metabolites to total conversion slightly decreased upon a prolonged 
incubation of 1,4-DCB, whereas polar metabolites formed during prolonged incubation of 
1,2-DCB amounted to more than 40 % of total conversion. The apparent low conversion 
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Table 4.2 Effect of ascorbic acid on the microsomal conversion of 1,2- and 1,4-DCB to 
ethylacetate extractable and protein bound metabolites. 
Substrate 
Incubation 
1,2-DCB 
Control 
+ 1 mM AA 
+ 10 mM AA 
1,4-DCB 
Control 
+ 1 mM AA 
Co val ent 
binding 
(%) 
100 
31.9± 7.8 
27.5± 4.7 
100 
6.6± 6.3 
Conversion 
(%) 
100 
98.5+ 1.3 
72.2 ± 0.8 
100 
126.5+ 33.2 
Percentage of total metabolites 
Polar 
42.4 
37.5 
35.0 
7.8 
5.5 
DCHQ 
26.1" 
28.1 
29.9 
35.3d 
61.7 
DCC 
12.1b 
(25) 
18.1 
(50) 
16.2 
(63) 
1.9e 
12.5 
DCP 
19.4e 
(12) 
16.3 
(8) 
18.8 
(9) 
22.5f 
(8) 
20.3 
(10) 
Note. Incubations were performed with DEX-microsomes for 15 min as described under 
Materials and Methods, in the absence (control incubation) or presence of ascorbic acid (AA). 
Data are based on 2-4 incubations and are expressed as percentage of the conversion and 
covalent binding in control incubations (25.9 ± 0.7 and 7.3 + 0.8 nmol/mg/15 min for 1,2-
DCB, respectively; 11.0 ± 0.9 and 5.3 + 0.7 nmol/mg/15 min for 1,4-DCB, respectively; all 
data are corrected for blank incubations without NADPH). * 2,3-DCHQ, b sum of 3,4- and 
4,5-DCC; the number in brackets denotes the amount of 4,5-DCC expressed as percentage of 
total DCC. c sum of 2,3- and 3,4-DCP; number in brackets denotes the amount of 3,4-DCP 
expressed as percentage of total DCP. d 2,5-DCHQ; e 3,5-DCC; f sum of 2,4- and 2,5-DCP; 
the number in brackets denotes the amount of 2,4-DCB expressed as percentage of total DCP. 
rates between 2.5 min and 15 min of incubation might be due to (i) a relatively high 
degree of secondary metabolism {cf., Table 4.1); (ii) the high volatility of the parent 
compound, causing lower actual substrate concentrations, thereby further increasing the 
contribution of secondary metabolism to overall conversion; and possibly (iii) protein 
inactivation due to covalent binding (see below). 
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Covalent binding to protein and DNA 
The nature of the metabolites that bound to protein was further investigated by 
performing incubations in the presence of ascorbic acid, a reducing agent. As shown in 
Table 4.2, covalent binding upon metabolism of 1,4-DCB was nearly completely 
inhibited by the addition of 1 mM of ascorbic acid to the incubation mixture. A 
concomitant increase in the formation of 2,5-DCHQ, and to a lesser extent 3,5-DCC, 
was observed. Binding due to metabolism of 1,2-DCB was decreased by 68 % in the 
presence of 1 mM of ascorbic acid, with a less pronounced increase in the formation of 
DCHQ and DCC. A ten-fold increase in the concentration of ascorbic acid diminished 
the covalent binding only by an additional 5 %, whereas it inhibited conversion of 1,2-
DCB to ethyl acetate extractable metabolites by nearly 30 %. 
Covalent binding to calf-thymus DNA (1 mg) added to a standard microsomal 
incubation amounted to levels just slightly above background, i.e., 0.1 nmol/mg/ 15 min, 
for both 1,2-DCB and 1,4-DCB, indicating that these compound are not metabolized to 
products with a high genotoxic potential (data not shown). This is in agreement with 
recent observations on the low extent of DNA-binding of metabolites of 1,4-
dibromobenzene (Colacci et al., 1990), and is consistent with the low reactivity of 
chlorinated benzoquinones towards nucleic acids (Den Besten et al, 1991a). 
Molecular orbital computer calculations 
In order to see whether theoretical data would provide support for the observed 
metabolite profiles of the two isomers of DCB, molecular orbital (MO) computer 
calculations were carried out. An important factor which has to be taken into account is 
that arene oxides are in dynamic equilibrium with their oxepin form (Boyd and Jerina, 
1985). Experimental evidence for the existence of differences in reactivity between arene 
oxides and their oxepin tautomers has never been provided, hampered by difficulties 
associated with studying equilibria. However, theoretical MO studies can overcome this 
problem. Therefore, Table 4.3 presents results from AMI semi-empirical MO 
calculations for the various arene oxide-oxepin tautomers from 1,2- and 1,4-DCB. These 
data indicate that the intrinsic chemical characteristics of the various arene oxides and 
their corresponding oxepins derived from 1,2-DCB are comparable to those derived 
from 1,4-DCB. Thus, differences in product formation and/or covalent binding of 1,2-
and 1,4-DCB cannot simply be explained by differences in calculated chemical reactivity 
of their respective arene oxide intermediates. 
Furthermore, as demonstrated by an MO study the arene oxide-oxepin equilibrium is 
influenced by the substituent pattern of the ring (Hayes et al., 1980). Table 4.3 shows 
the ratio's for the number of resonance structures of the respective arene oxides and 
oxepins, determined as previously described (Hayes et al, 1980). From the ÔHF, 
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Table 4.3 Molecular orbital characteristics for DCB arene oxides and oxepins as calculated 
by semi-empirical AMI calculations. 
Compound 
12-DCB-23-oxide 
12-DCB-34-oxide 
12-DCB-45-oxide 
14-DCB-12-oxide 
14-DCB-23-oxide 
12-DCB-23-oxepin 
12-DCB-34-oxepin 
12-DCB-45-oxepin 
14-DCB-12-oxepin 
14-DCB-23-oxepin 
Frontier orbital 
CI 
0.60 
0.42 
0.32 
0.04 
0.58 
0.25 
0.38 
0.44 
0.46 
0.20 
C2 
0.04 
0.65 
0.32 
0.02 
0.02 
0.05 
0.19 
0.44 
0.37 
0.43 
density 
C3 
0.02 
0.02 
0.59 
0.61 
0.02 
0.36 
0.42 
0.14 
0.13 
0.43 
on 
C4 
0.54 
0.02 
0.02 
0.38 
0.58 
0.13 
0.39 
0.38 
0.40 
0.20 
C5 
0.28 
0.49 
0.02 
0.27 
0.32 
0.36 
0.15 
0.38 
0.37 
0.34 
C6 
0.37 
0.23 
0.59 
0.54 
0.32 
0.30 
0.41 
0.14 
0.19 
0.34 
07 
0.10 
0.09 
0.10 
0.11 
0.09 
0.01 
0.00 
0.00 
0.00 
0.01 
Rest of 
molecule 
0.05 
0.06 
0.04 
0.03 
0.07 
0.09 
0.06 
0.08 
0.08 
0.05 
Charge on CI C2 C3 C4 C5 C6 07 
-0.08 
-0.05 
-0.05 
+0.05 
+ 0.05 
-0.09 
-0.05 
-0.01 
-0.01 
-0.01 
-0.14 
-0.15 
-0.15 
-0.02 
-0.02 
-0.04 
-0.11 
-0.14 
-0.02 
-0.11 
-0.11 
-0.11 
-0.14 
-0.13 
-0.21 
-0.22 
-0.22 
-0.21 
-0.09 -0.01 -0.01 -0.09 -0.11 -0.11 -0.22 
-0.09 +0.03 -0.02 -0.17 -0.11 -0.12 -0.16 
-0.05 
-0.05 
+ 0.04 
-0.12 
-0.12 
-0.05 
-0.01 
-0.01 
+ 0.01 
-0.19 
-0.17 
-0.01 
-0.01 
+ 0.01 
-0.05 
-0.12 
-0.19 
+ 0.01 
-0.11 
-0.11 
-0.10 
-0.19 
-0.16 
-0.11 
-0.18 
-0.19 
-0.17 
-0.17 
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Table 4.3 -continued-
HF 
(kcal/mol) 
20.36 
15.01 
16.12 
19.07 
13.76 
8.32 
5.45 
4.09 
6.48 
4.54 
E(LUMO) 
(eV) 
-0.62 
-0.64 
-0.61 
-0.61 
-0.69 
-0.72 
-0.73 
-0.75 
-0.79 
-0.77 
E(LUMO+l) 
(eV) 
0.62 
0.76 
0.77 
0.57 
0.68 
0.28 
0.42 
0.56 
0.28 
0.43 
A H F oxepin-oxide 
(kcal/mol) 
-12.04 
-9.56 
-12.03 
-12.59 
9.22 
Ratio resonance 
structures 
oxideroxepin" 
3:5 
4:4 
3:5 
2:5 
5:2 
Note. For easier comparison, numbering of the atoms was chosen in such a way that in the 
oxide and the oxepin the same atom numbers are connected to the oxygen atom. The oxygen 
atom was always numbered 7. a Calculated as described by Hayes et al, 1980. 
calculated as the HF of the oxepin minus the HF obtained for the corresponding arene 
oxide, it follows that a higher number of resonance structures for the oxepin form is 
reflected by a relatively more thermodynamically stable oxepin with respect to the arene 
oxide, i.e., a more negative ÔHF. This is in accordance with observations based on 
MIND03 calculations for other substituted arene oxides (Hayes et al, 1980). From the 
ÔHF data presented in Table 4.3 it follows that the oxide-oxepin equilibrium will be 
shifted more in favor of the oxepin, when going from l,4-DCB-l,2-oxide/oxepin > 1,2-
DCB-2,3-oxide/oxepin = l,2-DCB-4,5-oxide/oxepin > l,2-DCB-3,4-oxide/oxepin > 
l,4-DCB-2,3-oxide/ oxepin. Such a shift in the arene oxide/ oxepin equilibrium may be 
of importance, especially when these two tautomers would show a differential reactivity 
for specific reactions. 
In fact, results from the AMI calculations indicate that the frontier orbital 
characteristics for nucleophilic attack (Fleming, 1976) on the respective arene oxides and 
corresponding oxepins vary considerably (Table 4.3). In the arene oxides, the carbon 
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atoms connected to the oxygen atom contain almost no frontier orbital density for 
nucleophilic attack, making their electrophilic reactivity low. In contrast, the same 
carbon atoms in the oxepin contain significant frontier density for nucleophilic attack. 
This implies that the reactivity of these carbon atoms for nucleophilic attack is 
significantly increased going from the oxide to the oxepin. Since nucleophilic attack on 
the arene oxide-oxepin by for instance a water molecule in the active site of the enzyme 
epoxide hydrolase will occur at these carbon atoms, it can be derived that, if no other 
structural characteristics are taken into account, oxepins might be better substrates for 
epoxide hydrolase than the corresponding arene oxides. 
Discussion 
Hepatotoxicity of dichlorobenzenes has been shown to correlate with the extent of 
covalent binding to liver protein, which has been reported to be 6-fold respectively 10-
fold higher following a single dose of 1,2-DCB compared to an equivalent dose of the 
1,4-isomer (Reid and Krishna, 1973; Stine et al., 1991). The involvement of oxidative 
metabolism in the covalent binding and hepatotoxicity of 1,2-DCB was demonstrated in 
rats, which were pretreated with either an inducer (phénobarbital, PB) or an inhibitor 
(SKF-525A) of cytochrome P450 (Reid and Krishna, 1973). Induction of the cytochrome 
P450 activity had no effect on the (lack of) hepatotoxic potential of 1,4-DCB (Stine et 
al., 1991), whereas covalent binding to liver protein was actually decreased in rats 
pretreated with PB (Reid and Krishna, 1973). These results strongly suggest a crucial 
role for cytochrome P450 in the oxidation of the 1,2-substituted isomer to reactive (and 
toxic) species, and of the 1,4-substituted isomer to harmless metabolites. Therefore, the 
present study was directed at a comparison of the microsomal oxidation of the 
hepatotoxic 1,2-DCB and the non-hepatotoxic 1,4-DCB. 
The present study indicates that the selective high contribution of cytochrome P450IIIA 
(induced by DEX) towards the oxidation of chlorinated benzenes as previously 
demonstrated for hexachlorobenzene (Van Ommen and Van Bladeren, 1989), 
pentachlorobenzene and 1,2,4-trichlorobenzene (Den Besten et al., 1991a), appears to be 
less prominent for lower chlorinated benzenes like DCB. Apparently, with decreasing 
degree of chlorination, the contribution of other P450 isoenzymes (especially P450IA 
isoenzymes) becomes more important. 
In Figure 4.4, a schematic overview is presented of the different pathways in the 
oxidation of 1,2-DCB (A) and 1,4-DCB (B) by rat liver microsomes. 1,2-DCB is mainly 
oxidized to 2,3-DCP, and to a lesser extent to 3,4-DCP. The absence of 2,6-DCP as a 
metabolite of 1,2-DCB corresponds with the absence of 2,6-dimethylphenol as a 
microsomal metabolite of o-xylene (Kaubisch et al., 1972), suggesting that in a 
microsomal incubation the 2,3-disubstituted-l,2-epoxide is not formed. 2,5-DCP was the 
major DCP-isomer formed upon microsomal oxidation of 1,4-DCB, with only a trace 
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amounts of 2,4-DCP detected. This is in agreement with the in vivo metabolic profile in 
rat urine, in which only a trace of 2,4-DCP was present (Hawkins et al., 1980). 
In addition to phenol formation, microsomal oxidation of dichlorobenzenes results in 
the formation of major amounts of hydroquinones and minor amounts of catechols, which 
increase in the presence of ascorbic acid, indicating that their oxidized analogs 
(semiquinone anions or benzoquinones) contribute to the covalent binding. In vivo and in 
isolated hepatocytes, catechols are primarily formed by oxidation of dihydrodiols. 
However, due to the absence of the cytosolic enzyme dihydrodiol dehydrogenase in 
microsomal preparations, catechol formation in microsomal incubations must arise from a 
subsequent oxidation of the primary phenols (Miller et al., 1990). 
An interesting feature in the microsomal metabolism of 1,2-DCB as compared to 1,4-
DCB is the formation of a relatively high amount of dihydrodiols. These polar 
metabolites are formed by the epoxide hydrolase catalysed conjugation of epoxides with 
water. Results from AMI semi-empirical computer calculations suggested that the oxepin 
forms of the various DCB arene oxides have better substrate characteristics for the 
nucleophilic attack by a water molecule than the corresponding arene oxide tautomers. 
These theoretical data can be helpful in finding a rationale for the observed differences in 
microsomal formation of polar dihydrodiols of 1,2- and 1,4-DCB. From arene oxides/ 
oxepins which are relatively more in the oxepin form, formation of polar dihydrodiol 
metabolites might be favored, whereas isomerization to phenols -which is well known to 
arise from rearrangement of the oxide tautomer (Jerina et al., 1971)- and subsequent 
oxidation of the phenol to secondary metabolites becomes relatively more important when 
the arene oxides/ oxepin equilibrium is shifted in favor of the oxide tautomer. For those 
intermediates that actually may serve as substrate for the epoxide hydrolase-catalysed 
conjugation with water, the relative importance of the oxepin declines in the order: 1,2-
DCB-4,5-oxide/ oxepin > l,2-DCB-3,4-oxide/ oxepin > l,4-DCB-2,3-oxide/ oxepin. 
Thus, relatively more oxepin intermediates can be expected in the oxidation of 1,2-DCB 
compared to 1,4-DCB, and this would explain the observation that from 1,2-DCB 
relatively more polar metabolites are formed than from 1,4-DCB. The near-absence of 
covalent binding of 1,4-DCB to liver protein in vivo is not simply due to the inability of 
cytochrome P450 to produce reactive metabolites of this substrate per se. The present 
study clearly demonstrates that in a subcellular system, 1,4-DCB is readily oxidized to 
reactive species which covalently interact with protein. Apparently, in the in vivo 
situation, other factors are involved which modulate the generation of reactive species -
and ultimately hepatotoxicity. For example, the P450 isoenzyme status may influence the 
extent to which a compound is bioactivated, as illustrated by the differential effect of 
P450-inducers on the covalent binding observed (Figure 4.1). However, this can not be 
the only explanation for the isomer-specific hepatotoxicity of dichlorobenzenes, since in 
the absence of ascorbic acid PB-microsomes clearly increase covalent binding of 1,4-
DCB (Figure 4.1), whereas exposure of PB-pretreated rats to 1,4-DCB does not results 
in covalent binding to liver protein (Reid and Krishna, 1973) and does not lead to 
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hepatotoxicity (Stine et al., 1991). A main additional factor in vivo may be the 
abundance of reducing equivalents (see below). 
An interesting observation of the present study is the fact that ascorbic acid only 
partially inhibited protein binding of 1,2-DCB, whereas protein binding of 1,4-DCB 
metabolites was nearly completely inhibited. These data seem to indicate that (i) covalent 
binding of 1,4-DCB is completely due to quinone metabolites; and (ii) upon microsomal 
metabolism of 1,2-DCB, reactive species other than quinone or catechol metabolites are 
formed that interact with macromolecules. Most likely candidates are intermediates 
(presumably epoxides) formed upon the primary oxidative event. However, based on 
AMI computer calculations (Table 4.1) no differences are observed in intrinsic chemical 
parameters of the various arene oxides (and their oxepins) derived from either 1,2- or 
1,4-DCB. In addition, based on studies with bromobenzene, serious questions are raised 
with respect to the alkylating potency of halobenzene-epoxides towards protein 
nucleophiles, since (i) conjugation of bromobenzene-3,4-epoxide with glutathione 
requires enzymatic catalysis (Monks et al., 1982); and (ii) bromobenzene derived 
epoxide adducts account for only < 0.5% of total protein binding in vivo (Slaughter and 
Hanzlik, 1991). Moreover, the reactivity towards protein of epoxides formed in the 
oxidation of higher chlorinated benzenes was negligible (Den Besten et al., 1989; Den 
Besten et al., 1991a; Van Ommen and Van Bladeren, 1989). 
A more likely explanation for the observed difference in the residual protein binding in 
the presence of ascorbic acid can be found in the secondary oxidation of the phenolic 
metabolites. Recent studies have pointed at the existence of different mechanisms for the 
cytochrome P450-mediated oxidation of para- and non-para-halogenated phenols 
(Rietjens and Vervoort, 1991; Den Besten et al., in preparation). The cytochrome P450 
dependent oxidation of halophenols with a halogen substituent at the para-position with 
respect to the hydroxyl moiety (such as 3,4-DCP) will result in the direct formation of a 
reactive benzoquinone and elimination of the halogen as a halogen anion. Oxidation of a 
non-parc-substituted halophenol (such as 2,5-DCP) results in the formation of 
hydroquinone, which needs further oxidation to its benzoquinone derivative before it is 
sensitive to nucleophilic attack. Chemical reduction by ascorbic acid of reactive 
benzoquinone metabolites formed directly from the phenol precursor may be less 
efficient, and consequently incomplete, compared to the ascorbic acid-mediated 
prevention of the oxidation of the hydroquinone metabolite. This would explain the 
ascorbic acid mediated inhibition of covalent binding during 1,2- and 1,4-DCB 
metabolism in an another way than by assuming an additional and different type of 
binding species for the two compounds. 
In conclusion, the difference in hepatotoxicity of 1,2-DCB vs 1,4-DCB appears to 
correlate with the degree of microsomal protein binding in the presence of reducing 
equivalents. Although the experimental data in the present study do not strictly rule out a 
role for epoxides in the covalent binding (and hepatotoxicity) of 1,2-DCB, theoretical 
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data did not provide support for significant differences in the stability and reactivity of 
the various epoxides (and oxepins) derived from either 1,2- or 1,4-DCB. Direct 
formation of quinone metabolites in a single oxidation step is suggested as an explanation 
for the observed differences in protein binding. This might contribute to differences in in 
vivo covalent binding (and/or toxicity) between the two isomers, because reducing 
equivalents present in a cell may (completely) prevent formation of quinones in the 
metabolism of 1,4-DCB but not in the metabolism of 1,2-DCB. 
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CYTOCHROME P450 MEDIATED OXIDATION OF 
/wra-HALOGENATED PHENOLS TO BENZOQUINONES 
AND NON-para-HALOGENATED PHENOLS TO 
HYDROQUTNONES AS PRIMARY REACTION PRODUCTS 
Abstract 
The mechanism of oxidative dehalogenation of halogen-substituted arènes is still a 
matter of debate. In the present study, pentafluoro- and pentachlorophenol and their non-
para-halogenated analogs were used as model compounds and metabolite patterns were 
determined using "F-NMR and HPLC. In order to study the primary oxidation products, 
microsomal incubations were performed using different electron and oxygen donors. Both 
in an aerobic, NADPH-driven system and in an anaerobic, cumene hydroperoxide-driven 
system, tetrahalogenated phenols were oxidized to their corresponding hydroquinones. 
However, the formation of tetrahalohydroquinone as a product of the cytochrome P450 
oxidation of pentahalogenated phenols was only observed in the NADPH-driven system. 
Cumene hydroperoxide-dependent cytochrome P450 mediated oxidation of pentafluoro-
phenol and [l4C]-pentachlorophenol resulted in the formation of fluoride anion and 
covalently bound material, respectively. Addition of reducing equivalents (like NADH) to 
these incubations resulted in the formation of the halohydroquinones with a concomitant 
decline in the formation of fluoride anion (in the case of pentafluorophenol) or covalently 
bound material (in the case of [14C]-pentachlorophenol). Based on these results, it was 
concluded that cytochrome P450-mediated oxidation of the non-para-halogenated phenols 
results in the formation of their para-hydroxylated derivatives, i.e., hydroquinones, as 
the primary reaction products. However, oxidation at a halogenated para-position with 
respect to the hydroxyl moiety is proposed to result in the formation of the reactive 
benzoquinone derivative as the primary reaction product with the concomitant loss of the 
halogen as a halogen anion. This direct formation of reactive benzoquinones upon 
cytochrome P450 catalyzed oxidation of halogenated aromatic compounds may very well 
have toxicological implications. 
C. den Besten, E. Duizer, J. Vervoort, I.M.C.M. Rietjens, P.J. van Bladeren, manuscript in 
preparation 
Oxidation of 'halogenatedphenols to hydroquinones and benzoquinones 
Introduction 
In the toxicity of halogenated benzenes, bioactivation to chemically reactive species is 
thought to be involved (Brodie et al., 1971). Indeed, during microsomal metabolism of 
chlorinated benzenes a considerable amount of covalent binding to protein is observed. 
Secondary benzoquinone metabolites formed upon further oxidation of the primary 
phenols have recently been implicated to be the reactive species involved in the 
metabolism of hexachlorobenzene (Van Ommen et ai, 1986a), pentachlorobenzene (Den 
Besten et al., 1989), 1,2,4-trichlorobenzene (Den Besten et al., 1991), 1,2- and 1,4-
dichlorobenzene (Den Besten et al., 1992), and bromobenzene (Buben et al., 1988). This 
prompted us to investigate more closely the mechanism of formation of these 
benzoquinones from the primary phenol metabolites. 
Traditionally, the enzymatic oxidation of aromatic compounds has been considered in 
terms of epoxidation (Jerina and Daly, 1974). In the last decade, evidence has been 
gathered that cytochrome P450-mediated oxidation of aromatic rings does not proceed by 
a concerted process, i.e., direct oxygen insertion across a carbon-hydrogen bond or a 
carbon-carbon double bond (Burka et al., 1983, Korzekwa et al., 1989, Guengerich and 
MacDonald, 1984). Rather, a mechanism has been proposed involving the initial 
formation of an intermediate iron-oxo-x-complex, which proceeds via a tetrahedral 
intermediate (either a (bi-)radical or a nonradical cationic intermediate) and subsequently 
rearranges to the observed products (Guengerich and MacDonald, 1990). In addition, for 
compounds containing hydroxyl- or amino substituents, oxidation proceeding via an 
initial hydrogen radical or electron abstraction provides an additional possible mechanism 
(Koymans et al., 1989). 
In the past it has been suggested that oxidation of arènes at a halogenated position, as 
in the case of pentachlorophenol, proceeds by a mechanism analogous to arene oxidation 
at a non-halogenated position resulting in a hydroxylated product (Ahlborg et al., 1978, 
Van Ommen et al., 1986b). Tetrachlorohydroquinone has indeed been detected as a 
metabolite of pentachlorophenol both in vitro (Van Ommen et al, 1986b) and in vivo 
(Renner and Hopfer, 1990). Taking the P450 reaction as a net two-electron transfer, the 
halogen is formally lost as a halogen cation (depicted in route a, Figure 5.1). However, 
the actual mechanism of (oxidative) dehalogenation resulting in a hydroxylated product is 
still a matter of debate; particularly, the nature of the halogen ion lost has never been 
unambiguously demonstrated. Direct formation of tetrachlorobenzoquinone upon 
oxidation of pentachlorophenol accompanied by loss of a halogen anion (route c, Figure 
5.1) has been suggested as one of the alternative pathways (Van Ommen and Van 
Bladeren, 1989). Theoretically, formation of the semiquinone anion radical accompanied 
by the formal loss of a chlorine radical is also feasible upon oxidation of 
pentachlorophenol (route b, Figure 5.1). 
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Figure 5.1 Possible pathways of cytochrome P450-mediated oxidation of PCP, taking into 
account the electron balance for the P450 reaction. PCP might be oxidized to tetrachloro-
hydroquinone via elimination of a chloride cation {route a), to tetrachlorosemiquinone anion 
radical via elimination of a chloride radical (route b), or to tetrachlorobenzoquinone via 
elimination of a chloride anion (route c). 
The current lack of experimental evidence favouring any of these mechanisms is due 
to several complicating factors that are present when performing mechanistic studies with 
these substrates. On the one hand, direct formation of benzoquinones may be masked by 
their swift covalent binding to protein due to their high reactivity (Van Ommen et al., 
1988a). On the other hand, the presence of reducing equivalents like NADPH makes it 
impossible to probe the cytochrome P450-dependent oxidation, since any benzoquinone 
formed may subsequently be reduced to its hydroquinone. 
In recent studies using fluoroanilines and 19F-NMR (Rietjens et al., 1990, Rietjens 
and Vervoort, 1991) evidence was obtained for the formation of benzoquinoneimines and 
a halogen anion as the primary reaction products of the cytochrome P450-dependent 
oxidation of /»ara-fluorinated anilines. The present study was undertaken to test whether 
the cytochrome P450-dependent oxidation of para-halogenated phenols proceeds by a 
similar reaction pathway. Pentafluorophenol and 2,3,5,6-tetrafluorophenol were used as 
model substrates to investigate the oxidation at a halogenated and a non-substituted 
position para with respect to the hydroxyl moiety. In addition, the conversion of their 
chlorinated analogs was studied to investigate whether the type of halogen substituent 
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influences the mechanism of oxidation. Based on the results obtained, a plausible reaction 
pathway for the cytochrome P450-dependent dehalogenation and oxidation of halophenols 
is presented. 
Materials and Methods 
Chemicals 
Pentafluorophenol (PFP), 2,3,5,6-tetrafluorophenol (TFP), 2,3,5,6-tetrafluorohydro-
quinone (TFHQ), pentachlorophenol (PCP) and 2,3,5,6-tetrachlorophenol (TCP) were 
purchased from Aldrich (Steinheim, Germany). 2,3,5,6-Tetrafluorobenzoquinone (TFBQ) 
was from Fluorochem (Derbyshire, UK). 2,3,5,6-Tetrachlorohydroquinone (TCHQ) was 
obtained by the ascorbic acid-mediated reduction of its tetrachlorobenzoquinone analog 
(Merck, Schuchard, Germany). [14C]-Pentachlorophenol was from Sigma, Chemical Co. 
(St. Louis, MO, USA), and had a radiochemical purity of 99.9 %. NAD(P)H was from 
Boehringer-Mannheim (Mannheim, Germany). Cumene hydroperoxide (CumOOH) was 
from Aldrich (Steinheim, Germany). 
Preparation of microsomes 
Microsomes from untreated rats were prepared as previously described (Den Besten et 
al, 1989) and stored at -80° C until used. Protein was determined according to Lowry 
using bovine serum albumin as a standard (Lowry et al., 1951). Cytochrome P450 was 
determined as described by Omura and Sato (1964). 
Microsomal incubations 
Microsomal incubations (final volume of 2 ml) were carried out as previously 
described. In short, fluorinated phenols (3 mM final concentration) in acetone (2.5 % 
final concentration) were added to an incubation mixture containing 0.1 mM potassium 
phosphate pH 7.4 and microsomal protein (2 nmol P450/ml) in glass culture tubes with a 
teflonized rubber cap. After 2 min of preincubation at 37° C, the reaction was started by 
the addition of NADPH (1 mM final concentration). Reactions were terminated after 5 
min by the addition of HCl (0.6 N final concentration). Ascorbic acid (1 mM final 
concentration) was also added to prevent oxidation of the hydroquinone formed. The 
reaction mixtures were frozen in liquid nitrogen and stored at -20°C. After centrifugation 
upon thawing, the supernatant was made anaerobic by four cycles of evacuation and 
filling with argon, and directly analysed by 19F-NMR. In some incubations, cumene 
hydroperoxide (CumOOH, 0.25 mM final concentration, suspension in water) was used 
as an oxygen donor, and NADH (1 mM final concentration) as a reducing agent. For 
these incubations, the preincubation mixture as well as the CumOOH solution and the 
NADH solution were made anaerobic by four cycles of evacuation and filling with argon. 
The reactions were started by the addition of CumOOH and/ or NADH. 
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Similar incubations were performed with 2,3,5,6-tetrachlorophenol (TCP). 
Incubations were also performed with [14C]-labeled pentachlorophenol (PCP, 1.4 /xCi in a 
final volume of incubation of 1.0 ml) to detect covalent binding to protein in addition to 
metabolite formation. Extraction of acid-precipitated incubation mixtures with diethyl 
ether and subsequent HPLC analysis of the concentrated sample as previously described 
(Den Besten et al., 1989) could not be used in incubations containing CumOOH due to a 
number of UV-detectable disturbing peaks which were also present in blank incubations 
(i.e., without substrate). Therefore, all incubations with chlorophenols were stopped by 
freezing the reaction mixture in liquid nitrogen and after centrifugation upon thawing, the 
supernatant was directly analysed by HPLC. Product ratio's thus analysed were 
comparable to those obtained after the procedure of concentrating the sample by 
extraction with organic solvents. 
HPLC analysis 
Supernatants from the chlorophenol incubations were analysed by HPLC, using a 
Perkin Elmer Series 4 equipment with a 150 x 4.6 mm Nucleosil 5C18 column. The 
eluent was monitored at 300 nm. The mobile phase consisted of an aqueous solution of 
0.5 % acetic acid and methanol (50 %/ 50%) for 5 min, followed by a linear gradient of 
2 % methanol per min to 90 % methanol and a second isocratic elution with 90 % 
methanol for 10 min (k' PCP 12.2, k' TCP 10.7, k' TCHQ 5.7, k' TCBQ 7.1). The 
amount of TCHQ was quantitated by comparing peak areas to the peak areas obtained 
from a series of standards (lower detection limit of 0.25 nM). The eluent of incubations 
with [14C]-PCP was also assayed for radioactivity. To this end, fractions of 0.5 ml were 
collected followed by scintillation counting (in 5 ml of Ultima Gold, Packard, Brussels, 
Belgium) in a TriCarb liquid scintillation counter (Packard). 
Covalent binding to protein 
After sampling the supernatant for HPLC analysis, protein was precipitated in the 
remaining supernatant by the addition of 5 ml of methanol. Upon centrifugation, the 
resulting protein pellet was extensively washed with organic solvents of decreasing 
polarity as previously described (Den Besten et al, 1991). Covalent binding to protein 
was measured as reported previously (Den Besten et al., 1991). Protein binding was 
corrected for the binding observed in incubations without an electron donor, which 
amounted to 2.5 ± 0.05 nmol/ 5 min/ nmol P450. 
19F-NMR measurements 
For 19F-NMR measurements samples were routinely made oxygen-free by four cycles 
of evacuation and filling with argon gas. "F-NMR measurements were performed as 
previously described (Rietjens et al., 1990). Briefly, a Bruker CXP 300 spectrometer 
operating at 282.3 MHz with a 10 mm 19F Bruker probe head and Norell (Landsville, 
NJ, USA) 10 mm NMR tubes were used. The sample volume was 1.71 ml, containing 
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100 /xl 2H20, and the temperature was kept at 7° C. Proton decoupling was achieved 
with the Waltz-16 pulse sequence at -16 dB from 20W. Nuclear Overhauser effects were 
eliminated using the inverse gated decoupling technique. Spectra were obtained with 30° 
pulses (6 us), a 50 kHz spectral width, repetition time of 1 s, quadrature phase detection 
and quadrature phase cycling (CYCLOPS). Between 20,000 and 50,000 scans were 
recorded. To improve signal to noise ratio, the free induction decays were multiplied by 
an exponential decay resulting in an increase of the linewidth by 5 Hz. The 
concentrations of the substrates and products were determined from the integrals of their 
"F-NMR resonances. Concentrations were calculated by comparison of these integrals to 
the integral from the "F-NMR resonance of /wra-fluorobenzoic acid added to each 
sample as an internal standard. Chemical shifts are reported relative to CFC13. 
Identification of ,9F-NMR resonances 
The "F-NMR chemical shifts for the standard compounds relative to CFC13 acquired 
under our standard experimental conditions (incubations performed in 0.1 M potassium 
phosphate pH 7.4, stopped by acidifying the reaction by the addition of 0.6 N HCl (final 
concentration), after which 1 mM ascorbic acid was added; measured at 7° C) were as 
follows: fluoride anion - 164.1 ppm; pentafluorophenol, - 167.2 ppm (F2,F6), - 169.5 
ppm (F3.F5), -174.7 ppm (F4); 2,3,5,6-tetrafluorophenol, - 146.0 ppm (F3,F5), - 166.9 
ppm (F2,F6); 2,3,5,6-tetrafluorohydroquinone, - 168.4 ppm (F2,F3,F5,F6). Resonances 
could be ascribed to specific fluorine substituents on the basis of (i) relative signal 
intensities, (ii) splitting patterns in proton coupled and decoupled spectra, and (iii) the 
knowledge that meta-substituents only slightly influence "F-NMR chemical shifts, 
whereas ortho- and ^ora-substituents have a much larger effect. 
Results and Discussion 
NADPH-Dependent microsomal oxidation of halophenols 
Fluorophenols. Incubation of TFP or its /7arû-fluorinated analog, PFP, with rat liver 
microsomes in the absence of an electron donor did not result in formation of metabolites 
(Figure 5.2a and 5.3a). In the presence of NADPH and molecular oxygen, formation of 
TFHQ is observed for both TFP and PFP (singlet at - 168.4 ppm, Figure 5.2b and 
5.3b). In addition to TFHQ, formation of a considerable amount of fluoride anion was 
observed in incubations with PFP (singlet at - 164.1 ppm, Figure 5.3b), whereas in 
incubations with TFP only a small amount of fluoride anion was detected (Figure 5.2b). 
From these data, which are quantitatively presented in Table 5.1, it can be derived that 
PFP and TFP were metabolized to a comparable extent in a NADPH-driven P450 
dependent oxidation. However, the ratio of fluoride anion to TFHQ is much higher for 
106 
Chapter 5 
PPM PPM 
Figure 5.2 "F-NMR spectra from 
microsomal incubations with 2,3,5,6-
tetrafluorophenol. 
Figure 5.3 19F-NMR spectra from 
microsomal incubations with penta-
fluorophenol. 
Note to Figure 5.2 and Figure 5.3 Different electron and oxygen donors were used, 
(a), Blank under aerobic conditions, but without an electron donor; (b), NADPH 
under aerobic conditions; (c), cumene hydroperoxide under anaerobic conditions; (d), 
cumene hydroperoxide + NADH under anaerobic conditions. Microsomal incubations 
with substrate and NADH gave similar results as blank incubations ("F-NMR spectra 
not shown). Control incubations with substrate and either cumene hydroperoxide or 
NADH did not result in any product formation (19F-NMR spectra not shown). The 
resonance marked 'IS' is derived from the internal standard pa/-a-fluorobenzoic acid. 
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Table 5.1 Conversion of 2,3,5,6-TFP and PFP to TFHQ and fluoride anion by rat liver 
microsomes in the presence of different electron and oxygen donating systems. 
Substrate 
Incubation 
conditions 
2,3,5,6-TFP 
Blank / 0 2 
NADPHC / 0 2 
CumOOH" 
CumOOH + NADHd 
NADH 
F" 
< 0.5" 
3.1 
107 
4.8 
< 0.5 
TFHQ 
< 0.1" 
7.2 
3.8 
16 
< 0.1 
Ratio 
F": TFHQ 
0.4 
29 
0.3 
Total 
MIN 
7.9b 
31 
17 
conversion 
MAX 
10b 
111 
21 
PFP 
Blank/ 0 2 
NADPHC / 0 2 
CumOOH" 
CumOOH + NADHd 
NADH 
< 0.5 
14 
211 
31 
< 0.5 
< 0.1 
3.4 
< 0.1 
14 
< 0.1 
4.1 
> 2100 
2.2 
6.0 
43 
18 
14 
> 2100 
31 
Note. Incubations were carried out as described under Materials and Methods, in a final 
volume of 2 ml. Blank incubations contained no electron donor. Product formation was 
analysed by "F-NMR. a Data are expressed as nmol product/ 5 min/ nmol P450. b Data are 
expressed as nmol substrate converted/ 5 min/ nmol P450. A distinction is made between 
'minimal' (MIN) and 'maximal' (MAX) conversion, based on the following assumptions: (i), 
for 2,3,5,6-TFP it is assumed that 1 molecule of TFP loses either 4 fluoride anions ('MIN') or 
1 fluoride anion ('MAX'), and (ii), for PFP it is assumed that 1 fluoride anion is derived from 
the conversion of PFP to TFHQ, whereas 4 fluoride anions ('MIN') or 1 fluoride anion 
('MAX') are derived from 1 molecule TFHQ upon binding to protein. c Incubations performed 
under aerobic conditions. d Incubations performed under anaerobic conditions as described 
under Materials and Methods. 
PFP than for TFP, even when corrected for the loss of the one fluorine atom in the first 
oxidation step of PFP (Table 5.1). 
Chlorophenols. Microsomal incubation with PCP and TCP resulted in the formation of 
TCHQ, although their rates of conversion were several fold lower compared to the 
conversion rates of their fluorinated analogs (Table 5.2). Using [14C]-labeled PCP, a small 
amount of protein binding was detected in addition to the formation of TCHQ. 
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Table 5.2 Conversion of 2,3,5,6-TCP and [UC]-PCP to TCHQ and covalently bound 
metabolites by rat liver microsomes in the presence of different electron and oxygen 
donating systems. 
Substrate 
Incubation 
conditions 
2,3,5,6-TCP 
Blank/ 02 
NADPHb / 0 2 
CumOOHc 
CumOOH+ NADHC 
NADH 
[l4C]-PCP 
Blank/ 02 
NADPHV 0 2 
CumOOHc 
CumOOH + NADHc 
NADH 
TCHQ 
< 0.1a 
1.4 
3.4 
48 
< 0.1 
< 0.1 
0.9 
< 0.1 
2.7 
n.d 
Protein 
binding 
2.5 
0.4 
29 
6.5 
n.d. 
Ratio 
Protein binding 
:TCHQ 
0.4 
> 290 
2.4 
Total 
conversion 
1.3 
29 
9.2 
Note. Incubations were carried out as described under Materials and Methods, in a final 
volume of 2 ml (for 2,3,5,6-TCP) and 1 ml (for [14C]-PCP). Blank incubations contained no 
electron donor. Product formation was analysed by HPLC as described under Materials and 
Methods. Protein binding data in the presence of electron donors are corrected for the amount 
of binding observed in blank incubations; n.d., not determined. a Data are expressed as nmol 
product/ 5 min/ nmol P450. b Incubations performed under aerobic conditions. c Incubations 
performed under anaerobic conditions as described under Materials and Methods. 
CumOOH-dependent microsomal oxidation of halophenols 
The mechanism of oxidation of halophenols to either benzoquinones or hydroquinones 
can not be studied under standard conditions, since any benzoquinone formed can be 
directly reduced by NADPH to its hydroquinone form (see below). To circumvent this 
problem, incubations were performed under anaerobic conditions using CumOOH as an 
oxygen donor. The CumOOH-dependent P450 monoxygenase activity is thought to 
proceed via a homolytic oxygen-oxygen bond cleavage, generating a cumyloxy radical 
and the equivalent of an iron-bound hydroxyl radical (Blake and Coon, 1981). 
Fluorophenols. In incubations of TFP under anaerobic conditions with CumOOH as 
the oxygen donor, the formation of TFHQ was readily observed (Figure 5.2c). Since in 
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the absence of reducing equivalents TFHQ can not be formed from TFBQ, TFHQ must 
be the primary product resulting from the cytochrome P450 conversion of TFP. 
However, when PFP was used as a substrate, the formation of TFHQ was not observed 
in the CumOOH-driven reaction mixture (Figure 5.3c). Nevertheless, CumOOH 
dependent microsomal oxidation of PFP resulted in the formation of a significant amount 
of fluoride anion, indicating that this substrate is converted into a defluorinated product 
other than TFHQ. Addition of reducing equivalents in the form of NADH to incubations 
containing PFP as a substrate and CumOOH as the oxygen donor for the cytochrome 
P450 reaction, resulted again in the formation of TFHQ. In addition, a concomitant 
decline in the amount of fluoride anion production was observed upon NADH addition to 
the PFP/CumOOH incubation (Figure 5.3d). Apparently, conversion of PFP results in 
the formation of a metabolite that can be reduced to TFHQ by NAD(P)H, suggesting it 
to be TFBQ. This would imply that the cytochrome P450-dependent conversion of PFP 
results in formation of the reactive TFBQ as the primary reaction product. The fluorine 
originally present at the /jara-position is lost from the molecule as a fluoride anion. In 
the presence of reducing equivalents, e.g., NAD(P)H, the benzoquinone metabolite is 
(partly) reduced to its hydroquinone derivative. Another part might end up bound to 
macromolecules. The absence of a 19F-NMR resonance representing TFBQ in the 19F-
NMR spectra can be explained by the fact that this compound avidly binds to microsomal 
macromolecules. The substantial increase in molecular weight of the fluorine containing 
metabolite due to this adduct formation gives rise to an increase in its rotational 
correlation time (decrease in T2) and consequently such an extensive linebroadening of 
its 19F-resonance that the signal cannot be observed in the "F-NMR spectrum. Binding of 
TFBQ to protein could proceed by an addition-elimination reaction as described for 
binding of chlorinated benzoquinones (Van Ommen et al, 1988b), resulting in loss of 
additional fluoride anions. To test this phenomenon, TFBQ was incubated with 
microsomal protein. In the "F-NMR spectrum of this incubation 99% of the fluorine 
intensity was present in the singlet at -164.1 representing fluoride anion, demonstrating 
that TFBQ indeed readily binds to protein resulting in fluoride anion production and 
disappearance of TFBQ ("F-NMR spectra not shown). 
In Table 5.1, total conversion and the ratio of fluoride anion to TFHQ are presented 
as well. Replacing NADPH and molecular oxygen as cofactors for the cytochrome P450 
mediated oxidation of fluorophenols by CumOOH results in a more efficient oxidation of 
both TFP and PFP. One reason contributing to this difference in oxidation rate might be 
a difference in the rate limiting factor in the two respective reactions. For example, in 
the NADPH-mediated oxidation the rate limiting step might be the donation of the first 
or second electron to the iron-substrate-porphyrin or the iron-substrate-oxygen-porphyrin 
complex, whereas another rate limiting factor will be involved in the CumOOH-driven 
reaction. 
Furthermore, in incubations with TFP the ratio of fluoride anion to TFHQ is increased 
to 29 in the CumOOH-driven reaction as compared to 0.4 in the NADPH-driven 
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reaction. This might be explained by 2 factors, (i) TFHQ itself is partly oxidized to 
TFBQ by a CumOOH dependent mechanism, thereby decreasing the amount of TFHQ 
detected, and (ii) TFBQ can covalently interact with microsomal protein by an addition-
elimination reaction, resulting in the loss of additional fluoride anions; in the absence of 
reducing equivalents this might occur to a much higher extent than in the presence of 
reducing equivalents, where part of the TFBQ can be reduced to TFHQ. 
Thus, the amount of TFHQ detected is a 'steady-state' concentration, dependent on the 
rate of its formation (by the P450-dependent conversion of the halophenols) and the rate 
of its disappearance due to its oxidation to TFBQ. Since the total conversion of both TFP 
and PFP at 5 min of incubation are comparable (Table 5.1), the amount of TFHQ 
formed from PFP and TFP should be similar. Thus, in theory, the absence of a 
detectable amount of TFHQ in the CumOOH/PFP incubation (Figure 5.3c) in contrast to 
its presence in similar TFP incubations (Figure 5.2c) could possibly be a result of 
inactivation of the P450, and thus inhibition of TFHQ formation occurring in these PFP 
incubations. However, similar experiments in which the samples were analysed at t = l , 
2.5 min or 10 min (instead of at 5 min) showed no TFHQ formation in the PFP 
incubations, and significant amounts of TFHQ in the TFP incubations, i.e., results 
similar to those presented in Figure 5.2c and 5.3c. In addition, with both substrates a 
time-dependent increase in fluoride anion production was observed, which was 
significantly higher in incubations with PFP compared to incubations with TFP (data not 
shown). These findings support the conclusion that PFP is converted to TFBQ as the 
primary product, which subsequently binds to microsomal protein with the concomitant 
release of fluoride anion. 
Chlorophenols. Incubations of chlorophenols in the presence of CumOOH produced 
similar results as those obtained for the fluorophenols, although both the lack of a 
reliable detection method for chloride anions and the lack of commercially available 
[14C]-TCP complicated the comparison of the conversion rates between TCP and PCP. 
The data in Table 5.2 show that by analogy with the oxidation of fluorophenols, the 
CumOOH-mediated oxidation of chlorophenols by cytochrome P450 proceeds at a higher 
rate compared to the oxidation with molecular oxygen, and NADPH as the electron 
donor. The amount of TCHQ formed in incubations with TCP was increased more than 2 
fold respectively 35-fold under anaerobic conditions with CumOOH and CumOOH in the 
presence of NADH, respectively, compared to the aerobic incubations in the presence of 
NADPH. In CumOOH-containing microsomal incubations with PCP, the formation of 
TCHQ was not observed. However, the extent of metabolism-dependent covalent binding 
to protein was nearly a 100-fold higher compared to the NADPH-dependent oxidation. 
Addition of NADH to these CumOOH incubations revealed the formation of TCHQ from 
PCP with a concomitant decrease in covalent binding. These results strongly suggest that, 
in analogy to the TFBQ formation from PFP, the reactive TCBQ is the primary P450 
oxidation product of PCP, which, in the presence of NAD(P)H, can easily be reduced to 
TCHQ. 
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Figure 5.4 HPLC elution patterns of incubations performed with 10 /tM TCBQ in the 
absence of electron donors, (a); in the presence of 1 mM NADH, (b) or 1 mM NADPH, 
(c); in the presence of microsomal protein (2 nmol/ ml) without electron donors, (d); (e), 
in the presence of microsomal protein and 1 mM NADH, (e) or 1 mM NADPH, (f). 
Reduction of TCBQ and TFBQ by NAD(P)H 
Additional experiments were performed to demonstrate that both NADH and NADPH 
were indeed capable of (chemically) reducing TCBQ into TCHQ thus (partly) preventing 
the protein binding of TCBQ (Figure 5.4). When TCBQ is added to a potassium 
phosphate buffer (0.1 M, pH 7.4), it is partly reduced to TCHQ (Figure 5.4a). In the 
presence of 1 mM NADH or NADPH, TCBQ was completely reduced to TCHQ (Figure 
5.4b and 5.4c, respectively). After incubation of TCBQ in the presence of microsomal 
protein but in the absence of reducing equivalents, TCBQ was not observed anymore in 
the soluble phase nor was any other product (Figure 5.4d), indicating the strong 
alkylating properties of this compound. However, the addition of either NADH or 
NADPH to these incubations containing protein and TCBQ again resulted in the detection 
of TCHQ, which amounted to 56 % and 30 % of the initial concentration of TCBQ for 
NADH and NADPH containing incubations, respectively (Figure 5.4e and 5.4f). These 
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findings were irrespective of the concentration of TCBQ used (either 10 /*M or 100 /*M). 
Similar results were obtained from incubations with TFBQ in the absence or presence of 
microsomal protein and NAD(P)H, although the reduction of TFBQ to TFHQ was never 
complete (data not shown). 
Concluding remarks 
Based on the results presented, a scheme for the cytochrome P450-dependent oxidation 
of halophenols at a /jtfra-halogenated and a non-/>ara-halogenated position is put forward 
in Figure 5.5. P450-dependent oxidation at a para-unsubstituted position proceeds via the 
formation of the hydroquinone as the primary product, which may subsequently be 
oxidized to its quinone derivative. However, the cytochrome P450-mediated oxidation at 
a para-halogenated position is proposed to proceed by direct formation of a benzoquinone 
and the loss of the halogen from the molecule as a halogen anion. These halobenzo-
quinones are highly reactive compounds and may covalently interact with cellular 
macromolecules. However, in the presence of NAD(P)H, or other reducing equivalents, 
part of the benzoquinone may be reduced to its (nonreactive) hydroxyquinone form. The 
proposed pathway for oxidation at a halogenated position corresponds to route c 
illustrated in Figure 5.1, which is favoured over the other 2 proposed pathways, i.e. 
route a in which the halogen is lost as a halogen cation and route b in which the halogen 
is lost as a halogen radical. This is further supported by the observation of a fluoride 
anion resonance in the 19F-NMR spectra. 
Recent studies on the P450-catalysed conversion of /jara-fluorinated anilines also 
indicated the direct formation of benzoquinoneimine with the concomitant loss of fluoride 
anions (Rietjens et al., 1990, Rietjens and Vervoort, 1991). It becomes tempting to 
suggest that the proposed pathway may be a general mechanism for the cytochrome P450 
dependent oxidation of substrates, which meets the following requirements: (i) the 
presence of an acidic proton in one of the substituents of the aromatic ring; and (ii) 
substituents with a 'good leaving group' character (e.g., halogens) in the ortho- orpara-
position. In fact, evidence has been gathered that the proposed mechanism may even be 
extended to compounds with electron-donating substituents in general such as fully 
halogenated aromatics e.g., hexahalobenzenes, resulting in the formation of a 
benzohaloquinone cation intermediate which may subsequently be reduced to its phenol 
derivative (Rietjens and Vervoort, 1992). 
113 
Oxidation of halogenated phenols to hydroquinones and benzoquinones 
[FeO]* 
[FeOf 
radical o-complex 
(see Guengerich & 
MacDonald, 1990) 
~|3 
Fe° 
oxidation 
3+ 
o-complex 
(see Guengerich & 
MacDonald, 1990) 
reduction 
F e " 
Figure 5.5 Proposed mechanism for oxidation of phenols at a halogenated and non-
halogenated para-position (X, halogen) by cytochrome P450 in a NADPH and molecular 
oxygen driven system. Initial attack by the iron-oxene species ([FeO]3+) results in the 
formation of a radical a-complex and a a-complex, as described by Guengerich and 
MacDonald (1990). Oxidation of substrates by cytochrome P450 in a CumOOH-driven 
system is believed to proceed via a mechanism involving hydrogen atom abstraction and 
subsequent radical combination reactions between the substrate, i.e., (phenoxy) radical, and 
iron-bound oxygen species (Blake and Coon, 1981). Finally, elimination of a proton in the 
case of a nonhalogenated position results in the formation of a hydroquinone, whereas 
elimination of a halogen anion results in the formation of a benzoquinone. 
The proposed pathway for oxidative dehalogenation may also be a relevant pathway in 
the P450-dependent oxidation of bromobenzene to protein alkylating species. In a recent 
in vivo study it was shown that the majority of the protein adducts observed in rat liver 
after bromobenzene exposure consisted of debrominated benzoquinone adducts (Slaughter 
and Hanzlik, 1991). This phenomenon can readily be explained by the mechanism 
proposed in the present study, in which the cytochrome P-450-dependent oxidation of 
/jara-bromophenol, a primary metabolite of bromobenzene, results in the formation of a 
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debrominated benzoquinone with the loss of the bromine from the molecule as a bromide 
anion. The reactive benzoquinone may subsequently bind to cellular macromolecules. 
Quinone metabolites may play a role in the toxicity of several xenobiotics, through 
arylation of cellular macromolecules and/or through their capacity to form a redox shuttle 
with their reduced counterparts, thereby generating reactive oxygen species and imposing 
a condition of cellular oxidative stress. The direct formation of benzoquinones may have 
toxicological implications, especially because in vivo it can be expected that 
hydroquinones will not be efficiently oxidized to their reactive quinone analogs, due to 
(i) competing pathways of conjugation, and (ii) the presence of reducing equivalents such 
as NAD(P)H, glutathione, ascorbic acid and vitamine E. However, for aromatic 
compounds from which benzoquinones are formed as a direct result of the cytochrome 
P450 mediated conversion, formation of the reactive intermediates can not be 
circumvented. 
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SUMMARY OF IN VITRO STUDIES 
The first part of this thesis is directed at the question whether a range of 
(poly)chlorobenzene congeners are oxidized to potentially reactive products which can 
covalently bind to protein. To this end, incubations were performed using rat liver 
microsomes (i.e., particles of the endoplasmatic reticulum, which contain the cytochrome 
P450-complex) and radiolabeled substrates. Special attention was directed at the nature of 
the conversion-dependent covalent binding to protein. 
In chapter 2, the cytochrome P450-mediated oxidation of pentachlorobenzene (PCB) 
to pentachlorophenol, and to a lesser extent to the various isomers of tetrachlorophenol, 
is described. In addition, a considerable amount of the metabolites became covalently 
bound to protein. Incubations performed in the presence of the reducing agent ascorbic 
acid indicated that benzoquinone metabolites are the most important binding species 
involved. However, based on the observation that the protein binding could never 
completely be inhibited by ascorbic acid, it was suggested that other reactive metabolites, 
presumably epoxide intermediates in the primary oxidation step, also take part in the 
protein binding. 
Chapter 3 deals with the microsomal oxidation of 1,2,4-trichlorobenzene (TRICB) to 
the various isomers of trichlorophenol and, to a lesser extent, to trichlorohydroquinone. 
The intermediacy of epoxides in the oxidation of 1,2,4-TRICB was indicated by the 
formation of two trichlorophenol isomers (i.e., 2,3,4- and 2,4,6-trichlorophenol), which 
could be formed upon an 'NIH'-like shift of their corresponding epoxide intermediates. 
In analogy with PCB, a sizeable amount of metabolites became covalently bound to 
protein. However, protein binding of 1,2,4-TRICB was completely prevented by ascorbic 
acid. Furthermore, not only in the case of 1,2,4-TRICB but also in the case of PCB, the 
extent of covalent binding was strongly correlated with the extent of secondary oxidation 
to hydroquinones (and not with the extent of the primary oxidation to phenols). Based on 
these observations, it was suggested that benzoquinone metabolites were the sole reactive 
species formed in the oxidation of both 1,2,4-TRICB and PCB. Rather than assuming a 
different nature of the binding species, the residual protein binding of PCB-metabolites in 
the presence of ascorbic acid (cf. chapter 2) could then be explained by an incomplete 
reduction of the reactive tetrachlorobenzoquinone to tetrachlorohydroquinone. 
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Chapter 3 also describes the differential role of the cytochrome P450 isoenzymes in 
the oxidation of these compounds. Microsomes from rats pretreated with dexamethasone 
(a selective inducer of P450IIIA1) showed the highest activity towards both PCB and 
1,2,4-TRICB. However, with decreasing degree of chlorination the contribution of 
P450IIIA1 to oxidation appears to become less prominent, and the relative contribution 
of other P450 isoenzymes becomes more important. This is further confirmed in chapter 
4 on the microsomal oxidation of different DCB isomers. 
Two isomers of dichlorobenzene (DCB), i.e. 1,2- and 1,4-DCB, are known to show 
pronounced differences in their hepatotoxic potency. In chapter 4, the microsomal 
oxidation of the toxic 1,2-DCB and the non-toxic 1,4-DCB was studied with special 
attention for possible differences in metabolic profile that might contribute to the isomer-
specific hepatotoxicity. Both isomers were oxidized by rat liver microsomes to reactive 
metabolites that became covalently bound to macromolecules. Interestingly, ascorbic acid 
completely inhibited the binding of 1,4-DCB metabolites, whereas ascorbic acid-mediated 
inhibition of protein binding by 1,2-DCB metabolites was never complete. Molecular 
Orbital AMI computer calculations on the arene oxide/oxepin intermediates derived from 
either 1,2- or 1,4-DCB revealed no differences in chemical reactivity and/or stability of 
the various arene oxides. This would argue against a differential role of arene oxide 
intermediates in the protein binding (and toxicity?) of 1,2- and 1,4-DCB. 
In anticipation of chapter 5, in which the mechanism of formation of the reactive 
benzoquinone metabolites from the primary halophenol metabolites is studied, the 
different binding behaviour of 1,2-DCB metabolites as compared to 1,4-DCB metabolites 
is explained by a direct oxidation of the primary phenols to reactive quinone metabolites 
in the case of 1,2-DCB, which does not take place in the case of 1,4-DCB. 
The results presented thus far stress the importance of secondary benzoquinone 
metabolites in the metabolic activation of chlorinated benzenes. This prompted us to 
investigate more closely the mechanism of formation of the reactive benzoquinones from 
the primary phenol metabolites. To this end, pentafluoro- and pentachlorophenol, and 
their non-para-halogenated analogs were used as model compounds, and their 
microsomal oxidation products were determined using "F-NMR and HPLC. However, 
exclusive evidence for the nature of the primary oxidation products of halophenols (i.e., 
either benzoquinones or hydroquinones) can not be obtained under standard conditions 
with molecular oxygen and NADPH as the electron donor, due to the fact that any 
benzoquinone formed can be directly reduced by NADPH to its hydroquinone form. 
Therefore, anaerobic incubations were performed using cumene hydroperoxide as the 
oxygen donor. Based on the results described in chapter 5, a plausible mechanism for the 
P450-dependent oxidation of halophenols at a para-halogenated and at a non-para-
halogenated position is put forward. Cytochrome P450-mediated oxidation at a non-para-
halogenated position with respect to the hydroxyl moiety results in the formation of the 
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/>öra-hydroxylated derivative, i.e. hydroquinone, as the primary reaction product. 
However, oxidation at a halogenated /jara-position is proposed to result in the direct 
formation of the reactive benzoquinone with the concomitant loss of the halogen from the 
molecule as a halogen anion. As discussed in chapter 11, the direct formation of reactive 
benzoquinone metabolites may very well have toxicological implications. 
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Chapter 7 
THE LIVER, KIDNEY AND THYROID TOXICITY 
OF CHLORINATED BENZENES 
Abstract 
The acute toxicity of a number of chlorinated benzenes, ranging from mono-
substituted to pentasubstituted benzenes, was studied in rats. Toxic effects on the liver, 
the kidneys and the thyroid were monitored after a single i.p. administration of 1, 2 or 4 
mmol/kg monochlorobenzene (MCB), 1,2-dichlorobenzene (1,2-DCB), 1,4-dichloro-
benzene (1,4-DCB), 1,2,4-trichlorobenzene (1,2,4-TRICB) and pentachlorobenzene 
(PCB). Due to its low solubility, 1,2,4,5-tetrachlorobenzene (TCB) was tested at a 
highest dose of 0.8 mmol/kg. 1,2-DCB and 1,2,4-TRICB produced the most severe 
hepatotoxic effects when compared with an equimolar dose of the other chlorinated 
benzenes, as determined by plasma ALT profile and histopathological changes after 72 
hr. MCB was considerably less hepatotoxic. Severe degenerative damage to the kidney 
was only observed in a few rats treated with 1,2,4-TRICB. However, protein droplets in 
the tubular epithelial cells were observed at 72 hr after administration of 1,4-DCB, 
1,2,4-TRICB, 1,2,4,5-TCB and PCB. In the latter two groups, these protein droplets 
were still observed nine days after administration. All chlorinated benzenes tested 
excluding MCB induced a reduction in plasma thyroxine levels. The extent of decrease in 
plasma thyroxine was more severe in rats treated with 1,2,4-TRICB or PCB and 
correlated well with the relative binding affinities of the phenolic metabolites to the 
plasma transport protein for thyroxine, i.e., transthyretin. The present study indicates 
that the establishment of a structure-activity relationships with regard to toxicity depends 
on the sensitivity of the respective target organs. In the series of (poly-)chlorinated 
benzenes studied, ranging from mono- to pentachlorobenzene, the most severe effects on 
liver, kidney and thyroid are observed for 1,2,4-substitution. 
C. den Besten, J.R.M. Vet, H.T. Besselink, G.S. Kiel, B.J.M. van Berkel, R. Beems, A. 
Brouwer and P.J. van Bladeren. Published in: Toxicol. Appl. Pharmacol. I l l (1991) 69-81. 
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Introduction 
A considerable number of studies on the toxicity of chlorinated benzenes indicates that 
the liver and the kidneys are the principal target sites. For example, degenerative 
changes in the liver and -to a lesser extent- in the kidneys were reported in rats exposed 
to 1,2-dichlorobenzene via inhalation (Cameron et al., 1937) or after oral administration 
(Hollingsworth et ah, 1958). Short-term dermal exposure of guinea-pigs to 1,2,4-
trichlorobenzene produced necrotic foci in the liver (Brown et al., 1969), whereas (mild) 
transient effects in liver and kidneys were observed in rats after 4 weeks of inhalation 
exposure to 1,2,4-trichlorobenzene, but not after 26 weeks (Coate et ah, 1977). In 
addition to histological changes in the liver and the kidneys, morphological changes in 
the thyroids were observed in a subchronic feeding study with several trichlorobenzene 
isomers (Côte et al, 1988) and tetrachlorobenzene isomers (Chu et al., 1984). 
Furthermore, reduced serum thyroid hormone levels were observed during 
hexachlorobenzene-induced porphyria (Kleiman de Pisarev et al, 1990). Adverse effects 
have also been reported on the immune system after exposure to monochlorobenzene 
(Kluwe et al, 1985) and hexachlorobenzene (Vos, 1989). Furthermore, severe porphyria 
with accumulation of phorphyrins in liver and their excretion into urine is observed after 
semichronic treatment with hexachlorobenzene (Goerz et al., 1977), whereas several 
lower chlorinated benzenes, e.g., 1,4-dichlorobenzene and 1,2,4-trichlorobenzene, have 
also been reported to cause a rise in urinary porphyrins after (short-term) treatment with 
a high dose (Rimington and Ziegler, 1963). 
Investigations into the mechanism of the toxic effects elicited by halogenobenzenes 
have been conducted nearly exclusively for the monosubstituted compounds, 
bromobenzene and chlorobenzene, and the fully substituted hexachlorobenzene. Covalent 
binding of bromobenzene to liver proteins was detected prior to the occurrence of liver 
necrosis (Reid and Krishna, 1973). A correlation between the extent of formation of 
reactive metabolites via biotransformation and the hepatotoxic potential was established 
for a number of halogenated compounds among which were 1,2-dichlorobenzene and 1,4-
dichlorobenzene. Subsequent studies indicated that bromobenzene was metabolized via a 
reactive 3,4-epoxide intermediate, which is capable of arylating nucleophilic sites on 
cellular macromolecules and causes a disturbance in cellular homeostasis, leading to cell 
death (Lau et al., 1980). However, the exact nature of the covalent binding species has 
not yet been confirmed, and the identification of bromobenzene adducts of liver proteins 
has only recently been undertaken (Weiler and Hanzlik, 1991). 
More recent investigations have focussed attention on another class of reactive 
metabolites, the quinones, which arise upon further oxidation of primary phenol 
metabolites. In fact, the covalent interaction with proteins observed during microsomal 
metabolism of hexachlorobenzene could be fully ascribed to the formation of quinone 
metabolites (Van Ommen et al., 1986). In addition, a major role for quinones is 
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suggested in the covalent binding to liver microsomes during the conversion of 
pentachlorobenzene (Den Besten et al., 1989). More interestingly, glutathione conjugates 
of quinones appear to be involved in the tubular necrosis observed after exposure to 
bromobenzene (Monks et al., 1985). This latter aspect has been the subject of an elegant 
series of investigations (Monks et al., 1988), but the final details of the mechanism of 
action remain to be elucidated. 
In an attempt to establish the generality of the metabolic activation via formation of 
quinone metabolites, a range of chlorinated benzenes from monochlorobenzene to 
pentachlorobenzene is being investigated with respect to their metabolic activation and 
their toxicity. Recently, we have demonstrated that the reactivity of primary (epoxide) 
metabolites of pentachlorobenzene and 1,2,4-trichlorobenzene towards microsomal 
protein is negligible, whereas their quinone metabolites exhibit a high alkylating potency 
towards protein (Den Besten et al., 1991). However, bioactivation in vitro does not 
always imply toxicity in vivo. Toxicity studies in combination with studies into the 
urinary and biliary metabolic profile are essential in order to further assess the role of 
potentially reactive metabolites like quinones in the observed effects. As a start, the 
present report describes the adverse effects of a range of chlorinated benzenes on three 
target organs, the liver, the kidney, and the thyroid, after a single i.p. treatment. The 
role of chemically reactive intermediates and biologically active (but chemically stable) 
metabolites in the various toxic symptoms is discussed. 
Materials and Methods 
Chemicals 
Monochlorobenzene (MCB), 1,2-dichlorobenzene (1,2-DCB), 1,2,4-trichlorobenzene 
(1,2,4-TRICB, all compounds of > 99% purity) and 1,4-dichlorobenzene (1,4-DCB, 
>98% purity) were obtained from Merck (Darmstadt, Germany). 1,2,4,5-Tetrachloro-
benzene (1,2,4,5-TCB, > 98% purity) and pentachlorobenzene (PCB, > 99% purity) 
were obtained from Riedel-de Haen (Seelze, Germany). Pentachlorophenol (Aldrich, 
Brussels, Belgium) was purified by acid-base extraction to remove possible traces of 
dioxines. 2,3,4,5-Tetrachlorophenol was from Fluka Chemie AG (Buchs, Switzerland). 
2,3,5,6-Tetrachlorophenol and 2,3,4-trichlorophenol were from Aldrich, and all other 
chlorophenols were obtained from Merck. 3,5,3',5'-tetra-L-thyroxine was from Sigma 
Chemical Co. (St. Louis, USA). Human transthyretin (TTR, purity 98 %) was from 
Calbiochem (Hoechst, Germany). [12,I]-L-Thyroxine was purchased from Amersham 
International (PLC, UK) and contained 10 % unbound iodide as determined by 
gelfiltration on Sephadex LH20 (Pharmacia LKB, Woerden, The Netherlands). Biogel 
P-6DG was obtained from Biorad laboratories, Richmond, CA, USA). 
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Animals 
Male Wistar rats (10-14 weeks of age) were housed in air-conditioned and light 
controlled rooms and were allowed food and water ad libitum. 
Toxicity studies 
Three day observation study. Groups of three rats were treated between 9 and 11 AM 
with a single i.p. dose of MCB, 1,4-DCB, 1,2-DCB (groups of four rats), 1,2,4-TRICB, 
and PCB at 1, 2 and 4 mmol/kg in arachidis oil (3.33 ml/kg except for the high dose of 
PCB which was administered at 5 ml/kg due to its low solubility). 1,2,4,5-TCB was 
administered in doses of 0.5 and 0.8 mmol/kg/5 ml, due to its limited solubility. Control 
rats were treated with arachidis oil. Body weight and general appearance were checked 
daily. Blood was collected from the retroorbital sinus under light ether anesthesia at 24, 
48, and 72 hr following exposure to the test compounds. Plasma was separated by 
centrifugation and stored at -20°C until analyses were performed. At 72 hr following 
exposure, the animals were killed by exsanguination via the abdominal aorta. The liver 
and the kidneys were excised and weighed. 
Nine day observation study. Based on studies with bromobenzene, it is believed that 
secondary metabolites formed in the liver, are transported to the kidney, where they are 
involved in the tubular degenerative changes (Monks et al., 1985). In order to take into 
consideration that this might be a relatively slow process, an additional study was 
performed in which rats (four per group) were treated with 1 and 2 mmol/kg of the test 
compounds (excluding 1,2-DCB) and were monitored for 9 days (216 hr). Blood samples 
were taken at 24, 48, 72, 144, 192, and 216 hr following exposure to the test 
compounds. In this study, one rat dosed with 2 mmol PCB/kg died between 48 and 72 hr 
after exposure. On autopsy, no gross abnormalities were observed on the liver and 
kidneys nor were any biochemical and histopathological indications of hepatotoxic or 
nephrotoxic damage observable. 
Depletion of liver glutathione. Rats were treated with 1,2,4-TRICB (4 mmol/kg, i.p.). 
Three rats per treatment were subsequently killed at time zero (control rats) or at 2, 5, 
10, 24 or 48 hr after dosing (both control rats and 1,2,4-TRICB-treated rats). The livers 
and kidneys were homogenized (25 % w/v) in ice-cold Tris-HCl (pH 7.4), and proteins 
were precipitated with a 10 % TCA-solution. Glutathione (GSH) was determined 
spectrophotometrically as described by Sedlack and Lindsay (1968). In a separate 
experiment, groups of 3 rats were treated (i.p.) with 0.8 mmol/kg 1,2,4,5-TCB, 1 
mmol/kg 1,2,4-TRICB, or 4 mmol/kg of the other chlorinated benzenes, and were killed 
at 0 hr (control rats) and 8 hr (control and treated rats) after dosing. GSH levels in 
livers and kidneys were determined as described above. 
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Histological determinations 
Sections of the liver and kidneys were preserved in 4 % buffered formalin (pH 7.4) 
and stained with hematoxylin and eosin for microscopic examination. 
Biochemical determinations 
Plasma alanine amino transaminase (ALT) activity and blood urea nitrogen level 
(BUN), indicative of overt hepatotoxicity and nephrotoxicity, respectively, were 
performed employing a Cobas-Bio centrifugal analyzer and commercially available kits. 
Plasma total thyroxine and total triiodothyronine levels were measured using the Amerlite 
TT4 and Amerlite TT3 assays (Amerham Nederland BV). 
In vitro competition assay for thyroxine (T4) 
A modification of the binding assay using the gel filtration procedure as described by 
Somack et al., (1982) was employed to determine the capacity of various chlorinated 
benzenes and their oxidative metabolites to compete with T4 binding sites on 
transthyretin (TTR), a major rat plasma transport protein for thyroxine. Briefly, the 
assay mixture contained 60 nM [125I]-L-T4 (70,000 cpm), 30 nM TTR and graded 
concentrations of T4 or chlorinated test compounds in methanol (final concentration 5 %) 
in 0.1 M Tris-HCl, pH 8.0, containing 0.1 M NaCl and 1 mM EDTA in a final volume 
of 200 /*1. The incubation was performed overnight at 4°C in small, airtight flasks to 
prevent evaporation of the test compounds. The assay mixture was placed on a gel-
filtration column, which was prepared in a 1 ml disposable syringe and was centrifuged 
(100 g, 1 min) immediately to minimize dissociation of the TTR-ligand complex. The 
column was washed once with 200 yX Tris buffer. Protein bound radioactivity was 
collected in these first two fractions, whereas free hormone binds tightly to the gel 
matrix and does not elute in the volumes used. The amount of radioactivity in the eluate 
was determined in a gamma counter (Multi Prias, Packard, Brussels, Belgium). 
Statistical evaluation 
Data obtained in the in vivo toxicity studies were tested for significant differences (p 
<0.05) using the Kruskal-Wallis nonparametric ANOVA test. 
Results 
Effect on Body Weight and Organ Weight 
Treatment of rats with 1,2-DCB (all doses), 1,2,4-TRICB (2 and 4 mmol/kg) and 
1,2,4,5-TCB (0.8 mmol/kg) resulted in significant body weight loss after three days 
(ranging from -6 to -13 % of initial body weight, data not shown). At 72 hr, relative 
liver weight was significantly increased in rats treated with the various chlorinated 
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Table 7.1. Effect of a single i.p. injection of various chlorinated benzenes on relative liver 
weight, and treatment-related histopathological changes in the liver. 
Liver wt/100 g Treatment-related histopathological 
body wt findings at 72 hr 
Treatment 
Dose at72hra at 216 hrb NRF CLH VAC DEG 
(mmol/kg) 
Control 
3.7 + 0.1 3.9 + 0.1 
MCB 
1 
2 
4 
1,4-DCB 
1 
2 
4 
1,2-DCB 
1 
2 
4 
1,2,4-TRICB 
1 
2 
4 
1,2,4,5-TCB 
0.5 
0.8 
PCB 
1 
2 
4 
4.4 ± 
4.3 ± 
4.6 ± 
4.2 + 
4.3 ± 
4.3 ± 
4.4 ± 
4.5 ± 
4.9 + 
5.4 ± 
5.2 + 
5.8 ± 
3.9 ± 
4.1 ± 
4.4 ± 
5.1 ± 
5.4 + 
0.2* 
0.1* 
0.1* 
0.2 
0.2 
0.1* 
0.1b* 
0.1b* 
0.2b* 
0.2* 
0.2* 
0.3* 
0.1 
0.1 
0.1* 
0.1* 
0.1 
4 .0+ 0.1 
4 .0+ 0.1 
NT 
4.1 + 0.1 
4.1 + 0.2 
NT 
NT 
NT 
NT 
4.2 ± 0.1 
4.5 ± 0.1 
NT 
NT 
4.7 + 0.1* 
4.4 + 0.1 
5.0 ± 0.2* 
NT 
3 
1 
0 
3 
3 
2 
0 
0 
0 
0 
0 
0 
3 
3 
0 
1 
0 
-
2(+3) 
-
-
-
1(+1) 
4(+7) 
4(+6) 
4(+9) 
3 
-
-
-
-
3(+4) 
2(+4) 
l(+2) 
1(+1) 
3 
4 
4(+12) 
4(+13) 
1 
3(+8) 
2(+3) 3(+4) 
2(+4) 1(+1) 
Note. Abréviations used: NT, not tested; NRF, no treatment related findings; CLH, 
centrilobular hypertrophy; VAC, vacuolation; DEG, hepatocellular degeneration + fibrosis. 
a
 Mean+SE, n = 3; b Mean+SE, n = 4; c Figure denotes number of animals with the 
lesion. Within brackets, the severity of the changes is given as the sum of the gradings 
assigned to the lesion: very slight, +1; slight, +2; moderate, +3; severe, +4. Arterisk (*) 
denotes statistically significant difference from control rats, p < 0.05. 
128 
Chapter 7 
Table 7.2. Effect of a single i.p. injection of various chlorinated benzenes on relative kidney 
weight, and treatment-related histopathological changes in the kidney. 
Treatment 
Dose 
(mmol/kg) 
Control 
-
MCB 
1 
2 
4 
1,4-DCB 
1 
2 
4 
1,2-DCB 
1 
2 
4 
1,2,4-TRICB 
1 
2 
4 
1,2,4,5-TCB 
0.5 
0.8 
PCB 
1 
2 
4 
Kidney wt/100 g 
body 
at 72 hr" 
0.67 ± 
0.72 ± 
0.73 ± 
0.73 + 
0.75 ± 
0.74 ± 
0.72 ± 
0.65 ± 
0.71 ± 
0.69 ± 
0.67 ± 
0.71 ± 
0.92 ± 
0.71 ± 
0.82 ± 
0.73 ± 
0.78 ± 
0.84 + 
0.02 
0.01 
0.03 
0.01 
0.04 
0.01 
0.03 
0.02b 
0.05b 
0.01b 
0.04 
0.01 
0.19 
0.01 
0.07* 
0.01 
0.03* 
0.05* 
wt 
at 216 hrb 
0.66 ± 0.02 
0.65+ 0.02 
0.65 ± 0.02 
NT 
0.66+ 0.05 
0.69+ 0.02 
NT 
NT 
NT 
NT 
0.67+ 0.01 
0.82 ± 0.12* 
NT 
NT 
0.73 ± 0.02 
0.69+ 0.05 
0.80 ± 0.05* 
NT 
Treatment-related histopathological 
NRF 
3 
3 
2 
3 
1 
1 
2 
3 
3 
3 
0 
0 
1 
0 
0 
0 
1 
2 
findings at 72 hr 
TUBDIL TUBDEG 
-
-
l(+2)c -
-
1(+1) -
-
-
-
-
-
-
-
l( + 3) K+2) 
-
-
-
l(+2) -
" 
PD 
-
-
-
-
K+2) 
2(+2) 
l(+2) 
-
-
-
3(+7) 
3(+4) 
K+l) 
3(+5) 
3(+6) 
3(+4) 
l(+2) 
l(+2) 
Note. Abbreviations used: NT, not tested; NRF, no treatment related findings; TUBDIL, 
tubular dilatation; TUBDEG, tubular degeneration; PD, presence of protein droplets. 
" Mean+SE, n = 3, b Mean+SE, n = 4. c Figure denotes number of animals with the 
lesion. Within brackets, the severity of the changes is given as the sum of the gradings 
assigned to the lesions: very slight, + 1 ; slight, +2, moderate, +3 . Arterisk (*) denotes 
statistically significant difference from control rats, p < 0.05. 
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benzenes (Table 7.1). The liver-to-body weight ratio was still significantly higher 216 hr 
after treatment with 1,2,4-TRICB, 1,2,4,5-TCB and PCB. Relative kidney weight was 
increased in rats treated with the higher chlorinated benzenes (Table 7.2). 
Effects on the Liver 
Plasma enzyme activity. Table 7.3 shows the plasma ALT levels in rats following i.p. 
dosing with a range of chlorinated benzenes. A rise in plasma ALT levels was observed 
in rats treated with 1,2-DCB, 1,2,4-TRICB, and to a lesser degree in rats treated with 
MCB. Depending on the test compound and on the dose used, plasma ALT levels peaked 
at the 24 - 48 hr time points, and decreased again thereafter. A dose-response 
relationship in plasma ALT level was observed for MCB and to some extent for 1,2,4-
TRICB, but not for 1,2-DCB. Furthermore, none of the rats used in the GSH-depletion 
study showed any signs of hepatotoxicity at 8 hr postdosing (data not shown). 
Liver glutathione level. A significant decrease in GSH equivalents was already 
noticeable 2 hr after exposure to a high dose of 1,2,4-TRICB (4 mmol/kg, i.p.) (Figure 
7.1). Although maximum GSH depletion was seen 5 hr after dosing, a significant 
increase in plasma ALT level was not observed until later between 10 hr and 24 hr after 
dosing. As the level of GSH equivalents was rebounding past control levels at 48 hr, 
plasma ALT levels showed a sharp decline. 
As is shown in Figure 7.2, the incidence of hepatotoxicity of a series of chlorinated 
benzenes as measured by elevated plasma ALT levels at 24 hr coincided with a fall in 
GSH equivalents 8 hr after dosing. However, the extent to which GSH was depleted did 
not correlate with the plasma ALT levels since MCB, a moderately hepatotoxic isomer, 
showed a similar GSH depletion compared to both 1,2-DCB and 1,2,4-TRICB, which are 
severely hepatotoxic. 
Histopathology of the liver. Exposure to the various chlorinated benzenes did not 
result in obvious microscopic liver changes after 8 hr. After 72 hr, distinct treatment 
related changes were observed which were characterized by hepatocellular hypertrophy, 
mainly in the low- and/or mid-dose groups and hepatocellular degeneration in the mid-
and/or high-dose groups (Table 7.1). The degenerative changes were characterized by 
swelling, degeneration and necrosis of centrilobular hepatocytes, accompanied by small 
aggregates of RES cells and lymphocytes, and proliferation of some fibroblasts. In 
relatively mild cases the changes were restricted to a small rim around the central veins. 
In more severely affected livers the changes occupied a larger part of the centrilobular 
areas. In control animals hepatocellular hypertrophy and degeneration were absent at 72 
hr. After 9 days, a minimal degree of centrilobular hypertrophy was observed in the liver 
of one or a few animals of most of the treatment groups and in a single control animal 
(data not shown). An increased incidence or severity of this change was observed in rats 
treated with 1,2,4,5-TCB and PCB. Only in the latter groups this change is considered to 
be due to the administration of these test compounds. 
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Table 7.3 Effect of a single i.p. injection of various chlorinated benzenes on plasma enzyme 
activity (alanine aminotransaminase, ALT). 
Treatment 
Control 
MCB 
1,4-DCB 
1,2-DCB 
1,2,4-TRICB 
1,2,4,5-TCB 
PCB 
Dose 
(mmol/kg) 
_ 
1 
2 
4 
1 
2 
4 
1 
2 
4 
1 
2 
4 
0.5 
0.8 
1 
2 
4 
33 
39 
116 
154 
36 
34 
34 
2105 
1826 
326 
1160 
2969 
2294 
33 
24 
± 3 
± 6 
± 20* 
± 35* 
± 2 
± 3 
± 1 
± 166a* 
± 104"'* 
± 166a* 
+ 164* 
± 608* 
± 994* 
± 1 
36 ± 4 
31 
27 
25 
± 1 
± 3 
± 1 
ALT 
Time after exposure (hr) 
48 
41 ± 
48 ± 
72 ± 
831 ± 
50 ± 
46 ± 
50 ± 
997 ± 
1841 ± 
840 ± 
373 ± 
631 + 
570 + 
3 
3 
13 
281* 
2 
3 
3 
169"'* 
487"-* 
21 la'* 
14* 
126* 
199* 
39 + 6 
49 + 3 
39 + 6 
39 + 
42 ± 
3 
5 
72 
44 ± 3 
55 + 3 
52 + 2 
149 ± 32* 
52 + 3 
49 ± 3 
61 ± 6 
146 ± lla'* 
309 ± 46a'* 
96 + 20a>* 
99 ± 8* 
127 ± 11* 
159 + 38* 
48 + 2 
50 + 4 
41 ± 5 
54 + 4 
56 + 9 
Note. Data are taken from the 3-day observation study and represented as mean+SE, 
n=3 (Units/liter). Plasma ALT values in the 9-day observation study showed a similar 
profile. a Mean + SE, n = 4. *, Statistically significant differences compared to control rats, 
p <0.05. 
Effect on the Kidneys 
Plasma BUN levels. The levels of plasma BUN remained within the normal range in 
all rats (5.4 - 8.5 mg BUN/ml), except for a single animal in the three day observation 
study treated with 4 mmol/kg 1,2,4-TRICB (12.6, 16.2, and 15.5 mg BUN/ml at 24, 48, 
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Figure 7.1 Plasma ALT levels (U/liter) ( • ) and hepatic glutathione content ( O ), 
expressed as percentage of time-matched oil-treated control rats, in rats treated with 4 
mmol/kg 1,2,4-TRICB. 
and 72 hr after dosing, respectively) and a single animal in the nine day observation 
study treated with 2 mmol/kg 1,2,4-TRICB (28.2, 68.4, 55.3 and 9.2 mg BUN/ml at 24, 
48, 72 and 216 hr after treatment, respectively). 
Kidney glutathione level. GSH levels in whole homogenates of the kidneys at 8 hr 
after a single i.p. dose of 4 mmol/kg MCB or PCB were slightly reduced to 76 and 71 % 
of the GSH content in control rats, respectively (Figure 7.2). Treatment of rats with the 
other chlorinated benzene isomers did not result in decreased GSH levels. 
Histopathology of the kidney. In the 1,2,4-TRICB treated rats with elevated BUN 
levels distinct kidney damage was observed, consisting of proximal tubular degeneration 
and dilatation (4 mmol/kg TRICB), and severe nephrosis (2 mmol/kg). The toxicological 
significance of these isolated findings is questionable, but treatment relationship cannot 
be excluded. Slight proximal tubular degeneration was observed in rats nine days after 
treatment with PCB. 
At 72 hr proteinaceous droplets were observed in the renal proximal tubular epithelial 
cells in all dose groups of rats treated with 1,4-DCB, 1,2,4-TRICB, 1,2,4,5-TCB and 
PCB, but not in the MCB group, the 1,2-DCB group and in the controls (Table 7.2). At 
216 hr, protein droplet formation was most pronounced in 1,2,4,5-TCB and PCB treated 
rats. 
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Figure 7.2 Hepatic ( D ) and renal ( B ) glutathione content at 8 hr post-dosing (i.p.) of 
arachidis oil (control) or various chlorinated benzenes. *, significantly lower compared to 
control, p <0.05. 
Interaction with Thyroid Hormone Homeostasis 
Plasma thyroid hormone levels. The effect of a single i.p. dose of chlorinated 
benzenes on plasma total thyroxine (TT4) and total triiodothyronine (TT3) levels 24 hr 
after exposure are shown in Table 7.4. With the exception of rats treated with MCB or 
the low dose of 1,4-DCB, a significant decrease in plasma TT4 was observed. No effect 
on plasma TT3 levels was observed, except for a slight reduction after treatment with 2 
mmol/kg PCB and a dramatic reduction after treatment with 1,2-DCB. 
Rats treated with 1,2,4-TRICB manifested a sharp decline in plasma TT4 levels, 
reaching a minimum level within 24 hr after exposure (Figure 7.3a). Plasma TT4 levels 
started to recover after 72 hr, and resulted in an 'overshoot' at 192 and 216 hr after 
exposure. The high dose PCB group demonstrated a prolonged reduction in plasma TT4 
(Figure 7.3b). In rats treated with 4 mmol/kg 1,2,4-TRICB, a significantly reduced level 
of plasma TT4 was already observed at 5 hr after exposure (32.1+2 nmol/1 in 1,2,4-
TRICB treated rats vs 45.2+4 nmol/1 in control rats), and reached minimum levels 
between 10 hr and 24 hr post-dosing (19+0.9 and 4.0+1.5 nmol/1 in 1,2,4-TRICB 
treated rats vs 39.5 + 1.5 and 40.5±0.4 nmol/1 in control rats). 
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In vitro binding studies with transthyretin. In order to investigate whether chlorinated 
benzenes and their metabolites are capable of competing with T4 for its TTR-binding 
site, in vitro binding studies were conducted with transthyretin (TTR). The binding 
constants derived from these competition experiments, and the binding affinities relative 
to T4 are shown in Table 7.5. Chlorophenols are capable of displacing T4 from its TTR-
binding site, but they differ greatly in their potency to do so. The affinity of PCP for the 
T4-binding site was distinctly higher than that of T4 itself. With decreasing degree of 
chlorination, the binding affinity for the T4 binding site on TTR decreased. Moreover, 
monochlorophenol (4-CP) did not show any detectable interaction, neither did PCB or 
lower chlorinated benzenes, nor 1,4-tetrachlorobenzoquinone, a compound with strong 
alkylating properties. However, 1,4-tetrachlorohydroquinone demonstrated a binding 
constant similar to that of 2,4,6-TRICP. 
Discussion 
Chlorinated benzenes are compounds with a low intrinsic toxicity and require 
metabolism to biologically reactive products in order to induce toxic effects in target 
organs like the liver, the kidneys or the thyroid. Recent in vitro studies implicated 
quinones as the ultimate reactive species that bind to proteins. In an attempt to assess the 
meaning of the metabolic activation in a subcellular system in terms of toxicity in vivo, a 
range of chlorinated benzenes was compared with respect to their ability to induce organ 
toxicity after a single i.p. treatment. Interaction between reactive products and cellular 
macromolecules in the liver is believed to occur only after insufficiency of cellular 
defense mechanisms, e.g., substantial depletion of glutathione. The important role for 
reactive electrophilic intermediates in the hepatotoxicity of various chlorinated benzenes 
was indicated by the fact that liver necrosis was preceded by severe GSH depletion. 
However, the extent of GSH depletion did not correlate with the degree of hepatotoxicity 
of MCB, 1,2-DCB and 1,2,4-TRICB. The absence of such a correlation has also been 
observed in a recent study on the isomer-specific toxicity of dichlorobenzene (Stine et 
al., 1991). 
1,2-DCB and 1,2,4-TRICB produced the most severe signs of hepatotoxicity, whereas 
MCB was only moderately hepatotoxic. The apparent lack of a dose-response relationship 
for 1,2-DCB may be explained by a saturation of metabolism, resulting in a (competitive) 
inhibition of the route of metabolic activation (e.g., secondary metabolism to quinones). 
The striking differences in hepatotoxic properties between 1,2-DCB and 1,4-DCB has 
been noted in earlier reports (Brodie et al., 1971) and could perhaps be ascribed to 
differences in the capacity to form reactive metabolites or in the nature of the reactive 
products. However, preliminary experiments show that during microsomal metabolism of 
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Figure 7.3 Plasma total thyroxine (T4) levels in rats after a single i.p. dose of 1,2,4-TRICB 
(A) and PCB (B). ( • ), Control rats; ( A ), ( D ), 1 mmol/kg i.p.; ( * ) , ( • ) , 2 
mmol/kg. *, significantly different from control rats, p <0.05. 
the non-hepatotoxic 1,4-DCB in vitro, substantial protein binding occurs (results to be 
published elsewhere). 
Previous studies on the microsomal metabolism of PCB (Den Besten et al., 1989, 
1991) have demonstrated its conversion to protein-binding quinone-metabolites. 
However, the lack of overt hepatotoxicity after a single i.p. treatment with PCB 
emphasizes that the extent to which a compound is activated to reactive products in vitro 
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Table 7.4 Plasma thyroxine and triiodothyronine concentrations at 24 hr after a single 
administration (i.p.) of a series of chlorinated benzenes. 
Compound 
dose (mmol/kg): 
MCB 
1,2-DCB 
1,4-DCB 
1,2,4-TRICB 
1,2,4,5-TCBC 
PCB 
Thyroxine* 
1 
42.0 ±1.4 
32.0±2.2* 
40.7 ±4.5 
19.9+4.3* 
28.8±2.7* 
13.9 ±0.6* 
TT4) (nmol/liter) 
2 
39.9 ±5.8 
26.8±2.5* 
34.3 ±1.2* 
6.4±1.7* 
NT 
11.3 + 1.2* 
Triiodothyronineb 
1 
0.66±0.14 
0.15±0.04* 
0.77+0.12 
0.69±0.10 
0.79±0.18 
0.51 ±0.09 
(TT3) (nmol/liter) 
2 
0.51 ±0.05 
0.17±0.05* 
0.78+0.06 
0.65+0.10 
NT 
0.48±0.06* 
Note. Plasma total thyroxine (TT4) and triiodothyronine (TT3) levels were determined as 
described under Materials and Methods. Values represent mean±SE (n=4). " The level of 
TT4 in control rats was 42.3±1.6 nmol/liter. b The level of TT3 in control rats was 
0.71+0.1 nmol/liter. c Due to its limited solubility, 1,2,4,5-TCB was administered in a dose 
of 0.8 mmol/kg. Values significantly different from control rats: *, p <0.05. NT, not 
tested. 
does not necessarily correlate with the observed toxic effects. On the one hand, this 
apparent discrepancy could be due to lack of hepatotoxicity of reactive quinone 
metabolites per se. On the other hand, the concentration of reactive metabolites at the 
target site may be influenced by factors, which play a role in the whole organism but not 
in a subcellular system. The lipophilicity of the compound and hence the extent to which 
it is bioaccumulated in the organism will determine whether the rate of formation of 
reactive products can reach a treshold level. Variation in the affinity of competing 
pathways between differently substituted benzenes may also play a critical role in the 
observed effects. 
Metabolic activation of halogenated benzenes is also thought to be involved in the 
nephrotoxic symptoms. For bromobenzene, compelling evidence is obtained that 
glutathione conjugates of secondary hydroquinone metabolites are implicated in the 
proximal tubular degeneration (Monks et al, 1985). In the present study, administration 
of up to 4 mmol/kg did not result in a distinct nephrotoxic effect. Since MCB has been 
described to be nephrotoxic at higher doses (9 mmol/kg, Reid, 1973), the dose-range 
applied in the present study might have been too low to cause tubular degeneration after 
treatment with the chlorinated benzenes. 
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Table 7.5 Relative binding affinity of chlorinated benzenes and metabolites for the T4 
binding site on transthyretin (TTR). 
Binding 
Compound IC50" affinity" 
Thyroxine (T4) 1.0 x 10"7 1.00 
Pentachlorophenol 4.0 x 10"8 2.50 
2,3,4,5-Tetrachlorophenol 1.1 x 10"7 0.91 
2,3,5,6-Tetrachlorophenol 2.2 x 10~7 0.45 
2,4,5-Trichlorophenol 5.0 x 10'7 0.20 
2,3,6-Trichlorophenol 1.8 x 10"6 0.06 
2,3,4-Trichlorophenol 2.5 x 20"6 0.04 
2,6-Dichlorophenol 1.0 x 10"5 0.01 
2,3-Dichlorophenol > 10"5 « 0.01 
4-Chlorophenol > 10"5 < 0.01 
1,4-TetrachIorohydroquinone 4.0 x 10"7 0.25 
1,4-Tetrachlorobenzoquinone *> 10"5 < 0.01 
Pentachlorobenzene > 10"5 < 0.01 
IC50 values were determined from the competition curves and represent the concentration 
(M) at 50 % of total [125I]T4 binding to TTR. 
Binding affinities of the test compounds are expressed relative to T4: 
IC50 T4 
1C50 test compound 
The accumulation of protein droplets, believed to be induced by a reversible 
interaction between certain xenobiotics or their metabolites and «2/t-globulin, has been 
described after chronic oral exposure to PCB (Linder et al., 1980) as well as after 
subchronic exposure to 1,4-DCB (Bomhardt et al., 1988). The mechanism has been 
suggested to be through binding of hydroxylated metabolites to a2/x-globulin 
(Charbonneau et al., 1989). From the present results it can be concluded that this is a 
rather general phenomenon for chlorinated benzenes: with the exception of MCB and 
1,2-DCB, all other compounds tested induced protein droplets to some extent. 
In the present study an additional reversible interaction between stable metabolites and 
a receptor molecule is demonstrated in vitro, which may be responsible for the severe 
disturbance of thyroid hormone homeostasis observed. Chlorinated benzenes other than 
MCB caused a moderate to severe reduction in plasma levels of thyroid hormone 
(thyroxine, T4). Similar reductions in plasma T4 levels have been described in rats 
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exposed to structurally related compounds like the polychlorinated biphenyls. In the latter 
case, (part of) this decrease might be explained by an interference of hydroxylated 
metabolites with plasma transport (Brouwer, 1989) through a displacement of T4 from its 
binding site(s) on transthyretin (TTR), a major T4 transport protein in the rat. In vitro 
experiments with purified TTR demonstrated that simple chlorinated phenols also possess 
the capacity to displace T4 from its plasma carrier protein, confirming a recent binding 
study with TTR and several chlorinated aromatics (Van den Berg, 1990). Metabolism 
seems to be a prerequisite, since the nonhydroxylated chlorobenzenes do not show 
affinity for the T4-binding site on TTR. The relative binding affinity of chlorinated 
phenols towards TTR increased with increasing degree of chlorination, which correlated 
well with the observation in vivo, i.e., a greater reduction in plasma T4 after exposure to 
the higher chlorinated benzenes. Addition of an extra hydroxyl substituent as in 
tetrachlorohydroquinone, a secondary metabolite, did not further increase the affinity of 
the phenol towards the thyroxine binding site(s) on TTR. Furthermore, tetrachloro-
benzoquinone, a strong alkylating compound with a high affinity towards protein thiols, 
did not interact with the thyroxine binding site(s), suggesting that cysteine residues do 
not play a role in the binding of thyroxine to TTR. 
However, it should be realized that in addition to reduced plasma binding of 
thyroxine, alterations in hepatic thyroxine metabolism may be involved in the reduction 
of plasma thyroid hormone. A recent study suggested that HCB treatment increased 
hepatic thyroxine deiodination (Kleiman de Pisarev et al., 1990). In addition, increased 
UDP-glucuronyltransferase (UDP-GT) activity could contribute to the reduced thyroid 
hormone levels, since thyroxine is glucuronidated prior to its bilary excretion. In fact, 
lower chlorinated benzenes are inducers of the UDP-GT activity (Carlson and Tardiff, 
1976). However, a significant reduction in plasma TT4 level is already noticed at 5 hr 
after treatment. Liver damage could reduce plasma T4 carrier protein, but this is not a 
major factor in the reduction of thyroxine levels, since nonhepatotoxic compounds like 
PCB and 1,4-DCB also reduce plasma TT4 levels. Liver damage could also result in 
suppressed activity of the microsomal deiodases, thereby limiting the conversion of T4 to 
T3. A reduction of plasma TT3 in rats treated with 1,2-DCB was indeed observed. 
However, 1,2,4-TRICB showed similar degenerative damage without an effect on plasma 
TT3 levels. 
It is evident from the results of the present study that the relationship between the 
extent of chlorination of the benzene ring and the type and degree of the observed 
adverse effects is target-organ specific. However, 1,2,4-TRICB was always among the 
compounds producing the most severe damage. For all of the effects observed, metabolic 
activation of the parent compound is believed to be involved. Several of the key-steps 
have been elucidated in vitro (Den Besten et al., 1991). In order to correlate these results 
to the present in vivo data, detailed in vivo metabolism studies are necessary. 
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THE ROLE OF OXIDATIVE METABOLISM IN 
HEXACHLOROBENZENE-INDUCED PORPHYRIA AND 
THYROID HORMONE HOMEOSTASIS: 
a comparison with pentachlorobenzene 
in a 13-week feeding study. 
Abstract 
Hexachlorobenzene (HCB) induces a broad spectrum of effects including disturbances 
in the haem synthesis (porphyria) and in thyroid hormone homeostasis. For most of its 
effects, biotransformation of the parent compound seems to be a prerequisite. The 
present study was designed to assess the relevance of the oxidative metabolites in HCB-
induced toxicity, with special attention for the role of the reactive tetrachloro-
benzoquinone (TCBQ). To this end, toxicity and biotransformation of HCB was 
compared with that of pentachlorobenzene (PCB), since this chemical is oxidized to the 
same products as HCB, i.e., pentachlorophenol (PCP) and TCBQ. Female Wistar rats 
received diets containing different dose levels of HCB or PCB for 13 weeks, with or 
without co-treatment with triacetyloleandomycin (TAO), a selective inhibitor of 
cytochrome P450IIIA1/2. Both HCB and PCB were oxidized to PCP and tetrachloro-
hydroquinone (TCHQ), the reduced analog of TCBQ. Rats treated with HCB (high dose) 
had significantly elevated levels of urinary porphyrins from the 4th week on and a 
significant hepatic accumulation of porphyrins at the end of the study. Both urinary 
porphyrin excretion and hepatic porphyrin accumulation were greatly inhibited in rats 
receiving co-treatment with HCB and TAO. However, the inhibition of HCB-induced 
porphyria by TAO cannot be explained by a diminished formation of the highly reactive 
TCBQ, since rats treated with a high dose of PCB, which had a several fold higher 
urinary excretion of PCP and TCHQ compared to a high dose of HCB, did not develop 
porphyria. Instead, the present study points to the involvement of a putative reactive 
intermediate in the primary oxidative step in HCB-induced porphyria, since based on 
paired observations of individual rats, the degree of porphyria was correlated to a high 
degree with excretion of PCP, whereas correlation of porphyria with early excretion of 
TCHQ was much weaker. This finding fits well with the fact that the mechanisms of 
oxidation of HCB to PCP and PCB to PCP are different. Cytochrome P450IIIA1/2 
C. den Besten, M.H.J. Bennik, I. Bruggeman, P. Schielen, F. Kuper, A. Brouwer, J.H. 
Koeman, J.G. Vos, P.J. van Bladeren, submitted 
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Abstract - continued-
appears to be involved in the conversion of HCB and PCB, since co-treatment of TAO resulted in 
a strongly diminished urinary excretion of PCP and TCHQ. Treatment with HCB as well as PCB 
results in disturbances of retinoid and thyroid hormone homeostasis. These effects, which have 
also been reported after exposure to polychlorinated biphenyls, originate from interference of 
hydroxylated metabolites (notably PCP) with the plasma thyroxine transport protein, 
transthyretin, and since this metabolite is formed from both HCB and PCB, this results in the 
same toxicity for both compounds. 
Introduction 
Hexachlorobenzene (HCB) and pentachlorobenzene (PCB) are chlorinated 
hydrocarbons, which have been used in the past as crop protectants. Nowadays, emission 
into the environment may occur due to their use as a chemical intermediate or by-product 
in industry, and their presence as an impurity in the formulation of several widely used 
pesticides (US EPA, 1985). 
As a consequence of the disastrous HCB-poisoning in eastern Turkey from 1955-1959 
(Peters et al, 1982), this chemical has been the subject of intense research. HCB has 
been shown to be hepatotoxic: effects on the liver range from hepatocellular enlargement 
to severe disturbance of the haem synthesis, resulting in accumulation of porphyrins in 
the liver and (massive) excretion of porphyrins into urine (Böger et al., 1979). HCB also 
has potent immunotoxic properties. In rats, HCB has been reported to induce immune 
stimulation (both humoral and cell-mediated; Vos et al.,1979; 1983), whereas in mice, 
HCB acts as an immune suppressor (Vos, 1986). More recently, effects of HCB on 
thyroid hormone homeostasis have been reported (Rozman et al, 1986; Kleiman de 
Pisarev et al, 1989). 
The mechanisms by which HCB exerts these adverse effects have been the subject of 
many studies over the past decades. For example, evidence has been obtained that 
disturbances in thyroid hormone homeostasis by HCB is, at least in part, related to 
alterations in thyroid hormone metabolism (e.g., increased deiodination and/or 
glucuronidation), resulting in increased elimination from the body (Kleiman de Pisarev et 
al., 1989). Impaired thyroid hormone synthesis does not seem to be involved (Kleiman 
de Pisarev et al., 1990). Recent studies, however, pointed at an important role for 
hydroxylated metabolites of HCB in the observed plasma thyroid hormone decrease 
through a mechanism involving plasma transport (Van Raaij et al, 1991). 
Furthermore, HCB-induced porphyria is believed to originate from a selective and 
irreversible inactivation of uroporphyrinogen decarboxylase (UROG-D), a key enzyme in 
haem synthesis (Elder et al, 1976). However, the mechanism of inactivation of 
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Figure 8.1 Formation of TCBQ as a common metabolite of HCB and PCB, and its 
proposed role in the induction of porphyria. 
UROG-D is still a matter of debate. One of the main hypotheses regarding the 
mechanism of HCB-induced porphyria is based on the assumption that the parent 
compound is oxidized to reactive derivatives (Debets et al., 1980b; Carpenter et al., 
1984), which may subsequently covalently bind in or near the active site of UROG-D, 
resulting in inactivation of this enzyme (Debets et al., 1981; Billi de Catabbi, 1991). 
Although biotransformation of HCB appears to be a prerequisite for its porphyrinogenic 
action, none of the known metabolites is directly porphyrinogenic when administered in 
vivo (Wainstok de Calmanovici and San Martin de Viale, 1980; Koss et al., 1979). Two 
oxidative metabolites, pentachlorophenol (PCP) and tetrachlorohydroquinone (TCHQ), 
displayed a direct inhibitory effect on partially purified UROG-D (Billi et al., 1986); 
however, the concentrations used in this study by far exceeded the level these compounds 
may reach in the liver as metabolites of HCB. Based on these studies, it appears that if a 
reactive metabolite is involved in the induction of porphyria, its metabolic formation in 
situ is a prerequisite. 
The formation of tetrachlorobenzoquinone (TCBQ), a secondary metabolite of HCB, 
can be hypothesized as a plausible pathway ultimately leading to porphyria. TCBQ has a 
143 
Metabolism and toxicity ofHCB and PCB 
uniquely high reactivity towards nucleophiles, due to its perhalogenated character. After 
reaction of TCBQ with a nucleophile (such as e.g., glutathione), the quinone structure is 
retained, and thus its reactivity (Van Ommen et al, 1988). The formation of TCBQ, as 
measured by the excretion of its reduced analog TCHQ, has been reported to be strongly 
correlated to the porphyrinogenic action of HCB (Van Ommen et al., 1989). However, 
direct proof for its involvement in HCB-induced porphyria is still lacking, since studies 
aimed at demonstrating the direct interaction of reactive metabolites with UROG-D have 
not been successful thus far. 
In vitro experiments with rat liver microsomes showed that the major P-450 
isoenzyme involved in the oxidation of both HCB (to PCP) and PCP (to TCBQ) belongs 
to the P450IIIA subfamily, which is induced by glucocorticoids and macrolide antibiotics 
(Van Ommen et al., 1989). Some macrolide antibiotics, like triacetyloleandomycin 
(TAO), induce P450IIIA1/2 to a high degree, but simultaneously form a catalytically 
inactive P450-TAO metabolite complex (Pessayre et al., 1981). In a recent study, TAO 
was used as a tool to selectively inhibit the oxidative biotransformation of HCB. In rats 
co-treated with HCB and TAO, a significantly decreased excretion of both PCP and 
TCHQ correlated with a greatly diminished extent of porphyria compared to rats treated 
with HCB alone (Van Ommen et al., 1989). Based on these results, it was suggested that 
the formation of the reactive TCBQ may be a crucial factor in the porphyrinogenic action 
of HCB. 
Interestingly, the microsomal oxidation of pentachlorobenzene has also been shown to 
result in the formation of the reactive TCBQ via oxidative dehalogenation of the primary 
metabolite PCP (Den Besten et al, 1989). Furthermore, microsomes from rats pretreated 
with dexamethasone, an inducer of cytochrome P450IIIA1, showed a high catalytic 
activity towards PCB similar to that of HCB (Den Besten et al, 1991). Thus, if the in 
situ formation of TCBQ is relevant to the development of porphyria, PCB should 
resemble HCB in its porphyrinogenic action, as hypothetically illustrated in Figure 8.1. 
Therefore, the present study was designed to seek further support for the role of the 
reactive TCBQ in HCB-induced porphyria by comparing both oxidation products and the 
development of porphyria in rats treated with HCB or PCB in their diet for 13 weeks. 
The contribution of P450IIIA to the observed effects is assessed by studying the effects 
in rats which were co-treated with TAO. Furthermore, a comparison between 
biotransformation of HCB and PCB, and their possible effects on other targets such as 
thyroid hormone homeostasis might indicate a role for common metabolites in these 
effects. Since structurally related compounds like the polychlorinated biphenyls have been 
described to disturb both thyroid hormone- and retinol homeostasis, the effects of HCB 
and PCB on plasma and liver retinol/ retinoid levels were also evaluated. 
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Materials and Methods 
Chemicals 
Pentachlorobenzene (>99.5 % purity) was purchased from Dr. Ehrenstorfer GmbH, 
Augsburg, Germany. Hexachlorobenzene (gold label, > 99 % purity) was purchased 
from BDH Chemicals Ltd., United Kingdom. Triacetyloleandomycin (TAO) was from 
Pfizer, Orsay, France. 
Animals and treatment 
One week prior to the start of the study, eighty-one female Wistar rats (160 - 200 g) 
were ad random divided into 9 treatment groups of 9 rats each, with each group having 
approximately the same mean body weight. Animals were housed in a temperature- and 
humidity-controlled room under a 12 hours light:dark cycle. Rats within each treatment 
group were randomly divided and housed in wire bottom cages (three rats per cage) in 
order to prevent the ingestion of urine and faeces. Food (standard laboratory chow, Hope 
Farms, Woerden, The Netherlands) and tap water were supplied ad libitum. After 1 
week of acclimatization, the rats were fed the following diets: Control; TAO (0.3 %); 
HCB low (0.015 %); HCB high (0.03 %); HCB high (0.03 %) + TAO (0.3%); PCB 
low (0.03 %); PCB high (0.13 %); PCB low (0.03 %) + TAO (0.3 %); PCB high 
(0.13 %) + TAO (0.3 %). All diets contained 4 % corn oil. Diets were prepared in two 
batches, at the start of the experiment and in week 7, and stored in a dark, cool room of 
low humidity. Accurate food consumption per cage was determined weekly and corrected 
for the chow spilled. One day each week, rats were transferred into individual 
metabolism cages for 24 hr urine collection. Body weight was measured weekly at the 
start of the experiment, and more frequently later when animals showed signs of distress. 
Clinical observations were made daily, and rats were terminated when a body weight loss 
of more than 10 % in 24 hr over two consecutive days occurred. Plasma was collected at 
t=0, 1 and 5 weeks by orbita punction under marginal ether anesthesia. Rats were killed 
after a treatment period of 13 weeks by exsanguination via the abdominal aorta under 
marginal ether anesthesia. Blood (7 ml) was collected and plasma was prepared in 
heparin-containing tubes by centrifugation. Liver, kidneys, thyroid, adrenal glands, 
spleen, thymus, popliteal and mesenteric lymph nodes were excised and weighed. 
Thyroid, adrenal glands and a sample of liver and kidney was fixed in buffered formalin 
for microscopical examination (H&E staining). Lungs were intratracheally fixed with 
gelatin and one lung was fixed in formalin for microscopical examination. The other 
lung, spleen, thymus and lymph nodes were frozen in liquid nitrogen for 
immunohistochemical analysis (results on lung and organs related to the immune system 
will be published elsewhere). Histopathological examination of liver, kidney, adrenal and 
thyroid was only performed on tissues obtained from control rats and rats fed diets 
containing TAO alone, HCB high, PCB high, HCB high+TAO and PCB high+TAO. 
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Two samples (of approximately 1 g each) of each liver were frozen in liquid nitrogen 
for determination of porphyrin content, and stored at -80 °C until analysis. The 
remaining part of the liver was weighed, frozen on dry ice in a 20 mM Tris-HCl buffer, 
pH 7.4, containing 250 mM sucrose, and stored at -80 °C. 
Biochemical determinations 
Plasma total thyroxine (TT4), total triiodothyronine (TT3) and free thyroxine (FT4) 
levels were measured by standard procedures using the Amerlite TT4, TT3 and FT4 
assays (Amersham, England). Plasma retinol and liver retinoids were determined in 
control rats and rats treated with HCB high and PCB high. Plasma retinol was extracted 
as previously described (Brouwer and Van den Berg, 1984). Livers were homogenized in 
ice-cold Tris-HCl (1/5, w/v) using a Teflon pestel. Whole homogenate samples were 
frozen at -80 °C for determination of retinoid content. Liver retinoids were extracted by 
a modification of the method of Olson (Olson et al., 1979) as previously described 
(Brouwer et al., 1988a). Extracts were analyzed for retinol and retinyl palmitate as 
reported (Brouwer et al., 1988a). Plasma asparagine amino transaminase (AST), alanine 
amino transaminase (ALT) activity and blood urea nitrogen level (BUN), indicative of 
hepatotoxicity and nephrotoxicity respectively, were determined employing a Cobas-Bio 
centrifugal analyzer and commercially available kits (reagents 3146, 3147 and 3162, 
Baker T.J., Deventer, The Netherlands; kit 7-15379, Hoffman-Laroche, Basel, 
Switzerland). 
Determination of porphyrins in urine and liver 
The amount of total porphyrin in urine was determined fluorimetrically according to 
Schwartz et al., (1976), modified by Debets et al., (1981). Liver porphyrin content was 
determined according to the same method, after preparations as described by Van 
Ommen et al, (1989). 
Determination of urinary excretion of PCP and TCHQ 
Urinary excretion of pentachlorophenol (PCP) and tetrachlorohydroquinone (TCHQ) 
was determined after 1, 4, 6, 8, 10, 12 and 13 weeks of treatment. Urinary metabolites 
were extracted as previously described (Van Ommen et al., 1989). Separation was 
achieved on a Nucleosil RP18 column (150x4.6 mm I.D.) with water and methanol as 
mobile phases (both containing 0.5 % acetic acid). The following gradient elution profile 
was applied: 2 min isocratically at 50 % methanol followed by an increase to 90 % 
methanol in 17 min, followed by 5 min stationary at 90 % methanol and concluded with 
10 min at 95 % of methanol. The flow rate was 1 ml/min, and the eluent was monitored 
at 300 nm. Analysis of urine extracts from HCB-treated rats revealed 2 major and 2 
minor peaks, whereas 5 major and 4 minor peaks were detected in the urine extracts 
from PCB-treated rats. A full report on the isolation and identification of these 
metabolites will be given elsewhere (Chapter 9). Comparison of the HPLC elution 
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profiles revealed that PCP and TCHQ were the only two common urinary metabolites 
derived from HCB and PCB. Quantification of the amounts of PCP and TCHQ was 
accomplished by comparing peak areas to those obtained from a calibration curve of 
reference standards. Recovery was determined by the addition of [14C]-PCP (10,000 
dpm) to urine samples as an internal standard prior to extraction. This amount of PCP 
did not contribute to the UV absorption at 300 nm during HPLC analysis. Routinely, a 
recovery of more than 70 % was obtained. 
Statistical analysis 
Data were analyzed statistically using a non-parametric ANOVA according to 
Kruskal-Wallis using Chi-squared approximation (two-sided). Correlation between 
metabolite excretion and porphyria was computed using Spearman's rank correlation 
coefficient, which was tested for significancy (two-sided) using Student's ^-distribution 
with n-2 degrees of freedom (n, number of paired observations). Data on the 
histopathological changes were analyzed statistically with the Fischer exact probability 
test (two-sided). 
Results 
Mortality and clinical symptoms 
Mortality and clinical symptoms were limited to rats in the HCB low, HCB high, and 
HCB high+TAO groups. In the HCB high group, 4 animals were sacrificed before the 
end of the study (i.e., after 57, 74, 81, and 88 days of treatment), because of severe 
weight loss and distress. In the HCB high+TAO group, one rat died after 85 days. 
These prematurely dead animals did not show signs of a higher extent of porphyria than 
surviving rats in the same group (data not shown). Skin lesions were observed in the 
HCB high group (from the 5th week on), in the HCB high+TAO group (from the 6th 
week on) and in the HCB low group (from the 8th week on). From week 8 on, rats in 
the HCB high and HCB high+TAO group developed tremors. 
Food intake and body weight gain 
Final body weight was significantly lower in rats treated with TAO alone, PCB high, 
and in the PCB +TAO treated rats (Table 8.1), which correlated with a significant 
decrease in food intake. As a result of decreased food intake, the amount of PCB 
ingested on a daily basis was slightly lower in the TAO co-treated animals (both PCB 
low and PCB high). Final body weight of surviving rats treated with HCB low or HCB 
high was not significantly different from control rats. 
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Table 8.1 Effect of HCB and PCB on body weight gain and food intake. 
Treatment 
Control 
Control+TAO 
HCB low 
HCB high 
HCB high+TAO 
PCB low 
PCB high 
PCB low+TAO 
PCB high+TAO 
Initial 
Body 
wt 
(g) 
174 + 
173 ± 
176 + 
179 + 
177 + 
173 ± 
173 ± 
177 + 
174 ± 
3 
3 
4 
3 
4 
3 
3 
4 
4 
Final 
Body 
wta 
(g) 
243+ 5 
216+ 41 
254+ 4 
260+ 6 
240 ± 3 
246+ 4 
227+ 31 
218+ 61 
222 ± 61 
Food Intake 
(g/cage/ 
week) 
295.7+ 0.2 
265.6 ± 0.61 
302.5+ 0.6 
315.1 ± 3.01 
287.5+ 3.4§ 
297.3+ 1.8 
288.1 ± 1.81 
263.7+ 2.81§ 
280.1 ± 2.71 
Amount of 
chemical 
ingested 
(mg/kg/d)b 
0 
0 
9.5 
19.0 
19.1 
19.1 
84.1 
17.9 
81.4 
Note. Groups of nine female rats were exposed for 13 weeks to HCB or PCB in their 
diet, with or without co-treatment with TAO, as described under Materials and Methods. 
Data are represented as Mean+SE. " Values represent mean±SE of 9 animals, except in the 
HCB high group (5 surviving rats) and in the HCB high+TAO group (8 surviving rats). b 
Approximate figure based on average food intake and body weight. 1 Statistically significant 
difference compared to control group, p <0.05; § Statistically significant difference 
compared to rats receiving same treatment without TAO, p <0.05. 
Organ weight to body weight ratio 
Table 8.2 shows organ weights expressed as unit of body weight (wt). All treatments 
resulted in a significant increase in liver-to-body weight ratio. Rats in the HCB high, 
HCB high+TAO, and PCB high+TAO groups had significantly higher kidney-to-body 
wt ratio's, whereas rats treated with PCB high alone showed a tendency to higher 
kidney-to-body wt ratio's (p = 0.057). Significantly higher adrenal-to-body wt ratio's 
were observed both in rats treated with the HCB high dose and HCB high+TAO, and 
also in rats treated with TAO alone. No significant alterations were observed in relative 
thyroid weights between control and treatment groups. 
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Table 8.2 Effect of HCB and PCB on relative organ weights. 
Treatment 
Control 
TAO 
HCB low 
HCB high 
HCB high+TAO 
PCB low 
PCB high 
PCB low+TAO 
PCB high+TAO 
Liver" 
3.13 
(0.17) 
3.68" 
(0.15) 
4.101" 
(0.10) 
6.341" 
(0.25) 
6.40"1 
(0.37) 
3.561 
(0.08) 
4.63™ 
(0.14) 
3.9111 
(0.14) 
4.98™ 
(0.09) 
Organ weight per 100 g Body wt" 
or 10,000 g Body wtb 
Kidney8 
(total of two) 
0.70 
(0.02) 
0.71 
(0.02) 
0.74 
(0.01) 
0.931" 
(0.04) 
0.84" 
(0.03) 
0.70 
(0.02) 
0.78 
(0.02) 
0.75 
(0.02) 
0.82" 
(0.02) 
Adrenal" 
(total of two) 
2.46 
(0.11) 
2.851 
(0.10) 
2.66 
(0.07) 
4.16« 
(0.46 
3.061 
(0.20) 
2.33 
(0.10) 
2.67 
(0.13) 
2.67 
(0.08) 
2.71 
(0.09) 
Thyroid" 
(total of two) 
0.93 
(0.12) 
0.85 
(0.10) 
1.13 
(0.11) 
0.84 
(0.09) 
0.92 
(0.11) 
0.71 
(0.09) 
0.82 
(0.14) 
0.85 
(0.09) 
0.90 
(0.14) 
Note. Groups of nine female rats received dietary treatment with HCB or PCB for 13 
weeks, with or without co-treatment with TAO, as described under Materials and Methods. 
Organ weights are expressed relative to a 100 g body wt, or relative to b 10,000 g body wt, 
and presented as mean (SE). Statistically significant differences compared to control rats are 
indicated as follows: 1/> <0.05, np <0.01, mp < 0.001. 
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Clinical chemistry parameters 
There were no significant differences between the different diets for plasma ALT, 
AST and BUN after 1, 5, or 13 weeks of treatment (data not shown), although two rats 
in the HCB high group had relatively high ALT values after 13 weeks (122 and 367 U/l 
versus 63+3 U/liter for control rats, mean±SE). 
Histopathology 
The histopathological observations are presented in Table 8.3. Hypertrophic 
hepatocytes with eosinophilic cytoplasm with thread-like basophilic structures were 
observed in the liver of animals in the HCB high group. The hypertrophy, which was 
especially prominent in the centrilobular area, was less severe in PCB high-treated rats. 
The incidence of inflammatory cell infiltrates, especially periportal mononuclear 
inflammatory cells, was increased in the HCB high rats only. In addition, minimal to 
moderate bile duct proliferation was found in the HCB high rats only. 
Effects on the kidneys and adrenals were observed only in the HCB high-treated rats. 
In the kidneys, an increased incidence of basophilic renal tubules and the presence of 
proteinaceous casts was observed in HCB-high rats, whereas in the adrenals hypertrophy 
and hyperplasia of the cortex cells was seen, occasionally accompanied by haemorrhage, 
cortical cell vacuolation and inflammatory cell infiltrates in the adrenal cortex. In several 
PCB-high treated rats, slight hypertrophy and hyperplasia of adrenal cortex cells was also 
observed. The meaning of these isolated findings remains unclear. 
Slightly activated appearance of the thyroid was observed in several animals in the 
HCB high-group, but the incidence was just outside the statistically significance range (p 
= 0.05). 
Treatment of rats with TAO alone resulted in changes in the liver, consisting of 
vacuolation of the hepatocytes, resembling macrovesicular fatty change. No distinct 
lobular pattern was observed. 
Combined exposure to HCB high + TAO or PCB high+TAO did not result in a 
diminution of the effects of HCB and PCB, respectively (Table 8.3). The only effect was 
noticed in the liver, where the cytoplasm of the hypertrophic hepatocytes was altered 
from eosinophilic with thread-like basophilia, as seen in the HCB and PCB group to a 
more homogeneous lightly-eosinophilic cytoplasm with accentuation of the cell membrane 
by a condensed eosinophilic staining. Hepatocyte vacuolation, as observed in the TAO 
group was also seen in the HCB high+TAO group, but not in the PCB high+TAO 
group. 
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Table 8.3 Histopathological lesions in rats treated with HCB and PCB with or without TAO. 
Tissue 
Observation 
Liver 
Hypertrophy 
Periportal mc infiltrate 
RES/necrotic hepatocytes 
Bile duct proliferation 
Kidney 
Basophilic tubules 
Proteinaceous cast(s) 
Adrenal 
Hypertrophy + 
Hyperplasia cortex cells 
Control 
0 
0 
5 (1.2) 
0 
2 (1.5) 
0 
0 
TAO 
0 
0 
8 (2.3) 
2(1.0) 
0 
0 
0 
HCB 
high 
91,1(3.2) 
6"(1.8) 
9 (2.2) 
9111(1.9) 
911(2.6) 
51(2.0) 
9111(4.0) 
PCB 
high 
9111(2.3) 
1 (1.0) 
4(1.3) 
0 
2(1.0) 
0 
8111(3.6) 
HCB high 
+TAO 
8111(2.9) 
6"(1.7) 
5(1.8) 
8111(1.9) 
71(2.7) 
6" (1.8) 
1 (2.0) 
PCB high 
+TAO 
9111(2.4) 
4(1.0) 
4(1.3) 
2 (1.0) 
5 (1.4) 
2 (1.0) 
2 (2.0) 
Thyroid 
Activated appearance 1 (2.0) 2 (2.0) 6 (2.0) 1 (2.0) 4 (2.0) 5 (2.2) 
Note. Female rats (nine per group) received dietary treatment with HCB or PCB, with 
or without co-treatment with TAO for 13 weeks, as described under Materials and Methods. 
At the end of the exposure period, liver, kidney, adrenal and thyroid were fixed in formalin 
for microscopic examination. Data represent incidence of lesion (average severity score 
within brackets) and are based on 9 rats per group, except in the HCB high+TAO group in 
which n=8 due to the premature death of one animal. Tissues of prematurely killed animals 
in the HCB high group (see text) are included. The average severity score was calculated on 
a scale of 1 to 5: minimal, 1; slight, 2; moderate, 3; marked, 4; severe, 5. Statistically 
significant differences are indicated as follows: 1 p <0.05, 11 p <0.01, m p <0.001. 
Urinary excretion of porphyrins 
As shown in Figure 8.2, urinary excretion of porphyrins was significantly increased 
in rats treated with a high dose of HCB from the 4th week on. Addition of TAO to the 
diet greatly reduced the porphyrinogen^ activity of HCB to levels observed after 
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exposure to a low dose of HCB (0.015 %), which were only significantly different from 
control values from the 10th week on. Rats treated with PCB (high dose) also had very 
slightly but statistically significantly elevated urinary porphyrin levels compared to 
control rats. However, in PCB-treated rats there was no sign of progressive porphyria 
with treatment time, but urinary porphyrin levels rather decreased at the end of the 
treatment period. 
A. 
Contro l 
Figure 8.2 Urinary excretion of porphyrins in untreated female rats (A) and female rats, 
which received dietary treatment with HCB (B) or PCB (C) for 13 weeks, with or without 
co-treatment with TAO. Data are presented as mean+SE. Symbols: (A), O , control; • , 
TAO-control: (B), v , HCB-low; A , HCB-high; A , HCB-high+TAO; (C), O , PCB-Iow; 
• , PCB-low+TAO; D , PCB-high; • , PCB-high+TAO. Statistically significant 
differences compared to control rats are indicated as follows: * p <0.05, " p <0.01, *** p 
< 0.001. In Figure C, porphyrin content is significantly different from control rats, 
p<0.05, at all time points in PCB-high treated rats, and, with the exception of week 8 and 
week 10, in PCB-high+TAO treated rats. 
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Table 8.4 Effect of HCB and PCB on liver porphyrin levels. 
Treatment 
Control 
TAO 
HCB low 
HCB high 
HCB high+TAO 
PCB low 
PCB high 
PCB low+TAO 
PCB high+TAO 
Porphyrin 
Otg/g liver) 
0.28± 0.02 
0.24± 0.02 
3.23± 2.601 
42.57± 17.07111 
2.34± 1.55" 
0.25 ± 0.02 
0.32+ 0.02 
0.22± 0.01 
0.24+ 0.02 
level8 
(range) 
(0.21 - 0.40) 
(0.16- 0.35) 
(0.20 - 24.0) 
(2.72 - 147.67) 
(0.24 - 14.67) 
(0.15 - 0.29) 
(0.25 - 0.44) 
(0.16- 0.27) 
(0.17 - 0.35) 
Note. Groups of nine female rats received dietary treatment with HCB or PCB, with or 
without co-treatment with TAO for 13 weeks, as described under Materials and Methods. 
Liver porphyrin levels were determined fluorimetrically as described under Materials and 
Methods, and are expressed as mean+SE (range) of 9 animals. Livers of prematurely dead 
animals are included. Statistically significant differences are indicated as follows: 1/> <0.05, 
"p <0.01, mp < 0.001. 
Accumulation of porphyrins in liver 
As shown in Table 8.4, rats in the HCB high group had significantly elevated 
accumulation of porphyrins in the liver. The addition of TAO to their diet diminished 
this accumulation to a great extent, although not completely. A few rats in the HCB low 
group also had higher liver porphyrin levels. Rats treated with PCB did not show any 
signs of accumulation of porphyrins in liver. 
Thyroid hormone homeostasis 
In Figure 8.3, the effects of HCB and PCB on plasma thyroid hormone levels are 
presented. Rats treated with HCB (both low and high dose) had significantly decreased 
plasma TT4 (total thyroxine; Figure 8.3A), plasma FT4 (free thyroxine; Figure 8.3B) 
and plasma TT3 (total triiodothyronine; Figure 8.3C) levels after 5 and 13 weeks of 
treatment. In rats treated with PCB (both low and high dose), maximally decreased levels 
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of TT4 (Figure 8.3D), FT4 (Figure 8.3E) and TT3 (Figure 8.3F) were already observed 
after 1 week of treatment. After 13 weeks, however, plasma TT3 levels in PCB-treated 
rats were back to control levels, whereas in HCB-treated rats TT3 levels were still 
significantly decreased at the end of the study. Rats treated with TAO alone showed 
plasma thyroid hormone levels higher than untreated (control) rats (p < 0.01 after 5 
weeks (TT4) and 13 weeks (TT3)), making the changes observed in rats receiving co-
treatment with HCB or PCB rather difficult to interpret. 
Retinoid homeostasis 
Liver and plasma retinoid levels in rats receiving the HCB high or the PCB high 
treatment are presented in Table 8.5. One control rat showed an extremely high liver 
retinol level (248 ^g/g liver) compared to the other rats in the same group (29+3.7, 
mean±SE, n = 8), resulting in a high standard error. This value was, however, not 
omitted, since it did not influence statistical significancy between treatment groups 
(control vs HCB or control vs PCB). 
As shown in Table 8.5, liver retinol content was significantly decreased in rats treated 
with a high dose of HCB compared to control rats. In addition, the amount of liver 
retinyl palmitate was decreased both in HCB high and PCB high-treated rats. 
Plasma retinol levels were decreased after 13 weeks of treatment with a high dose of 
HCB. In contrast, plasma retinol levels in PCB high-treated animals were significantly 
higher compared to levels in control rats, both after 1 week and 13 weeks of treatment. 
Urinary excretion of PCP and TCHQ 
Urinary excretion of PCP and TCHQ, the reduced equivalent of the reactive TCBQ, 
as determined by HPLC, is shown in Figure 8.4A, B, and C for HCB, and in Figure 
8.4D, E and F for PCB treated rats, respectively. In fact, PCP and TCHQ were the only 
two common urinary metabolites after administration of HCB and PCB to rats. 
Figure 8.3. Plasma total thyroxine (TT4; A, D), free thyroxine (FT4; B, E) and total 
triiodothyronine (TT3; C, F) levels in female rats which received dietary treatment with 
HCB or PCB for 13 weeks, with or without co-treatment with TAO. Data are presented as 
mean+SE. Symbols indicate the following: ( • ), control; ( O ) TAO-control; ( A ) HCB 
low or PCB low; ( A ) PCB low+TAO; ( • ) HCB high or PCB high; ( D ) HCB 
high+TAO or PCB high+TAO. * significantly different from levels in control rats, 
p<0.05, " p <0.01, *** p <0.001. a control significantly different from all other 
treatments, p <0.05; b control significantly different from all other treatments with the 
exception of PCB high+TAO, p <0.05. 
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A full report on the identification of urinary metabolites of HCB and PCB will be given 
elsewhere (Chapter 9). 
When the content of HCB in the feed is doubled from 0.015 % (HCB low) to 0.03 % 
(HCB high), the excretion of PCP and TCHQ is increased disproportionally (cfg. Figure 
8.4A,B). Co-administration of HCB high with TAO resulted in a strongly diminished 
excretion of both metabolites to amounts comparable to those excreted by rats treated 
with a low dose of HCB (Figure 8.4C). Similarly, the administration of TAO to the 
PCB-containing diets inhibited the oxidation of PCB to PCP and TCHQ (both PCB low 
dose (not shown) and high dose, Figure 8.4F). 
The present study was aimed at the comparison between HCB and PCB with respect to 
the role of their oxidation products in toxicity. Therefore, it is important to compare the 
extent of formation of the two common oxidation products between treatment groups. 
Comparison of a similar dose (0.03 %) of HCB and PCB (i.e., HCB high vs PCB low, 
Figure 8.4B vs Figure 8.4D) reveals that, with the exception of the first 4 weeks, HCB 
was converted to PCP to a higher extent than PCB was. In contrast, urinary TCHQ 
excretion was significantly higher in PCB low treated rats (Figure 8.4D) compared to the 
HCB high treated rats (Figure 8.4B) until week 10 (with the exception of week 6), 
whereas after 13 weeks of treatment excretion of TCHQ was significantly higher in HCB 
high treated rats. 
When the concentration of PCB in the feed is increased to 0.13 % (PCB high), the 
excretion of PCP is strongly increased in the first 2 weeks of exposure, and then reaches 
a plateau, indicating saturation of this pathway (Figure 8.4E). PCP excretion in rats 
treated with the HCB high dose (0.03%) reached the same plateau value after 12 weeks. 
TCHQ excretion is also increased in PCB high-treated rats compared to PCB low-treated 
rats, and reaches a plateau after 6 weeks. With exception of the last 2 weeks of the 
treatment period, excretion of these two metabolites is significantly higher in the PCB 
high rats (0.13 %) when compared to rats treated with the HCB high dose (0.03 %). 
During the whole exposure period, excretion of PCP and TCHQ is significantly higher in 
rats treated with the PCB high dose (0.13%) compared to rats treated with the HCB low 
dose (0.015 %, Figure 8.4A). 
Discussion 
Porphyria is one of the most striking consequences of exposure to HCB. In spite of the 
fact that a great number of studies appears to indicate a crucial role for oxidative 
biotransformation of HCB in its porphyrinogen^ action (Kerklaan et al, 1977; Debets, 
1980a; Wainstok de Calmanovici et al, 1984; 1989), direct evidence which proves that 
the origin of porphyria is connected to the metabolic activation of HCB is still scanty. 
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Figure 8.4. Urinary excretion of PCP ( • ) and TCHQ ( • ) in female rats which received 
dietary treatment with 0.015% HCB (HCB low, A), 0.03% HCB (HCB high, B) and 0.03% 
HCB + TAO (HCB high+TAO, C), 0.03% PCB (PCB low, D), 0.13% PCB (PCB high, 
E), and 0.13% PCB + TAO (PCB high+TAO, F). Data are presented as mean+SE. 
significantly different from excretion in rats receiving the same treatment without TAO, 
p<0.05 , ** p <0.01, *** p <0.001; a significantly different levels compared to PCB low-
treated rats (cf. Figure 8.4D), p <0.05, aa P<0.01; b significantly different levels compared 
to HCB high treated rats, p <0.05, BD p <0.01, 
levels compared to HCB low treated rats, p <0.05, ' 
BDD
 p < 0.001; c significantly different 
p <0.01,ccc/7 <0.001. 
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Table 8.5 Effect of HCB and PCB on liver retinoid levels and plasma retinol levels. 
Liver retinoid 
retinol" 
retinyl 
palmitatec 
Plasma retinold 
a t t= 0 
after 1 week 
after 13 weeks 
control 
53.3± 24.5 
2.16+ 0.08 
0.34+ 0.01 
0.22+ 0.01 
0.21+ 0.01 
HCB high 
15.8± 3.6M1 
1.04+ 0.04M" 
0.32+ 0.02 
0.22+ 0.01 
0.16± 0.01e'1 
PCB high 
22.7+ 3.9 
1.30± 0.091" 
0.34± 0.02 
0.34+ 0.02111 
0.34± 0.03" 
Note. Groups of nine female rats received dietary treatment with HCB or PCB with or 
without TAO for 13 weeks, as described under Materials and Methods. Plasma retinol and 
liver retinoid levels are determined as described under Materials and Methods. Data 
(mean+SE, n=9) are expressed per a /*g/g liver, c mg/g liver, and d ugl ml. b Liver 
retinoid levels in prematurely dead rats are also included. e Due to prematurely killed 
animals, data are based on n = 5 rats. Statistically significant differences compared to control 
rats are indicated as follows: 1 p<0.05,11 p<0 .01 , 1 " p<0.001. 
The experimental design used in the present study, in which HCB and PCB were 
compared with respect to their main adverse effects, allowed us to assess the contribution 
of in situ formation of TCBQ, the highly reactive metabolite of HCB and thus a likely 
candidate for the porphyrinogenic species. 
Previous reports indicate the involvement of cytochrome P450IIIA1/2 in the 
microsomal oxidation of HCB (Van Ommen et al., 1989) and PCB (Den Besten et al., 
1991) to PCP and TCHQ. The present study clearly shows that extrapolation of these 
microsomal findings to the in vivo situation is valid, since selective inactivation of 
cytochrome P450IIIA1/2 by TAO in rats treated with HCB or PCB results in a dramatic 
decrease in the urinary excretion of PCP and TCHQ. 
The present study confirms earlier findings by Van Ommen et al, (1989) that, in 
addition to decreased metabolite excretion, the porphyrinogenic action of HCB was 
greatly reduced when rats were treated with a combination of HCB+TAO. In HCB 
treated groups, (mean) excretion of both PCP and TCHQ as a function of treatment time 
was compared with the extent of urinary porphyrin excretion as a function of treatment 
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time using Spearman rank correlation, and were found to be strongly correlated (r= 
0.943, 0.886, 0.899 for excretion of PCP vs urinary porphyrin excretion in the HCB 
low, HCB high and HCB high+TAO treatments; r= 0.771, 0.999, 0.579 for excretion 
of TCHQ vs urinary porphyrin excretion in the HCB low, HCB high and HCB high + 
TAO treatments). However, a statistically significant correlation between two factors that 
both increase with prolonged treatment time does not necessarily imply a causal 
relationship, but may simply be due to a common cause, i.e., the exposure to HCB. 
Because variation in the extent of porphyria between rats within each HCB treatment 
group is considerable (cf. Figure 8.2 and Table 8.3), a more meaningful correlation can 
be computed based on paired observations made on individual rats within each treatment 
group. Thus, the question may be raised whether within each HCB-exposed group, rats 
which are highly porphyric also have a high metabolite excretion, and vice versa, rats 
which are less porphyric have a lower extent of metabolite excretion. Correlation 
coefficients thus calculated are presented in Table 8.6. These data indicate that the 
correlation between oxidative biotransformation cumulated over the entire treatment 
period and porphyria at the end of the study is rather weak, with a statistically significant 
correlation observed only between urinary excretion of PCP in rats receiving the HCB 
low treatment and liver porphyrin accumulation. However, when all paired observations 
concerning metabolite excretion and porphyria in rats receiving the HCB low, HCB high 
or HCB high+TAO treatments were combined, urinary excretion of both PCP and 
TCHQ were significantly correlated with the extent of porphyria. 
Inhibition of UROG-D has been shown to be an early event in HCB-induced 
porphyria, preceding the manifestation of the porphyric condition (Koss et al, 1983; 
Smith et al, 1986). For example, UROG-D activity dropped soon after the start of HCB 
exposure in mice, but overt porphyria was not observed until weeks later (Smith and 
Francis, 1983). With respect to this long latency period in the induction of porphyria, it 
might be relevant to compare the degree of urinary metabolite formation in the first part 
of the exposure period with the degree of porphyria observed at the end of the study. 
These data are also included in Table 8.6. Both for the HCB high group and for the 
combined treatments, the degree of porphyria correlated well with the excretion of PCP, 
whereas correlation between porphyria and excretion of TCHQ was much weaker. These 
data are not supportive for the involvement of the reactive TCBQ, the oxidized analog of 
TCHQ, in HCB-induced porphyria. 
In the present study, urinary metabolite excretion and the degree of porphyria was also 
monitored in rats treated with PCB. This chemical is also oxidized to PCP and TCHQ 
(Den Besten et al., 1989; 1991). Rats receiving the PCB high dose had a several fold 
higher urinary excretion of both PCP and TCHQ compared to rats receiving the HCB 
high treatment. Although rats receiving the PCB high treatment had slightly elevated 
urinary porphyrin levels compared to control rats, PCB does not cause hepatic porphyria 
in a way similar to HCB, because of the fact that (i) no sign of liver porphyrin 
accumulation was observed, and (ii) urinary porphyrin levels actually decreased at the 
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end of the treatment period instead of showing a progressive increase. More likely, the 
slight increase in urinary porphyrins may be the result of the ability of PCB to induce 
hepatic haem-containing microsomal enzymes (which is indicated by the increased liver 
weight and centrilobular hypertrophy), rather than originating from a disturbance in the 
haem synthesis. A similar effect has also been described for 1,2,4-trichlorobenzene 
(Kociba et al, 1981). Thus, although (i) TCBQ was generated in PCB-treated rats in a 
mechanism comparable to TCBQ formation in HCB-treated rats (i.e., via oxidative 
dehalogenation of the primary metabolite PCP), and (ii) urinary TCHQ levels were even 
significantly higher in PCB high compared to HCB-treated rats, hepatic porphyria was 
only observed in HCB-treated rats. This provides an additional argument against a role 
for the oxidized analog of TCHQ, i.e., TCBQ, in HCB-induced porphyria. 
The present study does not rule out the involvement of an intermediate formed in the 
primary oxidation of HCB in the induction of porphyria, since the oxidation of PCB to 
PCP and of HCB to PCP occur via two qualitatively different pathways, resulting in a 
simple hydroxylation of the former and an oxidative dehalogenation of the latter. In fact, 
urinary excretion of PCP showed a good correlation with porphyria (Table 8.6). 
Recently, the cytochrome P450-mediated oxidation of hexahalobenzenes to 
pentahalophenols has been proposed to proceed by the formation of a reactive 
benzohaloquinone cation intermediate (Rietjens and Vervoort, 1992). Whether such an 
intermediate is actually formed upon oxidation of HCB to PCP and whether it has any 
relevance to HCB-induced porphyria, remains an interesting topic for future research. 
Several additional hypotheses have been put forward regarding the induction of 
porphyria by HCB (and related chemicals such as TCDD, polychlorinated -and 
polybrominated biphenyls), which favor the idea of inactivation of UROG-D activity by 
an indirect mechanism rather than by a direct, metabolite-enzyme interaction. For 
example, chemicals may induce specific cytochrome P450 isoenzymes (particularly 
enzymes of the P450IA family, Jacobs et al, 1989; Smith and De Matteis, 1990), 
resulting in an increased oxidation of uroporphyrinogen to uroporphyrin (De Matteis et 
al, 1988; Jacobs et al, 1989) and thereby contributing to porphyrin accumulation. In 
addition, the interaction of drugs with the microsomal monooxygenase system may also 
lead to an uncoupled electron transport, resulting in the formation of active oxygen 
species which can react with uroporphyrinogen or another susceptible target to produce 
the long-lived inhibitor of the uroporphyrinogen decarboxylase activity, which has been 
isolated from porphyric animals (Cantoni et al, 1984). The synergistic role of iron on 
chemical-induced porphyria, which has been demonstrated by a number of studies (Smith 
and Francis, 1983; Smith et al, 1986), could arise from the ferrous-iron supported 
radical reactions (e.g., with reduced forms of oxygen). Thus, inhibition of UROG-D may 
be regarded as a secondary effect, and not as the primary biochemical lesion. In spite of 
all the intense research in the past decades, pieces of the puzzle still need to fall in place 
before the mechanism of HCB-induced porphyria is fully elucidated. 
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Table 8.6 Relationship between excretion of urinary oxidative metabolites and porphyria. 
Treatment 
HCB low 
HCB high" 
HCB high+TAO 
Combined treatments'" 
Correlation coefficient between 
urinary porphyrin excretion at 13 weeks and 
cumulative excretion cumulative excretion 
over week 1 
PCP 
0.633 
-0.257 
(6) 
0.479 
( 8 )
 ... 0.773111 
(23) 
-13 of over week 1-6 of 
TCHQ PCP 
0.433 0.477 
0.600 0.9431" 
(6) (6) 
-0.192 0.503 
(8) (8) 
0.53611 0.815111 
(23) (23) 
TCHQ 
0.233 
0.771 
(6) 
-0.599 
(8) 
0.212 
(23) 
Treatment 
Correlation coefficient between 
liver porphyrin accumulation0 and 
cumulative excretion 
over week 1-13 of 
PCP TCHQ 
cumulative excretion 
over week 1-6 of 
PCP TCHQ 
HCB low 
HCB high" 
HCB high+TAO 
Combined treatments'" 
0.7671 
0.429 
(6) 
0.250 
(8) 
0.7081" 
(27) 
0.550 
0.257 
(6) 
0.200 
(8) 
0.58311 
(27) 
0.628 
0.543 
(6) 
0.350 
( 8 )
 . . . 0.712111 
(23) 
0.150 
0.600 
(6) 
0.033 
(8) 
0.281 
(23) 
Note. Urinary excretion of oxidative metabolites (PCP, TCHQ) and porphyrins were 
measured after 2, 4, 6, 8, 10, 12, and 13 weeks of treatment as described under Materials 
and Methods. Spearman's coefficient of rank correlation between these parameters were 
calculated for paired observations (n=9). If number of paired observations is less than 9 due 
to premature sacrifice of rats, the number of paired observations is expressed within 
brackets. * Data obtained from one prematurely killed rat, which nearly completed the 13-
week study (-)- at day 88), is included in the calculations. b 'Combined treatments' indicates 
that the correlation coefficient is calculated using paired observations of all HCB-exposed 
rats. ° Liver porphyrin accumulation at the end of treatment period; prematurely sacrificied 
rats were not included. ^ Statistically significant correlation between two parameters, p 
<0.05, 1 1 p <0.01, 111/><0.001. 
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Histopathological investigation revealed that HCB induced lesions in the adrenals, liver 
and kidneys. PCB induced identical but less severe effects in liver as HCB, whereas 
TAO induced liver effects not comparable to HCB and PCB. Furthermore, co-treatment 
of rats with TAO and either HCB or PCB did not diminish the effects of HCB or PCB 
alone, which would indicate that the parent compounds themselves or metabolites formed 
via a non-oxidative pathway (e.g., direct glutathione conjugation) were responsible for 
the observed histopathological changes. Alternatively, the formation of even small 
amounts of oxidative metabolites such as formed in rats co-treated with TAO, might be 
sufficient to elicit the observed effects. 
A remarkable outcome of the present study is the fact that exposure to either HCB or 
PCB results in a marked disturbance in thyroid hormone and retinoid homeostasis. A 
reduction in plasma thyroid hormone levels following exposure to HCB has been 
previously reported, although in those studies rats were treated with a much higher dose 
of HCB, and the decrease in plasma TT3 was equivocal (Rozman et al., 1986; Kleiman 
de Pisarev et al., 1989, 1990). The effects on retinoid homeostasis included both liver 
storage and plasma levels. The decrease in the liver retinoid storage by HCB or PCB 
indicates an increased mobilization of retinoids into the circulation, whereas the decline 
in both liver and plasma retinol in HCB high-treated rats suggests an enhanced 
elimination of retinoids from the organism (e.g., through increased glomerular filtration). 
The increase in plasma retinol observed in PCB high-treated rats can be explained by a 
more pronounced increase in the extent of mobilization from hepatic storage sites 
compared to the increase in the glomerular filtration processes. 
HCB and PCB share these effects on thyroid hormone and retinoid homeostasis with 
structurally related compounds like polychlorinated biphenyls, and a common mechanism 
is strongly indicated. Hydroxylated metabolites of polychlorinated biphenyls have been 
shown to interfere with plasma transport of thyroid hormones through displacement of 
thyroxine from its binding site on transthyretin (TTR), a major plasma transport protein 
for thyroxine in the rat (Brouwer, 1989). Recently, in vitro binding studies have shown 
that hydroxylated metabolites of HCB and PCB, i.e., PCP and TCHQ, also have a high 
affinity towards TTR (Van den Berg, 1990; Den Besten et al., 1991). In addition, in vivo 
studies reveal an inverse relationship between serum thyroid hormone levels and serum 
PCP concentrations after a single i.p. dose of PCP (Van Raaij, 1991). Thus, 
hydroxylated metabolites of HCB and PCB may be involved in the severely reduced 
plasma thyroid hormone levels, possibly through interference with thyroxine plasma 
transport as described above. The involvement of PCP and TCHQ in plasma thyroid 
hormone disturbance of the parent chlorinated benzenes is further supported in the 
present study by the observation that PCB is more extensively oxidized to PCP and 
TCHQ in the first week of treatment as compared to HCB. This correlates well with the 
observation that plasma thyroid hormone levels in PCB-treated rats are already 
maximally decreased within this first week of treatment. Unfortunately, no conclusions 
can be drawn from data obtained from rats which were co-treated with TAO, because 
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TAO itself is capable of causing a disturbance in thyroid hormone homeostasis (Perret et 
al., 1991). 
The disturbance in retinoid homeostasis may, at least in part, also be ascribed to the 
interference of the hydroxylated metabolites with TTR (Brouwer and Van den Berg, 
1986), since plasma retinol is transported bound to a complex of retinol-binding-protein 
(RBP) and TTR. Binding of hydroxylated metabolites of polychlorinated biphenyls to 
TTR has been shown to interfere with formation of the plasma transport RBP-TTR 
complex, probably through a conformational change in TTR (Brouwer et al., 1988b). An 
alternative way of interference of chlorinated aromatics with retinoid homeostasis is by a 
direct interaction with the hepatic storage and mobilization of retinol. 
Thus, polychlorinated compounds with a single aromatic ring have effects on thyroid 
hormone and retinoid status comparable to those observed after exposure to 
polychlorinated biphenyls, probably, at least in part, through a common mechanism 
involving their biotransformation to hydroxylated metabolites and the subsequent 
interaction with the plasma transport protein, TTR. An interesting topic for future studies 
is the relevance of the disturbance in thyroid hormone homeostasis and retinoid 
metabolism in the toxic effects observed for these compounds. 
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COMPARISON OF THE URINARY METABOLITE PROFILES 
OF HEXACHLOROBENZENE AND PENTACHLOROBENZENE 
IN THE RAT 
Abstract 
The urinary metabolite profile of hexachlorobenzene (HCB) and pentachlorobenzene 
(PCB) in the rat is compared after dietary exposure for 13 weeks. Both HCB and PCB 
are oxidized to pentachlorophenol (PCP) and tetrachlorohydroquinone (TCHQ), which 
were the only two mutual metabolites formed. Additional urinary metabolites of HCB are 
N-acetyl-.S-(pentachlorophenyl)-cysteine (PCP-NAC), quantitatively the most important 
product, and mercaptotetrachlorothioanisole (MTCTA), which was excreted as a 
glucuronide. PCB is more extensively metabolized to the major metabolites 2,3,4,5-
tetrachlorophenol (TCP), mercaptotetrachlorophenol (MTCP) and the glucuronide of 
pentachlorothiophenol (PCTP), and the minor metabolites methylthiotetrachlorophenol 
(MeTTCP), hydroxy tetrachlorophenyl sulphoxide (HTCPS), and to-(methylthio)-
trichlorophenol (teMeTTriCP). 
The biotransformation of HCB and PCB was modulated by selective inhibition of 
cytochrome P450IIIA1/2 in rats which received combined treatment of HCB or PCB with 
triacetyloleandomycin (TAO). Rats receiving this diet had a strongly diminished 
excretion of both PCP and TCHQ, as compared to rats fed HCB or PCB alone, 
indicating the involvement of P450IIIA1/2 in the oxidation of both compounds. However, 
the excretion of 2,3,4,5-TCP was not diminished by co-treatment of rats with PCB and 
TAO, indicating that (i) the oxidation of PCB to PCP and to 2,3,4,5-TCP does not 
proceed via a common intermediate, and (ii) oxidation of PCB to 2,3,4,5-TCP is not 
mediated by P450IIIA1/2. Co-treatment of rats with PCB and TAO had a differential 
effect on the excretion of sulfur-containing metabolites, resulting in a decrease in the 
excretion of PCTP glucuronide, whereas no change was observed in the excretion of 
MTCP, as compared to rats receiving PCB alone. The data presented in this study stress 
the importance of mechanistic in vitro studies, which should be directed at the interplay 
of P450-mediated oxidation and conjugation of the putative electrophilic metabolites with 
GSH, in order to delineate the pathways leading to the various metabolites. 
C. den Besten, M.M.H. Bennik, M. van Iersel, M.A.W. Peters, C. Teunis, P.J. van Bladeren, 
submitted 
Metabolism ofHCB and PCB in the rat 
Introduction 
The biotransformation pathways of the fungicide hexachlorobenzene (HCB)1, which 
is known for its porphyrinogenic action, has been extensively studied in many species 
including rat (Koss et al., 1976; 1978; Jansson and Bergman, 1978), rabbit and mouse 
(Renner and Nguyen, 1984). A range of sulfur-containing metabolites, non-sulfur 
phenolic metabolites and non-sulfur-non-oxygen-containing metabolites has been 
described (Koss et al, 1986; Renner, 1988). The formation of sulfur-containing 
derivatives proceeds via conjugation of HCB with glutathione, which is subsequently 
further processed into the corresponding mercapturic acid and other derivatives from that 
pathway (Renner et al, 1978). Conjugation with glutathione is also a major degradation 
route in the biotransformation of the fungicide pentachloronitrobenzene (PCNB), 
producing sulfur-containing metabolites similar to those described for HCB. For 
extensive reviews on the common biotransformation products of HCB and PCNB, the 
reader is referred to Renner and coworkers, (1981, 1984). 
Cytochrome P450-mediated oxidation of HCB results in the formation of 
pentachlorophenol (PCP) and tetrachlorohydroquinone (TCHQ) (Van Ommen et al., 
1986). The major isoenzyme involved in the hydroxylation of HCB has been indicated to 
be P450IIIA1/2 (Van Ommen et ai, 1989). Recent studies on the microsomal oxidation 
of chlorinated benzenes other than HCB revealed that pentachlorobenzene (PCB) is also 
converted to PCP and TCHQ (Den Besten et al, 1989). Again, cytochrome P450IIIA1/2 
was implicated to be the major P450 isoenzyme involved (Den Besten et al., 1991). 
Although these microsomal studies imply that PCB is degraded through 
biotransformation pathways identical to HCB, the extent to which they occur in vivo is 
not known. Therefore, the present study describes and compares the urinary metabolite 
profiles of HCB and PCB in rat. In order to assess the contribution of cytochrome 
P450IIIA isoenzymes to the in vivo biotransformation of HCB and PCB, urinary 
excretion profiles of rats treated with either HCB or PCB alone were compared to those 
of rats which received co-treatment with TAO, a compound which selectively inactivates 
P450IIIA1/2 by the formation of a stable metabolite-P450 complex (Pessayre et al., 
1981; Wrighton«a/., 1985). 
1
 Abbreviations: HCB, hexachlorobenzene; HTCPS, hydroxytetrachlorophenyl 
sulphoxide; MeTTCP, methylthiotetrachlorophenol; WsMeTTriCP, te(methylthio)-
trichlorophenol; MTCP, mercaptotetrachlorophenol; MTCTA, mercaptotetrachloro-
thioanisole; PCB, pentachlorobenzene; PCP, pentachlorophenol; PCP-NAC, N-acety\-S-
(pentachlorophenyl)cysteine; PCTP, pentachlorothiophenol; TAO, triacetyloleandomycin; 
TCHQ, tetrachlorohydroquinone; TCP, tetrachlorophenol. 
168 
Chapter 9 
Materials and Methods 
Chemicals 
Pentachlorobenzene (>99% purity) was purchased from Dr. Ehrenstorfer GmbH 
(Augsburg, Germany). Hexachlorobenzene (gold label, > 99% purity) was purchased 
from BDH (United Kingdom). Triacetyloleandomycin was from Pfizer (Orsay, France). 
Tetrachlorohydroquinone was from ICN Biomedicals (Zoetermeer, The Netherlands), 
2,3,4,5-tetrachlorophenol was from Fluka AG (Buchs, Schwitzerland), and pentachloro-
thiophenol was from ICN (Costa Mesa, CA, USA). For use as reference standards 
pentachlorothioanisole, 2,3,5,6-tetrachlorothioanisole, pentachlorophenylsulfoxide and -
sulphone were synthesized and purified by recrystallization as described by Koss et al. 
(1979) (cf. Debets et al, 1981). 
Animals and treatments 
As part of a 13-week feeding study, 24 hr urine was collected weekly from female 
Wistar rats (10 weeks old at the start of the experiment) fed diets containing 0.015 % 
HCB (HCB low), 0.03 % HCB (HCB high), 0.03 % PCB (PCB low) or 0.13% PCB 
(PCB high), respectively (nine rats per diet). Additional groups received co-treatment 
with TAO (0.3 %), i.e., 0.03 % HCB+TAO and 0.13 % PCB+TAO, respectively. All 
diets contained 4 % corn oil. One group of control animals (nine rats) received a diet 
which contained 4 % corn oil. The animals had free access to food and (tap) water. Rats 
were housed in wired-bottom cages (3 rats per cage) in a temperature- and humidity-
controlled room under a 12 hr light: dark cycle, and were transferred into individual 
metabolism cages every 7th day for collection of urine, which was stored at -20°C until 
analysis. A full report on the design and conduct of the study will be given elsewhere 
(Den Besten et al., in preparation). 
Extraction of urinary metabolites 
Samples (3 ml) of urine of individual rats were treated with ascorbic acid (1 mM 
final concentration) and 6 N HCl (0.6 N final concentration). The samples were extracted 
with diethyl ether (2x4 ml). After evaporation of the ether under a stream of nitrogen, 
the residues were dissolved in 300 ^1 of methanol and subjected to HPLC analysis (see 
below). 
Separation of urinary metabolites by HPLC 
Urine extracts were analyzed by HPLC (Perkin Elmer Series 4, Woerden, The 
Netherlands) using a Nucleosil C18 (150x4.6 mm I.D.) column. Flow rate was 1 ml/min 
and the eluent was monitored at 300 nm. Extracts were eluted using a mobile phase of 
methanol and water, both phases containing 0.5 % acetic acid. The following gradient 
was applied: 4 min stationary at 50 % methanol/ 50 % H20, followed by a linear 
gradient to 80 % methanol/ 20 % H20 in 28 min and 8 min stationary at 80 % methanol, 
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followed by a linear increase to 100 % methanol in 8 min and concluded by 5 min 
stationary at 100 % methanol. Peaks were collected separately. The mobile phase was 
evaporated under a stream of nitrogen, or when the peak eluted in a more polar region, 
water (2 ml) was added prior to extraction with diethyl ether. The residues were 
subjected to combined gas chromatography-mass spectrometry (GC-MS). Some 
metabolites were subjected to high resolution and/or field desorption mass spectrometry 
(FD-MS). 
GC-MS 
GC-MS was carried out with a Hewlett Packard 5970B instrument. GC separation 
was achieved on a DB17 column (film thickness 25 fim; 30 m long, 0.25 mm I.D.). The 
oven temperature was programmed at 7°C/min from 100°C to 280°C. The injector 
temperature was maintained at 200°C. Helium gas was used as the carrier gas at a flow 
rate of 20 ml/min. For high-resolution mass spectrometry, a MS902, equipped with a 
VG-ZAB console was used. 
Determination of UV absorption spectra 
In order to determine whether metabolites contained substituents sensitive to changes 
in pH, UV absorption spectra of the isolated metabolites were determined under acid and 
alkaline conditions during HPLC analysis using a Waters 991 photodiode array detector. 
Thus, isolated metabolites were run using the mobile phase (containing 0.5 % acetic 
acid), applying a gradient program as described below for 'quantification of metabolites'. 
In addition, isolated metabolites were also run under alkaline conditions using a mobile 
phase containing methanol and a Tris-phosphate buffer, pH 8.1, and the following 
gradient program: 5 min stationary at 20 % methanol, followed by a linear increase to 
100 % methanol in 20 min, and concluded with 10 min stationary at 100 % methanol. 
Quantification of metabolite, excretion 
For quantification of metabolite excretion by HPLC, the following gradient elution 
profile was used (0.5 % acetic acid in the mobile phase): 2 min stationary at 50 % 
methanol/ 50 % H20, followed by a linear increase to 90 % methanol/ 10 % H20 in 17 
min followed by 5 min stationary at 90 % methanol and concluded by 10 min stationary 
at 95 % methanol. Finally, the column was flushed with 100 % methanol for 5 min. 
In urine obtained after 1, 4, 6, 8, 10, 12 and 13 weeks of treatment, metabolite 
excretion of individual animals (nine rats per diet) was quantified by comparing peak 
areas to those obtained by a calibration curve of reference standards. For the metabolites 
TCHQ, 2,3,4,5-TCP and PCP, authentic reference standards were used. The remaining 
metabolites were projected on the calibration curve for 2,3,4,5-TCP in the case of 
structures containing 4 chlorine substituents, and on the calibration curve for PCP in the 
case of structures containing 5 chlorine substituents. Thus, amounts were calculated as 
nmol-equivalents of TCP/ 24 hr, and n mol-equivalents of PCP/ 24 hr, respectively. In 
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urine extracts from PCB-treated rats, the minor metabolites P6 and P7 (see under 
Results) were not quantified. Recovery was determined by the addition of [14C]-PCP 
(10,000 dpm) to urine samples as an internal standard prior to extraction. This amount of 
[I4C]-PCP did not contribute to the UV absorption of PCP at 300 nm during HPLC 
analysis. Recovery was generally higher than 70 %. 
It should be noted that faecal excretion, which largely contains the unchanged 
chemical, is not taken into account. Previous studies on the biotransformation of HCB 
(Koss et al., 1976) and a preliminary report on the biotransformation of PCB (Koss and 
Koransky, 1978) indicate that urinary metabolite excretion is a good representative of the 
total biotransformation. However, total excretion of some metabolites may be 
underestimated to some extent. 
Hydrolytic treatment of urine 
In order to identify metabolites which were excreted in the form of conjugates with 
glucuronic acid or sulphate, both complete urine samples and individual metabolites, 
which were isolated, collected as described above and concentrated in 30 n\ of methanol, 
were subjected to enzymatic hydrolysis with ß-glucuronidase (from E. coli K12, 
Boehringer, Mannheim, Germany) and arylsulphatase/ß-glucuronidase (from Helix 
Promatia, Boehringer, Mannheim, Germany) as previously described (Vervoort et al, 
1990). The aqueous incubation mixtures were subsequently extracted under acidic 
conditions with diethyl ether, and prepared for HPLC analysis as described above. 
Chemical structures of the aglycones were confirmed by GC-MS and/or FD-MS. 
In addition, urine samples were hydrolyzed under alkaline conditions as described by 
Rizzardini and Smith (1982) and subsequently processed as described above for 
enzymatic hydrolysis. 
Results 
Urinary metabolite profile of HCB and PCB 
Figure 9.1 A represents a typical HPLC chromatogram of extracts of urine obtained 
from rats fed HCB in their diet, showing 2 major metabolites (H3, H4) and 2 minor 
metabolites (Hl, H2). Figure 9.IB represents a typical HPLC chromatogram of extracts 
of urine obtained from rats fed PCB in their diet, showing 5 major metabolites (P3, P4, 
P5, P8, P9) and 4 minor metabolites (PI, P2, P6, P7). None of the peaks were observed 
in HPLC chromatograms of urine extracts from control rats (not shown). All 4 HCB 
metabolites and all 9 PCB metabolites were collected separately and prepared for analysis 
by combined GC-MS. In Table 9.1, chromatographic characteristics and mass spectral 
data of the individual peaks are presented. 
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Figure 9.1 Typical HPLC chromatograms of urine extracts obtained from rats fed HCB (A) 
and PCB (B). Metabolites of HCB are denoted HI, H2, H3, and H4. Metabolites of PCB 
are denoted PI, P2, P3, P4, P5, P6, P7, P8 and P9. Full description of extraction procedure 
and HPLC conditions is given under Materials and Methods. 
Identification of metabolites 
Comparison of the two metabolite profiles revealed that urine from HCB and PCB-
treated rats contained two common metabolites, one (HI and PI) with k' 6.9 and the 
other one (H4 and P8) with k' 21.4, with identical chromatographic behaviour to the 
authentic reference compounds TCHQ and PCP, respectively. The mass spectra of these 
compounds, whether authentic or metabolically formed, showed molecular ions at m/z 
246 (TCHQ) and m/z 264 (PCP), and chlorine clusters at the molecular ions indicating 4 
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and 5 chlorine atoms per molecule, respectively. The remaining 7 peaks in urine extracts 
from PCB-treated rats were not observed in urine extracts from HCB-treated rats. 
According to the typical chlorine clusters at the molecular ion, metabolite H3 
contained 5 chlorine atoms, H2 and P2, P3, P4, P5, P6 and P9 all contained 4 chlorine 
atoms, whereas metabolite P7 contained only 3 chlorine atoms. 
The mass spectra of H2, H3 and P3, P4, P6, P7, P9 contained a signal at m/z 45, 
which is characteristic of organic thiocompounds (CHS-ion), and a signal at m/z 79, 
which could possibly indicate the presence of a S02CH3 substituent on the aromatic ring 
(i.e., a methyl sulphone metabolite). However, the mass spectra of authentic chlorinated 
sulphones show a typical fragmentation pattern with a base peak at M+-63 (SOCH3) 
(Koss et al., 1979; Mayring et al., 1984; own observation from reference compounds), 
which was not observed in any of the metabolites (Table 9.1). Furthermore, the 
observation of the first mass fragment at M+-15 in the mass fragmentation pattern of 
metabolite H2, P3, P6, P7 and P9 (Table 9.1) indicates the presence of a methyl group. 
Metabolite P4 had a fragmentation pattern that showed characteristics of both a 
phenolic compound (M+-Cl+CO, also observed with authentic chlorophenols) and a 
sulphydryl compound (large intensity at M+-C1, and fragment at m/z 79, also observed 
with authentic (poly)chlorothiophenols), compatible with a mercapto-tetrachlorophenol 
structure (MTCP). The theoretical mass of this compound is 261.8580, whereas with the 
aid of high resolution MS an accurate molecular weight of 261.8584 was assessed. 
Furthermore, in agreement with a MTCP-structure is the fluctuation in the UV 
absorption spectrum, which was observed when using a mobile phase in the HPLC-
analysis with a low pH (Xmax 224 nm, 312 nm) or a high pH (Xmax 224 nm, 252 nm, 
340 nm). 
Chromatographic behaviour of metabolite P5 was identical to the reference 
compounds 2,3,4,5-/2,3,5,6-TCP. The mass spectrum of P5 was indicative for the 
2,3,4,5-isomer of TCP. This substituent pattern was further confirmed by reversed-phase 
HPLC analysis, in which separation of all three TCP-isomers was achieved using a 
potassium phosphate/ methanol gradient as previously described (Den Besten et al., 
1989; not shown). 
Metabolite P6 had a base peak at M+-15, which is characteristic for a sulphoxide 
substituent at the ring (Koss, 1979; own observation with reference compounds). The 
fluctuation in the UV absorption spectrum under acid conditions (Xmax 228 nm, 300 nm) 
and alkaline conditions (Xmax 213 nm, 250 nm, 319 nm) is compatible with an additional 
hydroxyl substituent. Based on these data, it was concluded that P6 was the sulphoxide 
derivative of MTCP (P4). 
Finally, metabolite P7 and P9 were analyzed with the aid of high-resolution MS in 
order to obtain further information on their molecular composition. The molecular weight 
of metabolite P7 amounted to 287.8997, corresponding to the molecular formula 
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C8H7OS2Cl3 (theoretical mass 287.9004). The accurate molecular weight of metabolite P9 
was 275.8736, corresponding to the molecular formula C7H4OSCI,, (theoretical mass 
275.8737). Taking these data together with the fluctuation observed in the UV absorption 
spectra under acid and alkaline conditions, P7 was characterized as tó(methylthio)-
trichlorophenol (teMeTTriCP; Xmax acid conditions 224 nm, 312 nm, Xmax alkaline 
conditions 228 nm, 351 nm) and P9 was characterized as methylthiotetrachlorophenol 
(MeTTCP; Xmax acid conditions 224 nm, 312 nm; Xmax alkaline conditions 221 nm, 
252 nm, 339 nm). 
Table 9.1 Chromatographic characteristics and electron impact mass spectral data of urinary 
metabolites from HCB and PCB. A full description of applied HPLC and GC-MS conditions 
is presented under Materials and Methods. a Percentage between brackets indicates intensity 
of peaks in mass spectrum. 
Parent 
compound 
peak 
HCB 
HI 
H2 
H3 
H4 
HPLC 
k' 
6.9 
14.0 
18.8 
21.4 
GC-
retention 
time 
(min) 
16.90 
22.01 
18.00 
16.16 
Mass spectral characteristics8 
M + 
246 
(100 %) 
292 
(100 %) 
280 
(100 %) 
264 
(100 %) 
Fragmentation 
pattern 
M+-36 (14 %) 
M+-64 (19 %) 
M+-71 (20 %) 
M+-99 (32 %) 
M+-15 (64 %) 
M+-51 (28 %) 
M+-35 (94 %) 
M+-70 (25 %) 
M+-36 (12 %) 
M+-64 (10 %) 
M+-99 (19 %) 
Calculated 
chemical composition 
of lost fragment 
HCl 
HCl + CO 
HCl + Cl 
HCl + CO+Cl 
CH, 
CH3+HC1 
Cl 
Cl+Cl 
HCl 
HC1+CO 
HCl + CO+Cl 
continued -
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Table 9.1 - continued 
Parent 
compound 
peak 
PCB 
PI 
P2 
P3 
P4 
P5 
P6 
P7 
P8 
P9 
HPLC 
k' 
6.9 
10.4 
13.2 
15.4 
18.3 
19.1 
20.5 
21.4 
22.1 
GC-
retention 
time 
(min) 
16.98 
12.48 
19.81 
19.02 
12.28 
22.19 
23.78 
16.16 
19.76 
Mass spectral characteristics 
Calculated 
M+ Fragmentation chemical composition 
pattern of lost fragment 
246 
(100 %) 
230 
(100 %) 
276 
(100 %) 
262 
(100 %) 
230 
(100 %) 
292 
(50 %) 
288 
(100 %) 
264 
(100 %) 
276 
(100 %) 
M+-36 (12 % 
M+-64 (18 % 
M+-71 (16 % 
M+-99 (23 % 
M+-36 (22 % 
M+-64 (18 % 
M+-99 (37 % 
M+-15 (49 % 
M+-33 (12 %; 
M+-43 (39 %' 
M+-35 (77 % 
M+-63 (24 % 
M+-99 (26 %) 
M+-36 (20 %; 
M+-64 (20 %} 
M+-99 (26 %) 
M+-15 (100 7 
M+-49 (18 %} 
M+-91 (32 %) 
M+-15 (54 %) 
M+-43 (30 %) 
M+-64 (12 %) 
M+-36 (12 %) 
M+-64 (10 %) 
M+-99 (19 %) 
M+-15 (49 %) 
M+-33 (14 %) 
M+-43 (28 %) 
) HCl 
) HCl+CO 
) HCl+Cl 
) HCl+CO+Cl 
HCl 
HCl + CO 
HCl + CO+Cl 
CH3 
SH 
CH3+CO 
Cl 
Cl + CO 
Cl + COH + Cl 
HCl 
HCl+CO 
HCl+CO+Cl 
») CH3 
HSO 
CH3+SO+CO 
CH3 
CH3+CO 
CO+HCl 
HCl 
HCl + CO 
HCl+CO+Cl 
CH3 
SH 
CH3+CO 
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Identification of conjugated metabolites 
GC-retention times and the mass spectral data of metabolite P2 and P3 were identical 
to those of metabolite P5 (identified as 2,3,4,5-TCP) and P9 (identified as MeTTCP). 
Their nature, however, was far more polar on reversed phase HPLC (see Figure 9. IB), 
indicating metabolite P2 and P3 to be conjugates of 2,3,4,5-TCP and MeTTCP. 
Similarly, the nature of the HCB-metabolites, H2 and H3 was far more polar on 
reversed-phase HPLC than was to be expected from their structures revealed by GC/MS 
(cf. Figure 9.1 A and Table 9.1). 
Treatment of urine samples from HCB- or PCB-treated rats with ß-glucuronidase 
resulted in the disappearance of metabolite H2, P2 and P3 upon HPLC-analysis, whereas 
all other peaks, including H3, were still observed (not shown). Treatment of urine 
samples with a mixture of arylsulfatase/ß-glucuronidase did not result in the 
disappearance of additional peaks. The individual metabolites were hydrolyzed with ß-
glucuronidase, and the extracts subjected to HPLC and GC/MS. The structures of the 
respective aglycons of H2 and P2 were thus confirmed to be mercapto-
tetrachlorothioanisole (MTCTA) and 2,3,4,5-TCP, respectively. Additional confirmation 
of the aglycone structure of H2 was obtained by high-resolution MS revealing an 
accurate mass of 291.8594 (theoretical mass of MTCTA: 291.8508). Attempts to identify 
the complete glucuronide structure by FD-MS were however not successful, due to the 
fact that the signals generated were too weak. 
HPLC-analysis of the extract from the incubation of P3 with ß-glucuronidase revealed 
the appearance of 2 peaks, one major metabolite (P3A) with k' 25.1 (=k' pentachloro-
thiophenol, PCTP), and one minor metabolite (P3B) with k' 22.1 (= k' MeTTCP, P9). 
The chemical structures of P3A and P3B were confirmed by GC/MS. 
Metabolite H3 was not sensitive to treatment with ß-glucuronidase or arylsulfatase, but 
was not observed anymore upon HPLC analysis after alkaline hydrolysis of urine. Based 
on the facts that (i) the chemical structure of H3 derived from GC/MS analysis was 
identical to authentic PCTP, (ii) H3 was sensitive to alkaline hydrolysis but was shown 
not to be a glucuronide or a sulfate, and (iii) the UV absorption spectrum (Xmax 224 nm, 
294 nm) was similar to that of N-acetyl-5-(pentachlorophenyl)-cysteine (PCP-NAC) 
described by Renner (1978), H3 was characterized as PCP-NAC. This was confirmed by 
performing direct inlet MS, which showed a weak signal indicating a cluster of 5 
chlorine atoms at M+ 409, and a strong signal at M+ 349 (M+ - C2H5NO, accurate mass 
of 349.8291; theoretical mass of C9H302SC15 is 349.8296). It should be noted that in 
HPLC runs H3 sometimes contained an additional minor peak. However, only one peak 
was detected when performing HPLC analysis under alkaline conditions (not shown). 
Since GC/MS and MS did not reveal an additional metabolite, we did not pursue any 
further identification of the minor peak. 
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Excretion of HCB-metabolites in a 13-week feeding study 
Urinary excretion profiles of the 4 metabolites of HCB were quantitatively determined 
in the 13-week feeding study in rats treated with 0.015% HCB (low dose) and 0.03 % 
HCB (high dose) and are presented in Figure 9.2A, B. All 4 metabolites were detected at 
all time points, except for MTCTA (H2), which was not yet detected in urine after 1 
week of treatment. 
With the exception of week 13 in the HCB-high group, PCP-NAC (H3) was 
quantitatively the most important metabolite of HCB in both dose groups during the 
entire treatment period, ranging from approximately 87 % (HCB low) to 92 % (HCB 
high) of total metabolites after 1 week of treatment to 63 % (HCB low) and 42 % (HCB 
high) after 13 weeks of treatment. Interestingly, in both the low and the high dose group, 
the urinary excretion of PCP-NAC reached a plateau after 4 to 6 weeks of treatment, 
followed by a further increase until 12 weeks of treatment, after which excretion of PCP-
NAC leveled off (low dose) or even decreased (high dose). 
With respect to the oxidative biotransformation of HCB, it is noteworthy that the 
urinary excretion of PCP is slightly more important in rats treated with the HCB high 
dose compared to rats treated with the HCB low dose, ranging from approximately 2 % 
(HCB low) and 4 % (HCB high) of total metabolites after 1 week to 24 % (HCB low) 
and 50 % (HCB high) after 13 weeks of treatment. 
Excretion of PCB metabolites in a 13-week feeding study 
Urinary excretion profiles of metabolites by rats fed a low dose of PCB (0.03 %) or a 
high dose of PCB (0.13 %) for 13 weeks are quantitatively presented in Figure 9.3A,B. 
These data show that the relative importance of several metabolites appears to be dose-
dependent. Formation of 2,3,4,5-TCP (both in free form, P5, and as a glucuronide 
conjugate, P2) was quantitatively the most important route for biotransformation of PCB 
in rats treated with a low dose (0.03%), amounting to 44 % of total metabolites after 1 
week to 35 % of total metabolites after 13 weeks. In PCB-high treated rats, formation of 
glucuronides (P3A, P3B) and MTCP (P4) was relatively more important, and excretion 
of 2,3,4,5-TCP amounted to approximately 12-15 % of total metabolites. Formation of 
PCP (expressed as percentage of total metabolites) was comparable in both dose groups. 
Consequently, during the whole treatment period the ratio of formation of total 2,3,4,5-
TCP-to-PCP was significantly higher in PCB-low compared to PCB-high treated rats 
(3.92+0.34 vs 1.38+0.07, PCB low vs PCB high, respectively; mean + SE over week 1, 
4, 6, 8, 10, 12, 13). 
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Figure 9.2. Urinary excretion of metabolites by rats fed 0.015 % HCB (A), 0.03 % HCB 
(B) and 0.03 % HCB + TAO (C) for 13 weeks. Metabolites were analyzed and quantified 
as described under Materials and Methods, and expressed as nmol equivalents PCP or TCP/ 
24 hr urine. Each data point represents mean of nine rats. In figure B, data at 10, 12 and 13 
weeks represent mean of respectively 8, 7, and 6 rats, due to premature kills. In Figure 
9.2C, data at 13 weeks represent mean of 8 rats, due to premature death of 1 rat. Symbols 
indicate the following: ( v ), HI; ( A ), H2; ( • ), H3; ( D ), H4. * denotes significant 
difference from levels observed in rats which received 0.03 % HCB alone, p <0.05; 
/7<0.01; '"p <0.001. 
Effect of TAO on the biotransformation of HCB and PCB 
Co-treatment of rats with TAO, a selective inhibitor of P450IIIA1/2, and HCB or 
PCB did not result in the formation of metabolites qualitatively different from treatment 
with HCB or PCB alone. Urinary metabolite excretion in rats which received TAO in 
their diet in addition to HCB high or PCB high is presented in Figure 9.2C and 9.3C, 
respectively. TAO significantly inhibited the formation of TCHQ (Hl), MTCTA-
glucuronide (H2), and PCP (H4) in HCB-high treated rats. The urinary excretion of 
PCP-NAC (H3), however, was influenced to a much lower extent. 
Co-treatment of rats with PCB high and TAO resulted in a significantly decreased 
excretion of TCHQ (PI), PCP (P8), and MeTTCP (P9). In addition, excretion of the 
glucuronides P3A,B was significantly lower in rats which received combined treatment 
with TAO. Interestingly, the urinary excretion of 2,3,4,5-TCP (P5) and MTCP (P4) was 
not affected by co-treatment with TAO. 
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Figure 9.3. Urinary excretion of metabolites by rats fed 0.03 % PCB (A), 0.13 % PCB (B) 
and 0.13 % PCB + TAO (C) for 13 weeks. Metabolites were analyzed and quantified as 
described under Materials and Methods, and expressed as nmol equivalents PCP or TCP/ 24 
hr urine. Each data point represents mean of nine rats. Symbols indicate the following: 
( v ), PI; ( A ), P2+P5; ( O ), P3; ( • ), P4; ( D ), P8; ( • ), P9. * denotes significant 
difference from levels observed in rats which received 0.13 % PCB alone, p < 0.05; 
/><0.01; "*/>< 0.001. 
Discussion 
Studies on the microsomal oxidation of HCB (Van Ommen et al., 1986) and PCB 
(Den Besten et al, 1989) revealed that both compounds are oxidized to PCP and 
TCHQ. The urinary metabolite profiles of HCB and PCB in vivo as found in the present 
study are summarized in Figure 9.4. It appears that the results obtained from microsomal 
incubations can be extrapolated to the in vivo situation, since both PCP and TCHQ are 
detected in urine derived from rats treated with HCB or PCB. However, no other mutual 
metabolites are formed. 
In rat liver microsomal incubations with PCB, oxidation at the unsubstituted position, 
resulting in the formation of PCP, and oxidation at a chlorine-substituted position, 
resulting in the formation of TCP occurred in a ratio of roughly 3:1 in favour of PCP 
formation (Den Besten et al., 1989). Surprisingly, the present study shows that in vivo 
formation of the oxidatively dechlorinated product (i.e., 2,3,4,5-TCP, P5) is favoured 
over oxidation at the unsubstituted position (i.e., PCP, P8), especially in rats treated with 
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the low dose. Furthermore, in a microsomal incubation all three isomers of tetrachloro-
phenol were detected (Den Besten et al, 1989), whereas in the present study only the 
2,3,4,5-TCP isomer was detected in urine. 
Selective blockage of cytochrome P450IIIA1/2 by the macrolide TAO was used as a 
tool to delineate the contribution of P450IIIA to the biotransformation of HCB and PCB. 
The inhibition of oxidative metabolism of HCB by TAO is in agreement with a previous 
study (Van Ommen et al, 1989). In the present study, the inhibitory action of TAO is 
extended to the oxidative biotransformation of PCB, showing a reduced formation of 
PCP (P8) and TCHQ (PI). 
An intriguing observation in the present study is the fact that co-administration of 
TAO and PCB strongly affected the excretion of PCP but not of the major metabolite 
2,3,4,5-TCP. This would indicate that (i) PCP and 2,3,4,5-TCP are not formed from a 
common intermediate (such as the putative 2,3,4,5,6-pentachloro-l,2-epoxide), and (ii) 
2,3,4,5-TCP is formed by a reaction not involving cytochrome P450IIIA1/2. In a recent 
study, a novel pathway has been proposed in the oxidative dehalogenation of 
hexahalogenated benzenes involving an intermediate benzohaloquinone cation (Rietjens 
and Vervoort, 1992). It could be hypothesized that PCB is oxidized at the unsubstituted 
position via a 'classical' hydroxylation pathway into PCP by the action of P450IIIA. This 
reaction would involve an intermediate pentachlorobenzene-l,2-epoxide or, based on 
more recent insights, a tetrahedral iron-oxene radical a-complex (Guengerich and 
MacDonald, 1990). On the other hand, oxidation of PCB at the chlorine substituted 
position resulting in the formation of 2,3,4,5-TCP, presumably catalyzed by a P450 
isoenzyme different from P450IIIA1/2, might involve a 2,3,5-trichlorobenzochloro-
quinone intermediate. This putative intermediate can readily be reduced to 2,3,4,5-TCP. 
The present study clearly emphasizes the need for future studies on the mechanism of 
oxidative dehalogenation of (lower) halogenated benzenes, in order to characterize (i) the 
different isoenzymes of P450 involved in the different oxidation pathways, and (ii) the 
nature of the respective intermediates formed. 
In addition to oxidized metabolites, both HCB and PCB are converted into sulfur-
containing derivatives, but the chemical nature of these metabolites derived from either 
HCB or PCB is remarkably different. In urine from HCB-treated rats, PCP-NAC (H3) 
was the major metabolite, and this is in agreement with previous studies in which PCP-
NAC was detected as PCTP by GC after alkaline hydrolysis of urine (Koss et al., 1979; 
Rizzardini and Smith, 1982; Jansson and Bergmann, 1978; Renner and Nguyen, 1984). 
The mercapturate is most likely formed via a mechanism involving a nucleophilic 
displacement of chlorine by glutathione. Interestingly, mercapturic acids are not observed 
in urine from PCB-treated rats, suggesting that a direct conjugation of polychlorinated 
benzenes with glutathione only takes place when all ring carbons contain halogens. This 
view is further supported by the previous observation that in the presence of rat liver 
cytosol hexafluorobenzene and pentafluorochlorobenzene were readily conjugated with 
glutathione (Rietjens and Vervoort, 1992), whereas pentafluorobenzene was not (Rietjens, 
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personal communication). It should be noted that PCTP was excreted as an S-glucuronide 
by PCB-treated rats. However, its formation can not readily be explained via the 
formation of PCP-NAC, since the mercapturate was not observed in urine-extracts from 
PCB-treated rats. 
In addition to PCP-NAC, HCB was converted into a disubstituted sulfur metabolite, 
i.e., MTCTA (H2). Formation of HCB metabolites with two sulfur-containing 
substituents is in agreement with previous studies (Jansson and Bergman, 1978; Renner 
and Nguyen, 1984). Interestingly, the present study indicates that MTCTA is excreted 
into urine solely as an S-glucuronide. 
PCB is more extensively metabolized to metabolites containing both sulfur- and 
oxygen substituents, such as the major metabolite MTCP (P4), and the minor metabolites 
hydroxytetrachlorophenyl sulphoxide (HTCPS, P6), ôwMeTTriCP (P7) and MeTTCP 
I OH 
PCP-NAC 
H3 
PCP 
H4 P8 
PCB 
y0 
2,3.4,5-TCP 
P5 (X = H) 
P2 (X = glucoronide) 
SCH3 
- Ù 
C l / ^ S - X 
MTCTA 
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C l / ^ 
PCTP -._ 
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Figure 9.4. Proposed pathways for the formation of the different urinary metabolites from 
HCB and PCB. In the lower part below the line, the metabolic routes are more speculative. 
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(P9). The formation of these metabolites is generally believed to involve conjugation of 
glutathione with an intermediate arene oxide. In fact, the absence of mercapturic acids 
from the urinary metabolite profile of PCB may originate from the chemical structure of 
the putative primary intermediate pentachlorobenzene-l,2-oxide, since attack by 
glutathione, most likely to take place at the least hindered CI carbon, will be readily 
followed by loss of hydrochloric acid resulting in a glutathione-5-yl-tetrachlorophenol 
structure, which may subsequently be processed in several steps to mercaptotetra-
chlorophenol, a major metabolite of PCB in the rat. Isomeric mercaptotrichlorophenols 
have been described as metabolites of 1,2,3,5-tetrachlorobenzene in the rat (Chu et ah, 
1984). Furthermore, the biliary excretion of monochlorohydroxy-sulfur derivatives has 
recently been reported for 1,3-DICB (Kimura et al, 1992). Thus, the formation of 
mercaptothiophenol derivatives from polychlorinated benzenes is indeed linked to the loss 
of a halogen substituent from the molecule. 
However, based on comparison of urinary metabolite profiles of rats treated with PCB 
with or without co-treatment with TAO, questions may be raised with respect to the 
actual precursor leading to the formation of MTCP (P4). Excretion of MTCP, which was 
not affected by co-treatment with TAO, is correlated with the excretion of 2,3,4,5-TCP 
(P5), and not with the excretion of PCP. This would imply that MTCP and 2,3,4,5-TCP 
are formed via a (common) pathway not involving the action of P450IIIA1/2, whereas 
PCP is formed via a different pathway, catalyzed by cytochrome P450IIIA1/2. 
Altogether, these data stress the importance that, in order to achieve a full understanding 
of the metabolic fate of halogenated benzenes, mechanistic studies into the oxidative 
pathways should be extended to and/or combined with studies on the interplay between 
the P450-mediated oxidation and conjugation with glutathione. 
The combined use of HPLC and GC/MS made it possible to establish the extent of 
excretion of conjugated metabolites. The use of GC/MS alone revealed only the aglycone 
structures, apparently due to the fact that the conjugates were easily hydrolyzed. The 
major route of conjugation appeared to be through glucuronidation of either a hydroxyl 
group, e.g., as in P2, or of a sulfhydryl group, e.g., as in H2 and P3. The lack of 
formation of sulphate conjugates from either HCB or PCB fits with the known inhibitory 
action of PCP on sulfotransferase activity (Meerman et al., 1983). 
An interesting observation is that 2,3,4,5-TCP is excreted both in its free form (P5) 
and as a glucuronide conjugate (P2), whereas PCP is detected in urine of HCB and PCB-
treated rats exclusively in its free form. This is in agreement with a previous study on 
the metabolic fate of PCP, in which only 9-16% of an oral dose of PCP was excreted in 
the form of conjugates into urine (Ahlborg et al, 1978). These data may indicate that 
PCP does not possess good substrate characteristics for glucuronidation. Furthermore, 
PCP-glucuronide has been described to be hydrolyzed under weakly acidic conditions 
(Lilienblum, 1985). Thus, part of the PCP detected in its free form in urine might 
originate from its glucuronide conjugate. 
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SUMMARY OF IN VIVO STUDIES 
In Part II of this thesis, the results on the in vivo studies are described, in which the 
toxicity of a range of (poly) chlorinated benzenes is assessed to target organs like the 
liver and the kidneys. Moreover, an attempt is made to correlate adverse effects with the 
nature of the metabolites formed. 
In chapter 7, a range of chlorinated benzenes was compared with respect to their 
ability to induce target organ toxicity after a single i.p. administration in the male rat. 
Toxic effects on the liver consisted of an increased liver-to-body weight ratio after 72 hr, 
and, in the case of the higher chlorinated benzenes, also after 216 hr. A varying degree 
of centrilobular hypertrophy and hepatocellular degeneration was observed in most of the 
treatment groups. 1,2-Dichlorobenzene and 1,2,4-trichlorobenzene produced the most 
severe hepatotoxic effects (as shown by a significant rise in plasma ALT levels and clear 
degenerative changes), whereas monochlorobenzene was also considerably hepatotoxic. 
In the present study, no hepatotoxic effects were observed for 1,4-dichlorobenzene and 
1,2,4,5-tetrachlorobenzene, whereas pentachlorobenzene induced only slight 
histopathological liver changes. No obvious degenerative effects on the kidneys were 
observed in the dose range studied. However, formation of protein droplets in the tubular 
epithelial cells was shown to be a general phenomenon for polychlorinated benzenes, and 
was more pronounced after exposure to the higher chlorinated benzenes. 
Interestingly, polychlorinated benzenes were shown to interfere with thyroid 
hormone homeostasis as demonstrated by a severe reduction in plasma thyroxine levels. 
They share this effect with the structurally related polychlorinated biphenyls (Brouwer, 
1989). The most severe disturbances in thyroid hormone homeostasis were observed for 
the higher chlorinated congeners. Evidence is presented for a role of the phenolic 
metabolites in the observed decrease of plasma thyroxine, through a selective interaction 
with a major plasma transport protein for thyroxine, i.e., transthyretine (TTR). 
In chapter 8 and chapter 9, results of a 13-week feeding study with hexachloro-
benzene (HCB) and pentachlorobenzene (PCB) in female rats are presented. We were 
interested in a comparison of these two congeners with respect to their toxicity and 
biotransformation, since in vitro studies had shown that both HCB and PCB are oxidized 
to pentachlorophenol and the reactive tetrachlorobenzoquinone (cf. Van Ommen et al., 
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1986, chapter 2, chapter 3). Moreover, the same P450 isoenzyme (i.e., cytochrome 
P450IIIA1/2) appeared to be involved in the oxidation of HCB and PCB. 
The study described in chapter 8 was designed to establish the relevance of the 
oxidative metabolites in the various toxic effects, with special attention for the role of the 
reactive tetrachlorobenzoquinone in porphyria. To this end, urinary exretion of 
pentachlorophenol and tetrachlorohydroquinone, the reduced analog of tetrachloro-
benzoquinone, was monitored throughout the study. In addition, the effect of selective 
modulation of cytochrome P450IIIA activity by co-treatment with the macrolide 
triacetyloleandomycin (TAO) on biotransformation and toxicity (especially porphyria) of 
HCB and PCB is established. 
As demonstrated in chapter 8, dietary exposure to HCB resulted in highly elevated 
urinary porphyrin levels and a severe hepatic accumulation of porphyrins. HCB-induced 
porphyria was strongly inhibited by co-treatment with TAO. Co-treatment of rats with 
TAO also significantly inhibited oxidative metabolism of HCB (and PCB). However, 
inhibition of HCB-induced porphyria can not be explained by a diminished formation of 
the highly reactive tetrachlorobenzoquinone, since rats treated with a high dose of PCB 
had a several fold higher urinary excretion of tetrachlorohydroquinone compared to rats 
treated with HCB, but did not develop porphyria. The present data may, however, be 
supportive for the hypothesis suggesting the involvement of a (putative) reactive 
intermediate in the primary oxidation in HCB-induced porphyria, since urinary porphyrin 
excretion was well correlated with the excretion of the primary phenol metabolite, 
pentachlorophenol. 
Chapter 8 also demonstrates that exposure to either HCB or PCB resulted in a 
disturbance of retinoid and thyroid hormone homeostasis. The involvement of a common 
mechanism for polychlorinated benzenes and -biphenyls is discussed, involving 
interference of hydroxylated metabolites with plasma transport. 
Chapter 9 describes the characterization of the urinary metabolite profile of HCB 
and PCB. Apart from the two common oxidative metabolites, pentachlorophenol and 
tetrachlorohydroquinone, striking differences were observed with respect to the nature of 
the sulfur-containing metabolites. HCB was metabolized to N-acetyl-S-(pentachloro-
phenyl)cysteine, quantitatively the most important metabolite, and mercaptotetrachloro-
thioanisole. PCB was more extensively metabolized to sulfur- and sulfur-oxygen 
containing metabolites, of which the major metabolites were pentachlorothiophenol 
glucuronide and mercaptotetrachlorophenol . 
In addition to the oxidation to pentachlorophenol, PCB is also oxidized to 2,3,4,5-
tetrachlorophenol. Interestingly, excretion of 2,3,4,5-tetrachlorophenol was not inhibited 
by combined treatment of rats with PCB and TAO, the selective inhibitor of 
P450IIIA1/2. This indicates that (i) PCB is oxidized to pentachlorophenol and 2,3,4,5-
tetrachlorophenol via different intermediates, and (ii) cytochrome P450IIIA is not 
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involved in the latter oxidation. Combined treatment of rats with PCB and TAO had a 
differential effect on the excretion of sulfur-containing metabolites. For example, the 
urinary excretion of mercaptotetrachlorophenol was not inhibited by TAO, whereas the 
excretion of pentachlorothiophenol glucuronide was strongly inhibited. Thus, these results 
stress the importance of detailed studies into the interaction between oxidizing systems 
(i.e., cytochrome P450 monooxygenases) and conjugating systems (i.e., glutathione S-
transferases, spontaneous conjugation with glutathione) in order to delineate the different 
metabolic pathways. 
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CONCLUSIONS AND PERSPECTIVES 
Introduction 
The experiments described in this thesis were undertaken to assess the relevance of 
biotransformation routes to the toxic effects elicited by halogenated benzenes. The 
ultimate aim is to establish more precisely what chemical species is responsible for which 
toxic effect. As has been demonstrated for numerous unsaturated compounds (vinyl 
chloride, polycyclic aromatic hydrocarbons, bromobenzene), cytochrome P450 is 
believed to play a pivotal role in the metabolic activation of halogenated benzenes. 
Therefore, our first goal was to establish the route of oxidative biotransformation of a 
range of polychlorinated benzene congeners, with special attention for the extent of 
covalent binding to protein and DNA, and for the nature of the binding species. To this 
end, we used radiolabeled compounds and microsomal preparations (Part I, summarized 
in chapter 6). In order to assess the relevance of the formation of the various oxidized 
metabolites, as determined in microsomal incubations, for the toxicity in vivo, two 
studies were conducted (Part II, summarized in chapter 10). In the first study, a range of 
polychlorinated benzenes was compared with respect to their adverse effects on target 
organs like the liver and the kidney. Interestingly, thyroid hormone homeostasis appeared 
to represent an additional common target for chlorinated benzenes. In the second study, 
two closely related congeners, hexachlorobenzene and pentachlorobenzene, which are 
oxidized via a common pathway by rat liver microsomes, were compared in a 13-week 
feeding study with respect to their toxicity (chapter 8) and their urinary metabolite 
profiles (chapter 9). 
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Biotransformation of poly chlorinated benzenes to reactive metabolites: 
I. nature of the reactive intermediates formed 
One of the main conclusions drawn from the studies described in the present thesis is 
that, irrespective of the substitution degree and pattern, chlorinated benzenes are 
bioactivated to reactive metabolites which covalently bind to protein and DNA in a 
microsomal system. As discussed in chapter 1 (cf. Figure 1.3), several reactive products 
can be envisioned departing from a simple halogenated benzene structure. Based on the 
results described in Part I, we propose that secondary benzoquinone metabolites, formed 
upon the oxidation of the primary phenol metabolites, are the ultimate chemically 
reactive species produced during oxidative biotransformation of chlorinated benzenes, 
although the involvement of their semiquinone anion radicals can not be excluded. New 
insights in the oxidative pathways and chemical nature of the (reactive) products are 
incorporated in Figure 11.1, and will be discussed below. 
The classical view on the formation of reactive benzoquinone metabolites from the 
parent halogenated benzenes consists of three oxidation steps: two subsequent P450-
mediated oxidations via a halophenol to a hydroquinone, which needs further oxidation, 
either enzymatically or chemically, to the reactive benzoquinone metabolites (Van 
Ommen et al, 1986, Den Besten et al., 1989). However, evidence presented in chapter 
5 indicates that the mechanism of formation of benzoquinone metabolites is dependent on 
the substitution pattern of the phenol precursor. The oxidative dehalogenation of 
halophenols, which results in the direct formation of benzoquinone metabolites without 
the obligatory intermediacy of the chemically stable hydroquinones, reflects a novel 
pathway of, possibly, paramount importance to the toxicity observed in vivo (see section 
II). Since the mechanism described in chapter 5 has also been shown to be valid for 
/jara-fluorinated anilines, this pathway may represent a general mechanism for the P450-
mediated oxidation of substrates, which possess an acidic proton in one of the 
substituents of the aromatic ring and an electron withdrawing substituent at the position 
to be oxidized. 
A recent study on the conversion of fully halogenated benzenes suggests the 
formation of a novel intermediate in the primary oxidation step (Rietjens and Vervoort, 
1992). These authors propose that the cytochrome P450-mediated formation of the 
primary phenol metabolite may occur without the intermediacy of an arene oxide, but 
rather via a halogeno-analog of a quinone (i.e., a benzohaloquinone cation). Future 
studies are required to validate the exact nature of the intermediate in the primary 
oxidation of fully halogenated benzenes, i.e., is it an epoxide (Figure 11.1 route a) or a 
benzohaloquinone (Figure 11.1 route b), or do they both serve as intermediates in the 
oxidation step (Figure 11.1 route a-c)? In addition, the generality of such a novel 
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mechanism needs to be established, i.e., may benzohaloquinone cations also serve as 
intermediates in the oxidation of lower halogenated benzenes? 
An intriguing outcome of the present study is that the epoxide intermediates in the 
primary oxidative step to phenols apparently possess negligible alkylating properties, and 
this poses a need for re-evaluation of the role of this species in the toxicity of substituted 
benzenes. In particular, questions may be raised with respect to the presumed role of the 
3,4-epoxide as the ultimate reactive species involved in bromobenzene-induced 
hepatotoxicity (Jollow et al., 1974; Lau et al, 1980). This widely accepted view on 
bromobenzene-induced hepatotoxicity is merely based on indirect evidence such as the 
observation of a good correlation between on the one hand the urinary excretion of the 
/jarabromophenyl mercapturic acid (which involves the intermediacy of the 3,4-epoxide), 
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Figure 11.1 The proposed mechanisms of oxidation of halogenated benzenes and -phenols to 
hydroquinones and benzoquinones, depending on the substituent para with respect to the 
position to be oxidized. For explanation, see text. The formation of a distinct epoxide in the 
several oxidation steps has never unambigously been established, and current knowledge 
suggests the intermediacy of a (radical) a-complex (Guengerich and MacDonald, 1990). For 
reasons of simplification, in the present figure only epoxide intermediates are presented. X, 
halogen; n, m denotes number of halogen substituents in which m-n + 1. 
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and on the other hand depletion of cellular glutathione and subsequent covalent binding to 
protein. However, conjugation of bromobenzene-3,4-epoxide with glutathione has been 
shown to require enzymatic catalysis (Jollow et al., 1974; Monks et al., 1982), 
suggesting that this species has low spontaneous alkylating properties towards (protein-) 
sulfur nucleophiles. Only recently attempts were undertaken to isolate and characterize 
bromobenzene-derived protein adducts from rat liver. Interestingly, bromobenzene 
derived epoxides accounted for less than 0.5 % of total protein sulfur adducts (Weiler 
and Hanlik, 1991, Slaughter and Hanzlik, 1991), whereas the 5-alkylation of protein 
nucleophiles in vivo by quinone metabolites was 10-15 times more extensive (Slaughter 
and Hanzlik, 1991). These findings are fully in line with the observations in the present 
thesis that benzoquinones derived from halogenated benzenes have far greater alkylating 
properties than the primary epoxide intermediates (chapter 2, 3, 4). 
The chemical structure of a compound is a main factor determining to which extent 
the various biotransformation pathways take place. For example, as discussed above, a 
main determinant for the oxidation pathway for halogenated benzenes or phenols appears 
to be the ring substituent at the para-position with respect to the position to be oxidized. 
However, equally important is the (iso-)enzyme status regarding the process of 
biotransformation in a particular cell or organ. The differential role of the various P450 
isoenzymes in the conversion of chlorinated benzenes is clearly demonstrated (i) in vitro, 
by the various degrees of biotransformation and bioactivation of different chlorinated 
benzenes in microsomal preparations derived from rats pretreated with different P450 
inducers (chapter 3, 4), and (ii) in vivo, by inhibition of the conversion of 
hexachlorobenzene and pentachlorobenzene through selective modulation of the 
cytochrome P450IIIA1/2 activity (chapter 8, 9). For both hexachlorobenzene and 
pentachlorobenzene, cytochrome P450IIIA1/2 appears to be the major isoenzyme(s) 
involved in their oxidation, both in vitro (Van Ommen et al., 1989, chapter 3) and in 
vivo (chapter 9). However, with decreasing degree of chlorination, the relative 
contribution of other isoenzymes, especially from the P450IA and P450IIB family, 
becomes more important as is demonstrated by studies on the microsomal oxidation of 
1,2,4-trichlorobenzene (chapter 3) and 1,2- and 1,4-dichlorobenzene (chapter 4). 
Interestingly, the fact that the ratio of covalent binding to total metabolism was always 
highest in microsomes from DEX-pretreated rats, indicates that P450IIIA1/2 is not only 
involved in the primary oxidation step, but may also catalyze the secondary oxidation to 
reactive benzoquinone metabolites. 
With respect to interspecies comparison of the microsomal oxidation studies, the 
major role of the P450IIIA family in the oxidation and metabolic activation of chlorinated 
benzenes may have rather interesting consequences. This family is one of the most 
conserved forms across species (Smith, 1991), and in humans cytochrome P450IIIA is 
the most abundant P450-isoenzyme involved in the oxidation of many substrates of a 
chemically diverse nature (George and Farrell, 1991). We recently obtained evidence 
that, indeed, human P450IIIA is a major isoenzyme involved in the oxidation of 
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chlorinated benzenes. Using a battery of human liver microsomes, which were fully 
characterized with respect to their P450-isoenzyme status, it was shown that the extent of 
oxidation of 1,2,4-trichlorobenzene was correlated to a high degree with the amount of 
P450IIIA3/4 in the microsomal preparation (Table 11.1). In addition, the oxidation of 
1,2,4-trichlorobenzene was weakly correlated to the P450IIA1 content. Rather surprising 
was the low correlation observed with isoenzymes from the P450IA family in these 
human liver microsomes, since both rat liver microsomes from animals pretreated with 3-
MC and ISF (inducers of P450IA1 and P450IA2, respectively, chapter 3) and purified 
P450IA1 and P450IA2 in a reconstituted system (Den Besten and Henderson, in 
preparation) did convert 1,2,4-trichlorobenzene to a considerable extent. 
Table 11.1 Spearman rank correlations of cytochrome P450 isoenzyme content 
with oxidation of 1,2,4-trichlorobenzene. 
P450 oxidation of 
isoenzyme 1,2,4-TRICB 
P450IA1 0.16 
P450IIA1 0.701 
P450IIB1 0.57 
P450IIC8 0.46 
P450IIC9 0.04 
P450IID6 -0.43 
P450IIE1 -0.06 
P450IIIA3/4 0.84w 
P450IVA1 -0.09 
Note. The relative level of P450 isoenzymes in a panel of human liver 
microsomes was identified and immunoquantified as reported elsewhere 
(Forrester et al., 1992). Conversion of 1,2,4-trichlorobenzene was determined 
as described in chapter 3. Values represent Spearman rank correlation 
coefficients. Significance of correlation: 1 p < 0.05, " 1 p < 0.001. 
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Biotransformation of chlorinated benzenes to (re-)active metabolites: 
II. Implications for toxicity 
The reactive metabolites derived from polychlorinated benzenes which attack 
nucleophilic sites in proteins have been identified as benzoquinones (Part I). Based on 
our studies and on recent evidence presented in the literature concerning protein-adducts 
derived from the model hepatotoxicant bromobenzene (Slaughter and Hanzlik, 1991), we 
propose that the hepatotoxicity of halogenated benzenes is linked to the formation of 
benzoquinone metabolites, and not to the formation of their primary epoxide 
intermediates. 
The toxic potential of quinones resides in their ability to alkylate cellular 
nucleophiles (such as glutathione or tissue macromolecules) and/or to cause oxidative 
stress via redox cycling between the semiquinone anion radical and the corresponding 
hydroquinone or benzoquinone (Figure 11.1). Which of these two molecular mechanism 
(or maybe both) is involved in the toxicity induced by benzoquinones formed in situ from 
polyhalogenated benzenes remains to be established. However, covalent binding to 
protein has been shown to be a good correlate with hepatotoxicity induced by 
halogenated benzenes (Brodie et ai, 1971, Reid and Krishna, 1973, Stine et al., 1991), 
and under normal circumstances hepatocytes appear to have adequate defense 
mechanisms to cope with oxidative stress. However, the establishment of a causal 
relationship between irreversible protein binding and halogenated benzene-induced 
hepatotoxicity remains a crucial matter for future research. 
A possible approach to this question includes the characterization of the target 
molecules for the benzoquinone metabolites. In view of the relatively high chemical 
reactivity, it was not surprising that binding to microsomal protein occurred in a rather 
non-selective way. However, the benzoquinone metabolites were stable enough to diffuse 
out of the microsomal membrane and arylate soluble proteins such as exogeneously added 
glutathione ^-transferases or bovine serum albumine (Den Besten, unpublished 
observations). In fact, chlorinated benzoquinones and their glutathione conjugates are 
potent irreversible inhibitors of both rat and human glutathione 5-transferases (Vos and 
Van Bladeren, 1990). 
As discussed in section I (and depicted in Figure 11.1), the mechanism of formation 
of the reactive benzoquinones appears to be dependent on the substituent of the phenol 
precursor at the position to be oxidized. Direct formation of benzoquinone metabolites in 
a single oxidation step at a halogenated position, as opposed to formation of 
hydroquinones which need subsequent oxidation to their reactive quinone form, may have 
considerable toxicological implications. For example, in the latter case multiple 
interactions, such as competing pathways of conjugation, or the abundance of reducing 
equivalents in a cell, may prevent the actual formation of the reactive species in vivo. In 
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contrast, formation of the reactive quinone species cannot be circumvented in the case of 
the direct oxidation pathway, and once formed, quinone metabolites may not be 
adequately detoxified. Thus, the hypothesis put forward in the present study is that 
differences observed between covalent binding to macromolecules (and hepatotoxicity) of 
different halogenated benzenes may (partly) be due to the differential mechanism of 
reactive benzoquinone formation as described in chapter 5. 
Although a previous study indicated that the porphyrinogenic action of 
hexachlorobenzene was directly related to the formation of the reactive 
tetrachlorobenzoquinone (Van Ommen et al., 1989), chapter 8 presents evidence which 
argues against such a relationship. Comparison of the urinary metabolite profiles and the 
toxic effects elicited by hexachlorobenzene and pentachlorobenzene revealed that in situ 
oxidative dehalogenation of pentachlorophenol to tetrachlorobenzoquinone does not 
appear to be involved in hexachlorobenzene-induced porphyria. The involvement, 
however, of a putative reactive intermediate in the primary oxidation step of 
hexachlorobenzene in its porphyrinogenic action, such as the recently proposed 
benzohaloquinone cation (Rietjens and Vervoort, 1992) can not be ruled out, and future 
studies should be directed to tackle this enigma. 
The present studies have not delivered evidence which would establish the role of 
glutathione conjugates of chlorinated hydroquinones formed in situ as proximate 
nephrotoxicants. However, the elegant studies conducted on bromobenzene-induced 
nephrotoxicity, in which (poly-)glutathione conjugates of bromohydroquinone are 
indicated as potent and selective nephrotoxicants, may be representive for the whole 
range of halogenated benzenes, since glutathione conjugates of several chlorinated 
hydroquinones have also been shown to be nephrotoxic (Mertens et al., 1991). 
In addition to the attention paid to the covalent interactions by chemically reactive 
metabolites, chapter 7 and chapter 8 emphasize the importance of selective non-covalent 
interactions by biologically 'active' metabolites. For example, protein droplet 
nephropathy observed in the male rat after exposure to polychlorinated benzenes (chapter 
7) is believed to be induced by a reversible interaction of stable derivatives with 
fl/pÄa2/^-globulin, a male rat specific protein. This phenomenon may ultimately lead to 
increased incidence of renal adenomas and carcinomas, due to a sustained process of 
cytolysis and compensatory cell proliferation. For man, protein droplet nephropathy 
probably has litle relevance, because of a lack of the a/p/îa2/i-globulin in the human 
population. 
Furthermore, polychlorinated benzene congeners resemble the structurally related 
polychlorinated biphenyls (Brouwer, 1989) in that they markedly disturb thyroid hormone 
homeostasis in rat, both after a single exposure (chapter 7) or semi-chronic treatment 
(chapter 8). This effect may (in part) be attributed to a common mechanism involving an 
interaction of the primary phenol metabolites with the plasma transport protein for 
thyroxine, transthyretine (chapter 7; Van den Berg, 1990). An additional effect of 
polychlorinated benzenes in common with polychlorinated biphenyls includes 
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disturbances in retinoid homeostasis (chapter 8). The relevance of the disturbance in 
thyroid hormone and retinoid homeostasis to halogenated benzene-induced toxicity, 
however, remains to be established. 
A few general points need to be addressed. Firstly, in interpreting the importance of 
covalent binding, it should be realized that microsomal systems may magnify the 
intensity of the oxidative pathways with respect to the more complex situation in vivo. In 
the present study this is demonstrated by the observation that the extent to which a 
compound is activated to reactive products in vitro, does not necessarily correlate with 
the observed toxic effects. Multiple factors may influence the ultimate outcome of a 
chemical insult, such as differences in absorption, distribution, biotransformation and 
excretion between the different polychlorinated benzenes. These factors play a role in 
vivo, but are absent in a microsomal system. 
Secondly, the delicate balance between activation and detoxication pathways is 
important in the manifestation of chemical-induced toxicity. Competing pathways such as 
conjugation with glucuronic acid, sulphate or glutathione may direct the proximate 
reactive metabolites away from their target sites. Once the formation of reactive 
benzoquinone metabolites can not be circumvented, the cell possesses additional 
protective systems, either of an enzymatic nature (e.g., DT-diaphorase, GSH peroxidase) 
or a chemical nature (e.g., reducing equivalents such as pyridine nucleotides, ascorbic 
acid or a-tocopherol). 
In order to overcome these difficulties, knowledge on biotransformation pathways 
should be combined with data on the actual concentrations of the relevant (iso-) enzymes 
in the different (target) organs, and data on the (toxico-)kinetic profiles of the different 
congeners. These parameters may then be used to obtain a 'Physiologically-Based 
Pharmaco-Kinetic' model, which should accurately describe, and ultimately predict, the 
concentration of a reactive intermediate or other active metabolite at the target site or in 
the target organ. This might provide us with explanations for the observed differences in 
target organ toxicity between the different (poly)chlorinated benzene congeners, and for 
the observed differences in the effect of different dose levels of the same congener. 
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Lipofiele xenobiotica worden in het lichaam door middel van biotransformatie 
omgezet in polaire metabolieten, zodat excretie via urine en/of faeces mogelijk wordt. In 
de meeste gevallen resulteert biotransformatie in de ontgifting van toxische stoffen. Er 
zijn echter vele stoffen bekend die op zichzelf weinig schadelijk zijn, maar juist als 
gevolg van biotransformatie worden omgezet in reactieve produkten (zgn. 'metabole 
activatie'), die vervolgens de normale fysiologie van een cel, weefsel of organisme 
kunnen verstoren. Voor een beter inzicht in de relatie tussen chemische structuur van een 
stof en zijn effect(en) op levende organismen is kennis van de verschillende routes, 
waarlangs een stof wordt omgezet, onontbeerlijk. 
In hoofstuk 1 wordt een beknopte beschrijving gegeven van de belangrijkste 
biotransformatie systemen, die betrokken zijn bij de omzetting van xenobiotica, en van 
de bijdrage die deze systemen kunnen leveren aan de metabole activering en/of toxiciteit 
van xenobiotica. Gehalogeneerde benzenen vormen een goed voorbeeld van een groep 
van stoffen, waarbij metabole activatie een rol speelt in de toxische effecten op de 
verschillende doelorganen (met name lever en nier). Figuur 1.2 (zie pagina 33) maakt 
duidelijk dat uit een betrekkelijk eenvoudige stof, zoals een halogeenbenzeen, 
verschillende reactieve intermediairen en metabolieten gevormd kunnen worden. Het vele 
onderzoek naar het mechanisme van levertoxiciteit door broombenzeen wijst op een 
belangrijke rol voor het intermediair 3,4-epoxide. Echter, tijdens de oxidatie van het 
volledig gesubstitueerde hexachloorbenzeen zijn het niet de epoxides, maar juist reactieve 
chinon metabolieten (met name tetrachloorbenzochinon), die covalent aan eiwit binden. 
Daarnaast zijn er sterke aanwijzigingen dat de niertoxiciteit door broombenzeen is toe te 
schrijven aan de vorming van chinon metabolieten, die na conjugatie met glutathion naar 
de nier getransporteerd worden en daar proximale tubulaire schade veroorzaken. 
Het onderzoek dat staat beschreven in dit proefschrift is uitgevoerd om meer inzicht 
te verkrijgen in het belang van de verschillende intermediairen en metabolieten in de 
toxiciteit van een hele serie gehalogeneerde benzenen. Experimenten zijn met name 
uitgevoerd met (poly-)chloorbenzenen. Enerzijds zijn er in vitro studies gedaan met [14C]-
gelabelde substraten en microsomale suspensies om de verschillende biotransformatie 
routes te karakterizeren en het belang van deze routes in de metabole activatie te 
evalueren (Deel I, hoofdstuk 2, 3, 4, en 5; samengevat in hoofdstuk 6). Anderzijds zijn 
in vivo studies uitgevoerd om (i) een inschatting te krijgen van de toxiciteit van een reeks 
chloorbenzenen op de verschillende doel organen, en (ii) meer inzicht te krijgen in de rol 
van de verschillende metabolieten in de toxische effecten (Deel II, hoofdstuk 7, 8, en 9; 
samengevat in hoofdstuk 10). 
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Deel I In vitro studies 
In het eerste deel van dit proefschrift komt de vraag aan de orde óf, en zo ja in 
welke mate, een serie polychloorbenzenen geoxideerd kan worden tot reactieve produkten 
die covalent aan eiwit kunnen binden. Hiertoe werden microsomale incubaties met [14C]-
gelabelde substraten uitgevoerd. 
In hoofdstuk 2 wordt de microsomale oxidatie van pentachloorbenzeen (PCB) naar 
pentachloorfenol beschreven. Daarnaast worden de verschillende isomeren van 
tetrachloorfenol gevormd alsmede tetrachloorhydrochinon. Tijdens de oxidatie van PCB 
worden metabolieten gevormd, die covalent binden aan eiwit. Incubaties uitgevoerd in de 
aanwezigheid van ascorbine zuur, een reductor, tonen het belang van chinon metabolieten 
in de eiwit binding aan. Vanwege het feit dat de eiwitbinding ondanks een grote 
overmaat ascorbine zuur nooit geheel voorkomen kan worden, wordt de suggestie gedaan 
dat andere metabolieten, waarschijnlijk de epoxides in de primaire oxidatie van PCB naar 
pentachloorfenol, ook een bijdrage leveren aan de eiwitbinding. 
Hoofdstuk 3 beschrijft de microsomale oxidatie van 1,2,4-trichloorbenzeen (1,2,4-
TRICB). 1,2,4-TRICB wordt geoxideerd tot de verschillende isomeren van trichloorfenol 
en, in mindere mate, tot trichloorhydrochinon. De vorming van de 2,3,4- en 2,4,6-
trichloorfenol kan verlopen via een zgn. 'NIH-shift' van de overeenkomstige epoxide 
intermediairen in de primaire oxidatie stap. In overeenkomst met het microsomaal 
metabolisme van PCB blijkt een belangrijk deel van de metabolieten covalent aan eiwit te 
binden. Opvallend is echter dat de eiwitbinding van 1,2,4-TRICB metabolieten volledig 
voorkomen wordt door de aanwezigheid van ascorbine zuur in de microsomale incubatie. 
Daarnaast blijkt dat zowel voor 1,2,4-TRICB als voor PCB de mate van eiwit binding 
sterk gecorreleerd is met de mate van secundaire oxidatie van de fenol metabolieten, en 
niet met de mate van primaire oxidatie van de benzenen. Op grond van deze 
waarnemingen wordt geconcludeerd dat chinon metabolieten de enige reactive species1 
zijn in de oxidatie van zowel 1,2,4-TRICB als PCB. In plaats van de aanname dat de 
'rest' binding van PCB metabolieten aan eiwit in de aanwezigheid van ascorbine zuur 
(zie hoofdstuk 2) veroorzaakt wordt door een ander type reactieve metaboliet, kan als 
verklaring dienen een onvolledige reductie van het reactieve tetrachloorbenzochinon tot 
tetrachloorhydrochinon. 
Hoofdstuk 3 beschrijft ook de invloed van de cytochroom P450 samenstelling van de 
microsomale suspensies op de oxidatie van PCB en 1,2,4-TRICB. Microsomen van ratten 
1
 hiermee wordt bedoeld 'reactieve intermediairen/ metabolieten, in het engels 
gewoonlijk aangeduid als 'reactive species'. Deze term is hier in het nederlands 
overgenomen. 
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voorbehandeld met dexamethason (DEX), een stof die de hoeveelheid P450IIIA1 sterk 
induceert, zetten de beide substraten het beste om, in analogie met wat gevonden was 
voor hexachloorbenzeen (HCB) (Van Ommen et al., 1989). Het blijkt echter dat met 
afnemende substitutie graad de bijdrage van P450IIIA1 aan de oxidatie minder prominent 
wordt, en de relatieve bijdrage van andere isoenzymen belangrijker. De microsomale 
studies met twee isomeren van dichloorbenzeen bevestigen deze tendens (zie hoofdstuk 
4). 
Van twee dichloorbenzeen isomeren (DCB; i.e. 1,2- en 1,4-DCB) is een groot 
verschil in hepatotoxiciteit beschreven (zie ook hoofdstuk 7). In hoofdstuk 4 wordt de 
microsomale oxidatie van de toxische 1,2-isomeer en de niet-toxische 1,4-isomeer 
beschreven, met speciale aandacht voor mogelijke verschillen in metabolieten profiel die 
een rol kunnen spelen in de isomeer-selectieve hepatotoxiciteit. Zowel 1,2- als 1,4-DCB 
worden geoxideerd tot metabolieten die covalent aan eiwit binden. Een interessante 
waarneming is echter dat de eiwitbinding van 1,4-DCB metabolieten door de reductor 
ascorbine zuur volledig geremd kan worden, terwijl dit voor 1,2-DCB slechts gedeeltelijk 
mogelijk is. 'Molecular Orbital' computer berekeningen aan de arene oxide/ oxepin 
intermediairen van beide substraten tonen echter geen verschillen aan in chemische 
reactiviteit en/of stabiliteit van de verschillende arene oxide intermediairen van 1,2-DCB 
versus 1,4-DCB. Dit pleit tegen een rol van arene oxide intermediairen in de ('rest') 
eiwit binding van 1,2-DCB. 
Vooruitlopend op hoofdstuk 5, waarin het mechanisme van de vorming van reactieve 
chinon metabolieten wordt bestudeerd, wordt het optreden van restbinding van 1,2-DCB 
metabolieten aan eiwit in aanwezigheid van een reductor verklaard uit een directe 
oxidatie van de para-gesubstitueerde fenol metaboliet (i.e., 3,4,-dichloorfenol) naar het 
reactieve benzochinon. Een dergelijke directe oxidatie van de primaire fenol metaboliet 
van 1,4-DCB (i.e. 2,5-dichloorfenol; bezit geen halogeen substituent para ten opzichte 
van de hydroxyl groep) is niet mogelijk. 
Bovenstaande studies benadrukken het belang van de vorming van secundaire chinon 
metabolieten in de metabole activatie van gechloreerde benzenen. Het is daarom van 
belang om het mechanisme van vorming van deze reactieve produkten te bestuderen. 
Hiertoe worden pentafluor- en pentachloorfenol, en hun niet paragesubstitueerde 
analogen gebruikt als model stoffen. De oxidatie produkten in een microsomale incubatie 
worden geïdentificeerd met "F-NMR en HPLC. Het karakter van de oxidatie produkten 
van de fenol substraten kan echter niet bestudeerd worden onder standaard condities met 
moleculaire zuurstof en NADPH als electronen donor voor cytochroom P450, vanwege 
het feit dat het aanwezige NADPH eventueel gevormd benzochinon (chemisch) kan 
reduceren tot hydrochinon. Daarom zijn anaerobe incubaties uitgevoerd, waarbij cumeen 
hydroperoxide werd gebruikt als zuurstof donor. Gebaseerd op de resultaten die 
beschreven staan in hoofdstuk 5, wordt een mechanisme voorgesteld voor de P450 
203 
Samenvatting 
afhankelijke oxidatie van halogeenfenolen, waarbij het al dan niet aanwezig zijn van een 
halogeensubstituent op de positie para ten opzichte van de hydroxyl groep een bepalende 
factor is voor het karakter van het produkt (i.e. hydrochinon vs benzochinon). 
Cytochroom P450 afhankelijke oxidatie op een niet-gesubstitueerde para positie resulteert 
in de vorming van het /jara-hydroxyl derivaat (i.e. hydrochinon) als primair produkt. 
Daarentegen resulteert cytochroom P450 afhankelijke oxidatie op een para positie waar 
een halogeen substituent zit in de directe vorming van een reactief benzochinon onder 
verlies van het halogeen als een halogeen anion. In hoofdstuk 11 wordt ingegaan op 
mogelijke toxicologische implicaties van directe vorming van reactieve benzochinon 
metabolieten. 
Deel II In vivo studies 
In deel II van dit proefschrift staan de resultaten van twee in vivo studies beschreven, 
waarbij de toxiciteit van een hele serie chloorbenzenen op de verschillende doel organen 
is vastgesteld. Tevens wordt getracht de diverse effecten te correleren met de vorming 
van verschillende metabolieten. 
In hoofdstuk 7 wordt een hele serie chloorbenzenen vergeleken met betrekking tot 
hun potentie om toxiciteit te veroorzaken in verschillende doel organen na een éénmalige 
i.p. toediening in de rat. Effecten op de lever bestaan uit een toegenomen relatief lever-
gewicht op 72 uur na toediening, hetgeen voor de hoger gechloreerde benzenen ook nog 
waarneembaar is na 216 uur. In de meeste behandelingsgroepen wordt een variabele mate 
van centrilobulaire hypertrofie en hepatocellulaire degeneratie waargenomen. Van alle 
congeneren die getest zijn, geven 1,2-dichloorbenzeen en 1,2,4-trichloorbenzeen de meest 
ernstige effecten, hetgeen blijkt uit een sterke stijging van de plasma ALT spiegels, en 
duidelijk waarneembare histopathologische degeneratieve veranderingen. Monochloor-
benzeen was minder toxisch. In deze studie worden geen schadelijke effecten op de lever 
waargenomen na blootstelling aan 1,4-dichloorbenzeen en 1,2,4,5-tetrachloorbenzeen, 
terwijl blootstelling aan pentachloorbenzeen resulteert in slechts geringe histo-
pathologische veranderingen in de lever. Hieruit kan dus geconcludeerd worden dat de 
mate van metabole activatie zoals waargenomen in vitro (deel I) geen goede weergave 
biedt van de potentie om leverschade te veroorzaken. 
Er worden in de gebruikte dosis range geen degeneratieve effecten waargenomen op 
de nieren. Wel blijkt de vorming van 'Protein Droplets' in de tubulaire epitheel cellen 
een algemeen verschijnsel te zijn na (éénmalige) blootstelling aan gechloreerde benzenen. 
Dit effect was sterker en gedurende langere tijd waarneembaar na blootstelling aan de 
hoger gechloreerde congeneren. 
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Een interessante waarneming betreft het feit dat chloorbenzenen de schildklier-
hormoon huishouding verstoren, hetgeen tot uiting komt in een sterke daling van de 
plasma thyroxine spiegels. Hoger gechloreerde benzenen veroorzaken een sterker daling, 
en deze daling blijkt tevens op te treden na subchronische toediening van een lage dosis 
(hoofdstuk 8). Verstoring van de schildklierhormoon huishouding is ook beschreven voor 
de polychloorbiphenylen (Brouwer, 1989), verbindingen die wat betreft chemische 
structuur grote overeenkomsten vertonen met chloorbenzenen. Er worden in hoofdstuk 7 
aanwijzingen geleverd voor een gemeenschappelijk werkingsmechanisme, waarbij de 
vorming van fenol metabolieten een cruciale factor is: door een selectieve interactie van 
fenol metabolieten met transthyretiene, een belangrijk plasma transport eiwit voor 
schildklierhormoon in de rat, wordt het plasma transport van thyroxine ernstig verstoord, 
hetgeen resulteert in verlaging van de plasma spiegels. 
In hoofdstuk 8 en 9 worden de resultaten beschreven van een 13-weken dieet studie 
in de rat (9) met hexachloorbenzeen (HCB) en pentachloorbenzeen (PCB). Vergelijking 
van de toxiciteit en van de biotransformatie van deze twee congeneren is interessant, 
aangezien in vitro studies hadden aangetoond dat zowel HCB als PCB geoxideerd worden 
tot pentachloorfenol (PCP) en het reactieve tetrachloorbenzochinon (TCBQ) (zie Van 
Ommen et al., 1986; hoofdstuk 2). Daarnaast zijn er sterke aanwijzing dat hetzelfde 
cytochroom P450 isoenzym (P450IIIA) betrokken is bij de omzetting van deze stoffen 
(Van Ommen et al., 1989; hoofdstuk 3). 
De subchronische studie beschreven in hoofdstuk 8 was met name gericht om meer 
inzicht te krijgen in de rol van de oxidatieve metabolieten in de diverse toxische effecten 
van HCB en PCB. Bijzondere aandacht was er voor de mogelijke rol van het reactieve 
TCBQ in het ontstaan van porfyrie. Hiertoe werd de excretie van PCP en tetrachloor-
hydrochinon, de gereduceerde vorm van TCBQ, in de urine gevolgd in de tijd. Daarnaast 
werd het effect bestudeerd van selectieve beinvloeding van de cytochroom P450IIIA 
activiteit op de toxiciteit (met name porfyrie) en de biotransformatie van HCB en PCB, 
door gelijktijdige behandeling met het macrolide triacetyloleandomycine (TAO). 
Blootstelling van ratten (9) aan HCB (300 ppm) via het voer resulteert in een sterke 
toename van de porfyrine excretie via de urine en in een sterke accumulatie van 
porfyrines in de lever. Deze effecten van HCB worden sterk geremd door gelijktijdige 
blootstelling aan TAO. Gecombineerde blootstelling van ratten aan HCB of PCB met 
TAO resulteert tevens in een duidelijk verlaagde uitscheiding van de oxidatieve 
metabolieten, PCP en TCHQ. De vermindering van de porfyrinogene effecten van HCB 
kunnen echter niet verklaard worden uit een verminderde vorming van het reactieve 
TCBQ, aangezien ratten die worden behandeld met een hoge dosis PCB (1300 ppm) een 
urinaire excretie van TCHQ hebben die enkele malen hoger is dan in ratten die het HCB 
dieet krijgen, terwijl deze ratten géén porfyrie ontwikkelen. De goede correlatie die werd 
waargenomen tussen porfyrie en PCP excretie kunnen echter wel de hypothese 
ondersteunen, waarin een reactief intermediair in de primaire oxidatie stap van HCB naar 
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PCP wordt voorgesteld als uiteindelijke porfyrinogene species. In dit opzicht is met name 
een nieuw gepostuleerd type (reactief) intermediär met een chinon-structuur (Rietjens en 
Vervoort, 1992) interessant voor verder onderzoek. 
In hoofdstuk 9 wordt de biotransformatie van HCB en PCB beschreven, waarin de 
metabolieten profielen in de urine worden vergeleken. Zoals reeds besproken in 
hoofdstuk 8, worden HCB en PCB in vivo geoxideerd tot PCP en TCHQ. Dit blijken 
echter de enige twee gemeenschappelijke metabolieten van HCB en PCB, die worden 
uitgescheiden via de urine. Overige metabolieten van HCB zijn het pentachloorfenyl-
mercaptuurzuur, kwantitatief de belangrijkste metaboliet, en mercaptotetrachloor-
thioanisool. PCB wordt omgezet in een groter aantal zwavelbevattende verbindingen, 
waarbij mercaptotetrachloorfenol en pentachloorthiofenol de belangrijkste produkten zijn. 
PCB wordt, behalve tot PCP, in belangrijke mate ook geoxideerd tot 2,3,4,5-
tetrachloorfenol (TCP). Opvallend is dat de excretie van 2,3,4,5-TCP niet geremd wordt 
door gecombineerde blootstelling van ratten aan PCB en TAO, de remmer van P450IIIA. 
Dit wijst erop dat (i) de oxidatie van PCB tot PCP en tot 2,3,4,5-TCP verloopt via 
verschillende routes, en dat (ii) cytochroom P450IIIA niet betrokken is bij de oxidatie 
van PCB tot 2,3,4,5-TCP. Gecombineerde blootstelling van PCB en TAO had geen 
éénduidig effect op de excretie van zwavelbevattende metabolieten. Zo blijkt bijvoorbeeld 
dat de excretie van mercaptotetrachloorfenol niet geremd wordt door TAO, terwijl die 
van (het glucuronide van) pentachloorthiofenol sterk geremd wordt. De resultaten van 
deze studie onderstrepen het belang van meer gedetailleerde studies naar de interactie 
tussen fase I metabolisme (oxidatieve systemen, met name cytochroom P450) en fase II 
metabolisme (conjugatieve systemen, met name glutation conjugatie) om uiteindelijk een 
beter begrip te krijgen van de routes waarlangs de verschillende metabolieten gevormd 
worden. 
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CumOOH 
CVB 
DCB 
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dichlorohydroquinone 
dichlorophenol 
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epoxide hydrolase 
gas chromatography 
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glutathione 5-transferase 
UDP-glucuronyl transferase 
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hexachlorobenzene 
heat of formation 
high performance liquid chromatography 
intraperitoneally 
isosafrole 
3-methylcholanthrene 
monochlorobenzene 
molecular orbital 
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nuclear magnetic resonance 
cytochrome P450 
phénobarbital 
pentachlorobenzene 
pentachlorophenol 
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per os 
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triiodothyronine 
thyroxine 
triacetyloleandomycin 
tetrachlorobenzene 
tetrachlorobenzoquinone 
tetrachlorohydroquinone 
tetrachlorophenol 
tetrafluorobenzoquinone 
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TFHQ 
TFP 
TRICB 
TRICC 
TRICHQ 
TRICP 
TTR 
UROG-D 
tetrafluorohydroquinone 
tetrafluorophenol 
trichlorobenzene 
trichlorocatechol 
trichlorohydroquinone 
trichlorophenol 
transthyretine 
uroporhyrinogen decarboxylase 
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De toxicologie ('leer der vergiften'; toxicon= vergift) houdt zich bezig met het 
bestuderen van de schadelijke effecten van lichaamsvreemde stoffen, ook wel xenobiotica 
genoemd (xenos= vreemd, bios= leven) in organismen (mens, dier). Het fundamenteel 
toxicologisch onderzoek richt zich daarbij vooral op het werkingsmechanisme van giftige 
stoffen: bijvoorbeeld, waarom leidt overmatige alcohol consumptie tot leverschade, 
waarom hebben rokers een grotere kans op longkanker, hoe kan verklaard worden dat 1 
tablet paracetamol de hoofdpijn doet verdwijnen, terwijl een overdosis paracetamol 
dodelijk kan zijn? 
Omdat (ingrijpend) onderzoek met mensen ethisch niet verantwoord is, maakt men in 
toxicologisch onderzoek veel gebruik van proefdieren (met name de rat en de muis). De 
gegevens uit dergelijk onderzoek kunnen dan vervolgens 'vertaald' worden naar de mens. 
Echter, voor veel vraagstellingen blijkt onderzoek aan het intacte dier (in vivo onderzoek) 
veel te complex te zijn. Men kan dan zijn toevlucht nemen tot in vitro onderzoek. Hierbij 
maakt men gebruik van organen, cellen uit organen, of van celbestandelen. Behalve een 
simplificatie van de werkelijke situatie is een groot bijkomend voordeel van in vitro 
technieken een sterk verminderd gebruik van het aantal proefdieren. 
Omzetting van stoffen in het lichaam: biotransformatie 
Via o.a. voedsel, drank, geneesmiddelen en inademing van lucht krijgen we veel 
lichaamsvreemde stoffen binnen, zowel van natuurlijke als industriële oorsprong. Om te 
voorkomen dat al deze stoffen zich gedurende het leven in ons lichaam (met name 
vetweefsel) stapelen, met alle nadelige gevolgen vandien, moeten we ervoor zorgen dat 
we deze stoffen weer kwijtraken, bijvoorbeeld door uitscheiding via urine, faeces of 
uitademingslucht. Om de uitscheiding te vergemakkelijken, wordt het merendeel van deze 
xenobiotica (die vaak een vetachtig karakter hebben) tijdens de rondgang door het 
lichaam zodanig veranderd, dat ze beter in water oplosbaar zijn. Het lichaam bezit 
daartoe speciale 'fabriekjes', enzymen genoemd, die de stoffen chemisch veranderen. Het 
hele proces van omzetting van een oorspronkelijke stof in één of meer producten 
(metabolieten) wordt 'biotransformatie' genoemd. Een van de belangrijkste 
biotransformatie enzymen is het cytochroom P450. Organen, die een belangrijke bijdrage 
leveren aan het biotransformatie proces zijn de lever, en in mindere mate de nieren, 
longen, darmen en huid. 
In het algemeen geldt dat de metabolieten van een stof minder actief (minder 'giftig') 
zijn dan de oorspronkelijke stof zelf. De omzetting van een stof in zijn metabolieten 
noemt men in dat geval ontgifting of detoxicatie. Echter, er zijn ook voorbeelden bekend, 
waarbij tijdens de biotransformatie metabolieten ontstaan die juist reactiever (giftiger) 
zijn dan de uitgangsstof. Men spreekt dan van bioactivatie. Met name de omzetting door 
het enzym cytochroom P450 heeft nogal eens bioactivatie tot gevolg. De reactieve 
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producten kunnen vervolgens reageren met bestandden in een cel, waardoor de cel 
afsterft. Gelukkig kent de cel een aantal beschermingsmechanismen, zodat een éénmaal 
gevormd reactief product weer snel ontgiftigd kan worden (bijvoorbeeld door de werking 
van andere biotransformatie enzymen). Duidelijk moge zijn dat de balans tussen 
bioactivatie en detoxicatie heel belangrijk is voor het uiteindelijk (toxische) resultaat. 
Dit proefschrift 
'De relatie tussen biotransformatie en toxiciteit van halogeenbenzenen ' 
De chemische structuur van een stof blijkt een uitermate belangrijk gegeven te zijn 
voor de al dan niet schadelijke werking van die stof. De toxicoloog streeft ernaar aan de 
hand van de chemische structuur van de stof de toxicologische werking te kunnen 
voorspellen. De praktijk leert echter dat dit vreselijk moeilijk is. 
In dit proefschrift staat een reeks van stoffen centraal die, wat betreft chemische 
structuur, veel op elkaar lijken. Deze stoffen bestaan uit een benzeen ring met één of 
meer 'halogeen' substituenten, zoals chloor (Cl), fluor (F) of broom (Br). Vandaar de 
naam: halogeenbenzenen. In dit onderzoek is vooral gewerkt met chloorbenzenen (zie 
figuur 1). Chloorbenzenen worden als product gebruikt in de chemische industrie. 
Cl Cl Cl 
benzeen mono- di- tri- hexa-
chloorbenzeen chloorbenzeen chloorbenzeen chloorbenzeen 
Figuur 1. Enkele voorbeelden van de gebruikte chloorbenzenen. Op ieder hoekpunt van de 
zesring (benzeen) kunnen substituenten geplaatst worden. 
Doel van het onderzoek 
In het algemeen geldt dat halogeenbenzenen pas nâ biotransformatie (dus activatie) 
aanleiding tot toxiciteit geven. Het is echter niet bekend welke metabolieten hiervoor 
verantwoordelijk zijn. Het onderzoek in dit proefschrift is dan ook gericht op de rol van 
biotransformatie in de toxiciteit van halogeenbenzenen. 
Experimenten, beschreven in deel I, zijn uitgevoerd om aan te tonen óf er reactieve 
metabolieten uit halogeenbenzenen worden gevormd, en zo ja, welke chemische structuur 
die reactieve producten hebben. In deel II worden studies beschreven die zijn uitgevoerd 
om een inschatting te krijgen van de schadelijke gevolgen van de vorming van die 
reactieve producten. 
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Deel I: Wat zijn de reactieve metabolieten? 
In de eerste fase is vooral 'in de reageerbuis' gewerkt (in vitro onderzoek). Hiertoe 
werden levers van ratten fijngemalen. Via een aantal voorbewerkingsstappen werden 
celbestanddelen geïsoleerd ('microsomen' genoemd), waarop het biotransformatie proces 
plaatsvindt. Aan deze microsomen zijn in de reageerbuis de verschillende chloorbenzenen 
toegevoegd en vervolgens is onderzocht welke metabolieten gevormd werden. 
Het bleek dat de uitgangsstof werd omgezet in meerdere producten, zoals epoxides, 
fenolen en chinonen (zie figuur 2). Daarnaast bleek een deel van de producten zo reactief 
te zijn, dat zij met celbestanddelen reageerden. Deze reactieve producten bleken 
'chinonen' te zijn. Verder onderzoek heeft uitgewezen dat de reactieve chinonen via 
verschillende 'routes' gevormd konden worden, afhankelijk van de plaats van de 
halogeen substituenten aan de benzeen ring. 
hydrochinon 
chloorbenzeen —— epoxide — » - fenol ^ 11 
chinon 
Figuur 2. Omzetting van een chloorbenzeen in verschillende producten. 
Deel II: Wat betekent dit voor de toxiciteit? 
Van groot belang is om te onderzoeken wat de uiteindelijke consequenties zijn van 
de vorming van reactieve metabolieten, zoals beschreven in deel I, voor het levende 
organisme. In een levend organisme spelen dermate veel complexe processen af, 
waardoor de uitkomsten, die in deel I onder gecontroleerde omstandigheden gevonden 
zijn, niet automatisch vertaald mogen worden naar het intacte organisme. Daarom staan 
in deel II van dit proefschrift twee studies beschreven die zijn uitgevoerd in het intacte 
proefdier, de rat (in vivo onderzoek). 
In de eerste studie is onderzocht hoe ratten reageerden op een behandeling met 
eenzelfde hoeveelheid van een reeks verschillende chloorbenzenen. Hierbij werd vooral 
gekeken naar effecten op de lever. De lever is het belangrijkste biotransformatie orgaan. 
Als er bioactivatie tot reactieve producten plaatsvindt, zal er in eerste instantie schade in 
dit orgaan optreden. 
Opmerkelijk was dat sommige stoffen waarvan in deel I aangetoond was dat zij 
omgezet werden in reactieve produkten (dus mogelijk giftig), in het intacte dier niet 
giftig waren. Een mogelijke verklaring hiervoor kan gevonden worden in de chemische 
structuur van de stof: zoals in deel I is aangetoond, bepaald de plaatsing van halogenen 
(b.v. chloor) aan de benzeen ring langs welke route de reactieve producten gevormd 
worden. Door de aanwezigheid van bepaalde beschermingsfactoren in het intacte dier kan 
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één route (route a-c) geblokkeerd worden: de vorming van giftige chinonen vindt dan niet 
plaats, waardoor er ook geen leverschade ontstaat. Wanneer chinonen langs de tweede 
route (route b) gevormd worden, kunnen de beschermingsfactoren echter tekort schieten, 
zodat schade kan ontstaan. Voor verduidelijking, zie figuur 3. 
-, * - ( * * ) 9een 
route a W / t0X lc l te i t 
bechermings- \ 
factoren | 
_ ^ ^ ( • • J toxiciteit! 
route b V d ^ 
1 
Figuur 3. Schematische voorstelling van de route voor de vorming 
van reactieve producten uit chloorbenzenen. 
In de tweede in vivo studie stonden twee stoffen centraal die zoveel op elkaar lijken, 
dat ze omgezet worden in hetzelfde product. Dit product bezit een chinon structuur en is 
derhalve zeer reactief. Volgens een bestaande hypothese zou dit chinon een rol spelen in 
een zeer specifiek toxisch effect dat men 'porfyrie' noemt. Indien dit het geval is, moeten 
beide stoffen porfyrie veroorzaken. 
Om de bovenstaande hypothese te testen werden ratten gedurende 13 weken lang via 
het voer blootgesteld aan hexachloorbenzeen en pentachloorbenzeen. Inderdaad bleken 
beide stoffen omgezet te worden in het reactieve chinon. Echter, 'porfyrie' werd alleen 
waargenomen in ratten, die blootgesteld waren aan hexachloorbenzeen. Hieruit kan de 
conclusie getrokken worden dat bij het ontstaan van porfyrie andere factoren dan chinon 
vorming bepalend zijn. Andere effecten, zoals leverschade en effecten op 
schildklierhormonen, waren wel hetzelfde in beide behandelingsgroepen, en metabolieten 
blijken hierin een belangrijke rol te spelen. 
Slotopmerking 
In dit proefschrift wordt aangetoond dat chinon-metabolieten veel reactiever zijn dan 
epoxides. Bovendien wordt een mechanisme voorgesteld dat verband legt tussen de 
structuur van de stof (halogenen aan de ring) en (lever) schade in het organisme. 
Vooralsnog is dit een model. Toekomstig onderzoek zal zich moeten richten op de 
directe link tussen de vorming van chinon metabolieten en het ontstaan van schadelijke 
effecten. 
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Nawoord 
Voor u ligt het tastbaar resultaat van vier jaar wetenschappelijk onderzoek. Vier jaar, 
waarin je als 'gedreven' onderzoeker gefixeerd bent op je eigen project: weinig andere 
zaken lijken belangrijker. Toch is de wereld om ons heen juist de afgelopen jaren enorm 
in beweging: wie had vier jaar geleden gedacht aan de val van de Muur, de hereniging 
van de twee Duitslanden, de uitéénvalling van de Sovjet Unie of een complete golfoorlog 
in het Midden-Oosten? Terugblikkend op deze gebeurtenissen, weet ik het in dit 
proefschrift beschreven onderzoek in het juiste perspectief geplaatst. 
Wetenschap is mensenwerk. Bij het tot stand komen van dit proefschrift is de 
bijdrage en inzet van velen dan ook onontbeerlijk geweest. Het risico lopend sommige 
mensen te kort te doen, wil ik toch een aantal mensen met name noemen. 
Dank, natuurlijk, aan mijn begeleider en promotor, Peter van Bladeren, die de gave 
bezit om met een minimale (tijds)inspanning een maximaal rendement te behalen. Peter, 
mocht ik in de beginfase van het onderzoek jouw standplaats bij TNO in Zeist nog als 
lastig beschouwd hebben, in de loop van het project heb ik er zeker mijn voordeel 
meegedaan. En, eenmaal in het bezit van een auto bleek Zeist plotseling heel centraal te 
liggen. Je wist altijd haarfijn de grote lijnen aan te geven op momenten dat ik in details 
dreigde te verstikken. Tevens mijn dank voor de snelle afwerking van de vele concept-
manuscripten in de laatste fase. 
Dank ook aan mijn tweede promotor, Jan Koeman, voor de geboden mogelijkheid 
om het in dit proefschrift beschreven onderzoek uit te voeren op zijn vakgroep. Jan, in 
het bijzonder dank voor je wezenlijke bijdrage aan hoofdstuk 8. 
Ik wil Ivonne Rietjens bedanken voor de enthousiaste en motiverende samenwerking. 
Ivonne, met recht mag ik stellen dat zonder deze samenwerking hoofdstuk 5 er niet was 
geweest, en waarschijnlijk hoofdstuk 11 niet zo'n mooie figuur had gehad. Dit laatste 
zelfs afgezien van het feit dat ik gebruik mocht maken van jouw Apple computer! In het 
bijzonder dank, ook aan Jacques Vervoort, voor het uitvoeren van de NMR metingen, 
hetgeen vaak ten koste ging van jullie weekend rust. 
Een grote bijdrage aan het in dit proefschrift beschreven onderzoek is geleverd door 
studenten. Zonder hun bijdrage zou dit boekje veel minder dik zijn geworden. Melanie, 
Anja, Brigitte, Marjan S., Marlies, Marjan van der R., Erwin en Marlou: bedankt voor 
jullie doorzettingsvermogen achter de HPLC. Jammer genoeg is die on-line 
radioactiviteitsdetector er nooit gekomen! Harry, Jürgen, Gert en Erik: 4 mannen 
tegelijkertijd, druk maar ó zó gezellig! Speciale dank aan Marjon, voor het produceren 
van een grote berg resultaten tijdens mijn afwezigheid. 
De afdeling MTT van TNO Zeist, met name Ben van Ommen, wil ik bedanken voor 
het feit dat zij bij tijd en wijle mij, en mijn 'non-GLP compliance' op hun lab dulden. 
Ben, het feit dat jij onder GLP kunt werken stemt mij hoopvol: ik weet zeker dat mij dat 
in de toekomst ook zal lukken! 
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Ron Hoogenboom en Theo Polman van de afdeling Toxicologie van het Rikilt 
hebben gedurende enkele maanden hun, voor mij doen, geavanceerde HPLC-aparatuur 
beschikbaar gesteld. Zonder die auto-injector moesten er waarschijnlijk nu nog urines 
'geprikt' worden! Ron en Theo, bedankt voor alle (sleutel) hulp en adviezen. 
Onmisbaar in dit onderzoek zijn geweest de mensen en dieren van het CKP, met 
name Jo Haas en Maria Peters. Dank voor het feit dat jullie de 13-weken studie zagen 
'zitten': het was een vreselijke partij werk, maar het heeft uiteindelijk geresulteerd in 
twee mooie hoofdstukken. Dank ook aan de mensen van het RIVM (met name Sjef Vos, 
Frieke Kuper en Koen Molenbeek) en RITOX (met name Peter Schielen, Nanne 
Bloksma) voor de prettige samenwerking, zowel achter de discussie tafel als in de sectie 
kamer. 
Mijn collega's van de vakgroep toxicologie wil ik allen bedanken voor de 
gezelligheid. Bert, het leven wordt nooit meer als vroeger: ik drink tegenwoordig zelfs 
automaten koffie! Dank ook voor het zorgvuldige correctie werk: jouw ogen blijken 
zoveel beter dan de mijne. In het bijzonder dank aan Irene Bruggeman, die op het 
moment dat het echt nodig was de helpende hand uitstak. Irene, onze 'dames' kregen een 
eerste klas verzorging! En, alle resultaten overziend, heeft TAO dus wel 'gewerkt'. 
In de loop van mijn onderzoek heb ik in belangrijke mate geprofiteerd van de ideeën 
en middelen die Bram Brouwer op onze vakgroep heeft ingebracht. Bram, bedankt voor 
het feit dat je altijd bereid bent mee te denken met andermans onderzoek. 
Door de hulp van Gré Heitköning bij het intypen van de tabellen kon het manuscript 
net op tijd naar de leescommissie, zodat deze promotie nog op de valreep in 1992 kon 
plaatsvinden. Bedankt, Gré. De medewerkers van de tekenkamer en fotolokatie wil ik 
bedanken voor de bewezen diensten binnen de vaak zo krappe deadlines. 
Ik ben de directie van Solvay Duphar B.V. in Weesp zeer erkentelijk voor de 
geboden mogelijkheid en tijd om dit proefschrift af te ronden. Natuurlijk ook een woord 
van dank aan mijn huidige collega's van de afdeling Toxicologie voor hun flexibele 
opstelling ten aanzien van mijn onregelmatige werktijden. Vanaf heden draai ik op volle 
kracht mee! 
Marita van Amstel en Harry Besselink hebben mij als paranimfen de afgelopen 
maanden heel wat werk uit handen genomen. Marita, jouw steun betreft niet alleen de 
mooie etiketjes via WP51, maar eigenlijk veel meer de hechte vriendschap van de 
afgelopen jaren. Harry, de talloze loopjes van en naar de fotolokatie hebben uiteindelijk 
geresulteerd in mooie figuren op de juiste grootte. Bedankt ook voor het correctie werk. 
Tot slot een woord voor mijn ouders, familie en vrienden: bedankt voor jullie 
interesse in mijn werk, alhoewel ik waarschijnlijk nooit in staat was de essentie echt over 
te brengen. Daarom voor jullie in dit boekje een eigen uitleg. Wie nog vragen heeft ... 
De laatste woorden in dit boekje zijn bestemd voor mijn grootste steun en toeverlaat, 
de relativerende Noot in mijn leven, en tevens 'mede-auteur' van pagina 209-212. Lieve 
Nico, eindelijk is dit boekje dan af. Vanaf nu kunnen we weer samen in de tuin werken. 
C enthalt ne 
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Cathaline den Besten werd geboren op 7 mei 1963 te Rotterdam. Zij behaalde 
haar VWO-diploma in 1980 aan de scholengemeenschap Melanchthon te Rotterdam. 
Vervolgens verbleef zij een jaar in St. Louis (Missouri, USA), alwaar het high-school 
diploma behaald werd. In 1982 begon zij met de studie Humane Voeding aan de 
Landbouwuniversiteit te Wageningen. Het propädeutisch examen werd behaald in oktober 
1983 (met lof). Tijdens de doctoraalfase werd onderzoek uitgevoerd op de vakgroepen 
Humane Voeding (prof.dr. J.G.A.J. Hautvast) en Toxicologie (prof.dr. J.H. Koeman). 
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Op 1 februari 1988 trad zij als onderzoeker in opleiding in dienst van de vakgroep 
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